Cover
Cover | 6 Months Ended |
Jun. 30, 2022 | |
Cover [Abstract] | |
Document Type | 6-K |
Entity Registrant Name | Barclays Bank PLC |
Amendment Flag | false |
Document Fiscal Year Focus | 2022 |
Document Fiscal Period Focus | Q2 |
Document Period End Date | Jun. 30, 2022 |
Entity Central Index Key | 0000312070 |
Current Fiscal Year End Date | --12-31 |
Condensed consolidated income s
Condensed consolidated income statement (unaudited) - GBP (£) £ in Millions | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | |||
Profit or loss [abstract] | ||||
Interest and similar income | £ 4,098 | £ 2,444 | [1] | |
Interest and similar expense | (1,865) | (921) | [1] | |
Net interest income | 2,233 | 1,523 | [1] | |
Fee and commission income | 4,008 | 4,070 | [1] | |
Fee and commission expense | (1,169) | (870) | [1] | |
Net fee and commission income | 2,839 | 3,200 | [1] | |
Net trading income | 5,026 | 3,467 | [1] | |
Net investment expense | (139) | (36) | [1] | |
Other income | 31 | 35 | [1] | |
Total income | 9,990 | 8,189 | [1] | |
Credit impairment (charge)/release | (293) | 288 | [1] | |
Net operating income | 9,697 | 8,477 | [1] | |
Staff costs | (2,600) | (2,385) | [1] | |
Infrastructure, administration and general expenses | (2,659) | (2,674) | [1] | |
Litigation and conduct | (1,833) | (164) | [1] | |
Operating expenses | (7,092) | (5,223) | [1] | |
Share of post-tax results of associates and joint ventures | 0 | 3 | [1] | |
Profit before tax | 2,605 | 3,257 | [1] | |
Tax charge | (476) | (594) | [1] | |
Profit after tax | 2,129 | 2,663 | [2] | |
Attributable to: | ||||
Equity holders of the parent | 1,801 | 2,360 | [1] | |
Other equity instrument holders | 328 | 303 | [1] | |
Profit after tax | £ 2,129 | [3] | £ 2,663 | [4] |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[3]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[4]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Condensed consolidated statemen
Condensed consolidated statement of comprehensive income (unaudited) - GBP (£) £ in Millions | 6 Months Ended | ||||
Jun. 30, 2022 | Jun. 30, 2021 | ||||
Statement of comprehensive income [abstract] | |||||
Profit after tax | £ 2,129 | £ 2,663 | [1] | ||
Other comprehensive (loss)/income that may be recycled to profit or loss: | |||||
Currency translation reserve | [3] | 2,008 | [2] | (552) | [1] |
Fair value through other comprehensive income reserve | [3] | (799) | (312) | [1] | |
Cash flow hedging reserve | [3] | (2,874) | [2] | (823) | [1] |
Other comprehensive loss that may be recycled to profit or loss | [3] | (1,665) | (1,687) | [1] | |
Other comprehensive income/(loss) not recycled to profit or loss | |||||
Retirement benefit remeasurements | 1,090 | [2] | 103 | [1] | |
Own credit | 855 | [2] | (47) | [4] | |
Other comprehensive income not recycled to profit or loss | 1,945 | 56 | [1] | ||
Other comprehensive income/(loss) for the period | 280 | (1,631) | [1] | ||
Total comprehensive income for the period | £ 2,409 | [2] | £ 1,032 | [4] | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[3]Reported net of tax.[4]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Condensed consolidated balance
Condensed consolidated balance sheet (unaudited) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | [3] | Dec. 31, 2020 | |||
Assets | ||||||||
Cash and balances at central banks | £ 221,698 | £ 169,085 | [1] | |||||
Cash collateral and settlement balances | 128,501 | 88,085 | [1] | |||||
Loans and advances at amortised cost | 180,098 | 145,259 | [1] | |||||
Reverse repurchase agreements and other similar secured lending | 1,060 | 3,177 | [1] | |||||
Trading portfolio assets | 126,896 | 146,871 | [1] | |||||
Financial assets at fair value through the income statement | 210,430 | 188,226 | [1] | |||||
Derivative financial instruments | 344,396 | 262,291 | [1] | |||||
Financial assets at fair value through other comprehensive income | 43,814 | 45,908 | [1] | |||||
Investments in associates and joint ventures | 24 | 24 | [1] | |||||
Goodwill and intangible assets | 1,656 | 1,449 | [1] | |||||
Property, plant and equipment | 1,330 | 1,248 | [1] | |||||
Current tax assets | 1,116 | 589 | [1] | |||||
Deferred tax assets | 3,052 | 2,981 | [1] | |||||
Retirement benefit assets | 5,234 | 3,879 | [1] | |||||
Other assets | 3,440 | 2,706 | [1] | |||||
Total assets | 1,272,745 | 1,061,778 | [1] | |||||
Liabilities | ||||||||
Deposits at amortised cost | 311,465 | 262,828 | [1] | |||||
Cash collateral and settlement balances | 123,387 | 79,047 | [1] | |||||
Repurchase agreements and other similar secured borrowing | 12,805 | 12,769 | [1] | |||||
Debt securities in issue | 68,656 | 48,388 | [1] | |||||
Subordinated liabilities | 32,241 | 32,185 | [1] | £ 32,005 | ||||
Trading portfolio liabilities | 75,880 | 53,291 | [1] | |||||
Financial liabilities designated at fair value | 255,787 | 251,131 | [1] | |||||
Derivative financial instruments | 321,526 | 256,523 | [1] | |||||
Current tax liabilities | 449 | 688 | [1] | |||||
Deferred tax liabilities | 0 | 6 | [1] | |||||
Retirement benefit liabilities | 236 | 246 | [1] | |||||
Other liabilities | 8,752 | 7,249 | [1] | |||||
Provisions | 2,645 | 1,110 | [1] | |||||
Total liabilities | 1,213,829 | 1,005,461 | [1] | |||||
Equity | ||||||||
Called up share capital and share premium | 2,348 | 2,348 | [1] | |||||
Other equity instruments | 9,794 | 9,693 | [1] | |||||
Other reserves | 53 | 861 | [1] | |||||
Retained earnings | 46,721 | 43,415 | [1] | |||||
Total equity | 58,916 | [2] | 56,317 | [2] | £ 53,636 | £ 53,710 | [3] | |
Total liabilities and equity | £ 1,272,745 | £ 1,061,778 | [1] | |||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[3]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Condensed consolidated statem_2
Condensed consolidated statement of changes in equity (unaudited) - GBP (£) £ in Millions | Total | Called up share capital and share premium | Other equity instruments | Other reserves | Retained earnings | ||||||
Beginning Balance, equity at Dec. 31, 2020 | £ 53,710 | [1] | £ 2,348 | [2] | £ 8,621 | [2] | £ 3,183 | [2] | £ 39,558 | [1] | |
Profit after tax | 2,663 | [1] | 303 | [2] | 2,360 | [1] | |||||
Currency translation movements | (552) | [3],[4] | (552) | [2] | |||||||
Fair value through other comprehensive income reserve | (312) | [1] | (312) | [2] | |||||||
Cash flow hedges | (823) | [3],[4] | (823) | [2] | |||||||
Retirement benefit remeasurements | 103 | [3] | 103 | [1] | |||||||
Own credit | (47) | [1] | (47) | [2] | |||||||
Total comprehensive income for the period | 1,032 | [1] | 303 | [2] | (1,734) | [2] | 2,463 | [1] | |||
Other equity instruments coupons paid | (303) | [1] | (303) | [2] | |||||||
Equity settled share schemes | [1] | 255 | 255 | ||||||||
Vesting of Barclays PLC shares under equity settled share schemes | [1] | (349) | (349) | ||||||||
Dividends paid - ordinary shares | [1] | (694) | (694) | ||||||||
Dividends paid - preference shares | [1] | (13) | (13) | ||||||||
Capital Contribution from Barclays PLC | [1] | 0 | |||||||||
Other movements | [1] | (2) | (2) | ||||||||
Ending Balance, equity at Jun. 30, 2021 | 53,636 | [1] | 2,348 | [2],[5] | 8,621 | [2],[5] | 1,449 | [2],[5] | 41,218 | [6] | |
Beginning Balance, equity at Dec. 31, 2020 | 53,710 | [1] | 2,348 | [2] | 8,621 | [2] | 3,183 | [2] | 39,558 | [1] | |
Profit after tax | 4,588 | ||||||||||
Ending Balance, equity at Dec. 31, 2021 | 56,317 | [6] | 2,348 | [5] | 9,693 | [5] | 861 | [5] | 43,415 | [6] | |
Profit after tax | 2,129 | [6] | 328 | [5] | 1,801 | [6] | |||||
Currency translation movements | 2,008 | [4],[6] | 2,008 | [5] | |||||||
Fair value through other comprehensive income reserve | (799) | [6] | (799) | [5] | |||||||
Cash flow hedges | (2,874) | [4],[6] | (2,874) | [5] | |||||||
Retirement benefit remeasurements | [6] | 1,090 | 1,090 | ||||||||
Own credit | 855 | [6] | 855 | [5] | |||||||
Total comprehensive income for the period | 2,409 | [6] | 328 | [5] | (810) | [5] | 2,891 | [6] | |||
Issue and exchange of equity instruments | 131 | [6] | 101 | [5] | 30 | [6] | |||||
Other equity instruments coupons paid | (328) | [6] | (328) | [5] | |||||||
Equity settled share schemes | [6] | 242 | 242 | ||||||||
Vesting of Barclays PLC shares under equity settled share schemes | [6] | (402) | (402) | ||||||||
Dividends paid - ordinary shares | [6] | (200) | (200) | ||||||||
Dividends paid - preference shares | [6] | (15) | (15) | ||||||||
Capital Contribution from Barclays PLC | 750 | 750 | [6] | ||||||||
Other movements | 12 | [6] | 2 | [5] | 10 | [6] | |||||
Ending Balance, equity at Jun. 30, 2022 | £ 58,916 | [6] | £ 2,348 | [5] | £ 9,794 | [5] | £ 53 | [5] | £ 46,721 | [6] | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]Details of share capital, other equity instruments and other reserves are shown on pages 42 to 43.[3]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[4]Reported net of tax.[5]Details of share capital, other equity instruments and other reserves are shown on pages 29 to 51.[6]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Condensed consolidated cash flo
Condensed consolidated cash flow statement (unaudited) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |||
Statement of cash flows [abstract] | |||||
Profit before tax | £ 2,605 | £ 3,257 | [1] | £ 5,418 | |
Adjustment for non-cash items | (7,938) | 5,078 | [2] | ||
Net (increase)/decrease in loans and advances at amortised cost | (22,252) | 2,932 | [2] | ||
Net increase in deposits at amortised cost | 48,637 | 5,036 | [2] | ||
Net increase in debt securities in issue | 20,268 | 13,508 | [2] | ||
Changes in other operating assets and liabilities | 14,462 | (8,814) | [2] | ||
Corporate income tax paid | (280) | (617) | [2] | ||
Net cash from operating activities | 55,502 | 20,380 | [2] | ||
Net cash from investing activities | (7,071) | (3,112) | [2] | ||
Net cash from financing activities | 488 | (2,883) | [2] | ||
Effect of exchange rates on cash and cash equivalents | 7,045 | (5,534) | [2] | ||
Net increase in cash and cash equivalents | 55,964 | 8,851 | [2] | ||
Cash and cash equivalents at beginning of the period | 185,860 | 173,125 | [2] | 173,125 | [2] |
Cash and cash equivalents at end of the period | £ 241,824 | £ 181,976 | [2] | £ 185,860 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Credit Risk
Credit Risk | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of credit risk exposure [abstract] | |
Credit Risk | Loans and advances at amortised cost by product The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure, as expected credit loss (ECL) is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios, the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Stage 2 As at 30.06.22 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total 1 Gross exposure £m £m £m £m £m £m £m Home loans 10,461 314 11 170 495 1,016 11,972 Credit cards, unsecured loans and other retail lending 29,940 2,944 187 201 3,332 1,682 34,954 Wholesale loans 124,360 11,154 79 322 11,555 707 136,622 Total 164,761 14,412 277 693 15,382 3,405 183,548 Impairment allowance Home loans 10 14 1 1 16 343 369 Credit cards, unsecured loans and other retail lending 679 685 55 81 821 883 2,383 Wholesale loans 246 196 1 1 198 254 698 Total 935 895 57 83 1,035 1,480 3,450 Net exposure Home loans 10,451 300 10 169 479 673 11,603 Credit cards, unsecured loans and other retail lending 29,261 2,259 132 120 2,511 799 32,571 Wholesale loans 124,114 10,958 78 321 11,357 453 135,924 Total 163,826 13,517 220 610 14,347 1,925 180,098 Coverage ratio % % % % % % % Home loans 0.1 4.5 9.1 0.6 3.2 33.8 3.1 Credit cards, unsecured loans and other retail lending 2.3 23.3 29.4 40.3 24.6 52.5 6.8 Wholesale loans 0.2 1.8 1.3 0.3 1.7 35.9 0.5 Total 0.6 6.2 20.6 12.0 6.7 43.5 1.9 As at 31.12.21 Gross exposure £m £m £m £m £m £m £m Home loans 9,760 548 22 83 653 958 11,371 Credit cards, unsecured loans and other retail lending 24,011 2,402 198 182 2,782 1,469 28,262 Wholesale loans 95,242 12,275 301 386 12,962 921 109,125 Total 129,013 15,225 521 651 16,397 3,348 148,758 Impairment allowance Home loans 8 33 1 1 35 343 386 Credit cards, unsecured loans and other retail lending 605 677 39 75 791 906 2,302 Wholesale loans 183 188 3 2 193 435 811 Total 796 898 43 78 1,019 1,684 3,499 Net exposure Home loans 9,752 515 21 82 618 615 10,985 Credit cards, unsecured loans and other retail lending 23,406 1,725 159 107 1,991 563 25,960 Wholesale loans 95,059 12,087 298 384 12,769 486 108,314 Total 128,217 14,327 478 573 15,378 1,664 145,259 Coverage ratio % % % % % % % Home loans 0.1 6.0 4.5 1.2 5.4 35.8 3.4 Credit cards, unsecured loans and other retail lending 2.5 28.2 19.7 41.2 28.4 61.7 8.1 Wholesale loans 0.2 1.5 1.0 0.5 1.5 47.2 0.7 Total 0.6 5.9 8.3 12.0 6.2 50.3 2.4 1 Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £173.9bn (December 2021: £135.5bn) and impairment allowance of £138m (December 2021: £104m). This comprises £7m (December 2021: £4m) ECL on £172.1bn (December 2021: £135.3bn) Stage 1 assets, £2m (December 2021: £0m) on £1.7bn (December 2021: £65m) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £129m (December 2021: £100m) on £133m (December 2021: £100m) Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £487m (December 2021:£499m). Movement in gross exposures and impairment allowance including provisions for loan commitments and financial guarantees The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in the Barclays Bank PLC Annual Report 2021. Transfers between stages in the tables have been reflected as if they had taken place at the beginning of the year. The movements are measured over a 6-month period. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2022 9,760 8 653 35 958 343 11,371 386 Transfers from Stage 1 to Stage 2 (219) — 219 — — — — — Transfers from Stage 2 to Stage 1 330 13 (330) (13) — — — — Transfers to Stage 3 (127) — (51) (3) 178 3 — — Transfers from Stage 3 14 — 21 2 (35) (2) — — Business activity in the period 1 1,185 2 — — — — 1,185 2 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 52 (13) 7 (4) 6 10 65 (7) Final repayments (534) — (24) (1) (81) (1) (639) (2) Disposals — — — — — — — — Write-offs 2 — — — — (10) (10) (10) (10) As at 30 June 2022 3 10,461 10 495 16 1,016 343 11,972 369 Credit cards, unsecured loans and other retail lending As at 1 January 2022 24,011 605 2,782 791 1,469 906 28,262 2,302 Transfers from Stage 1 to Stage 2 (1,293) (28) 1,293 28 — — — — Transfers from Stage 2 to Stage 1 944 199 (944) (199) — — — — Transfers to Stage 3 (356) (7) (270) (127) 626 134 — — Transfers from Stage 3 15 7 32 4 (47) (11) — — Business activity in the period 1 6,041 331 174 15 13 2 6,228 348 Refinements to models used for calculation 4 — 43 — 187 — 96 — 326 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 2,749 (453) 485 145 123 139 3,357 (169) Final repayments (2,019) (14) (193) (13) (112) (5) (2,324) (32) Disposals 5 (152) (4) (27) (10) (26) (14) (205) (28) Write-offs 2 — — — — (364) (364) (364) (364) As at 30 June 2022 3 29,940 679 3,332 821 1,682 883 34,954 2,383 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. Business activity reported within Credit cards, unsecured loans and other retail lending portfolio includes GAP portfolio acquisition in US cards of £2.7bn. 2 In H122, gross write-offs amounted to £560m (H121: £606m) and post write-off recoveries amounted to £20m (H121: £15m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £540m (H121: £591m). 3 Other financial assets subject to impairment excluded in the tables above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £173.9bn (December 2021: £135.5bn) and impairment allowance of £138m (December 2021: £104m). This comprises £7m ECL (December 2021: £4m) on £172.1bn Stage 1 assets (December 2021: £135.3bn), £2m (December 2021: £0m) on £1.7bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2021: £65m) and £129m (December 2021: £100m) on £133m Stage 3 other assets (December 2021: £100m). 4 Refinements to models used for calculation reported within Credit cards, unsecured loans and other retail lending portfolio include a £0.3bn movement in US cards. These reflect methodology changes made during the year. Barclays continually review the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. 5 The £0.2bn of disposals reported within Credit cards, unsecured loans and other retail lending portfolio relates to sale of NFL portfolio within US cards. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Wholesale loans As at 1 January 2022 95,242 183 12,962 193 921 435 109,125 811 Transfers from Stage 1 to Stage 2 (2,035) (4) 2,035 4 — — — — Transfers from Stage 2 to Stage 1 4,848 31 (4,848) (31) — — — — Transfers to Stage 3 (38) — (66) (1) 104 1 — — Transfers from Stage 3 32 — 1 — (33) — — — Business activity in the period 1 24,929 28 1,628 13 1 — 26,558 41 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 18,690 31 1,555 46 (10) 91 20,235 168 Final repayments (17,308) (23) (1,681) (26) (44) (40) (19,033) (89) Disposals 2 — — (31) — (46) (47) (77) (47) Write-offs 3 — — — — (186) (186) (186) (186) As at 30 June 2022 4 124,360 246 11,555 198 707 254 136,622 698 Reconciliation of ECL movement to impairment charge/(release) for the period £m Home loans (7) Credit cards, unsecured loans and other retail lending 473 Wholesale loans 120 ECL movement excluding assets derecognised due to disposals and write-offs 586 Recoveries and reimbursements 5 (31) Exchange and other adjustments 6 (245) Impairment release on loan commitments and other financial guarantees (40) Impairment charge on other financial assets 4 23 Income statement charge for the period 293 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. 2 The £0.1bn of disposals reported within Wholesale loans relate to debt sales undertaken during the year. 3 In H122, gross write-offs amounted to £560m (H121: £606m) and post write-off recoveries amounted to £20m (H121: £15m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £540m (H121: £591m). 4 Other financial assets subject to impairment excluded from the tables above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £173.9bn (December 2021: £135.5bn) and impairment allowance of £138m (December 2021: £104m). This comprises £7m ECL (December 2021: £4m) on £172.1bn Stage 1 assets (December 2021: £135.3bn), £2m (December 2021: £0m) on £1.7bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2021: £65m) and £129m (December 2021: £100m) on £133m Stage 3 other assets (December 2021: £100m). 5 Recoveries and reimbursements includes a net gain in relation to reimbursements from guarantee contracts held with third parties of £11m (H121 loss: £216m) and post write off recoveries of £20m (H121: £15m). 6 Exchange and other adjustments includes foreign exchange and interest and fees in suspense. Loan commitments and financial guarantees Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2022 53 — — — 1 — 54 — Net transfers between stages — — — — — — — — Business activity in the year 2 — — — — — 2 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 2 — — — — — 2 — Limit management and final repayments (13) — — — — — (13) — As at 30 June 2022 44 — — — 1 — 45 — Credit cards, unsecured loans and other retail lending As at 1 January 2022 78,655 36 3,214 33 32 20 81,901 89 Net transfers between stages (645) 4 361 — 284 (4) — — Business activity in the year 26,149 1 195 — — — 26,344 1 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 10,050 24 (1,156) 1 (259) 2 8,635 27 Limit management and final repayments (3,012) — (156) — (4) (1) (3,172) (1) As at 30 June 2022 111,197 65 2,458 34 53 17 113,708 116 Wholesale loans As at 1 January 2022 178,006 167 28,417 241 1,017 2 207,440 410 Net transfers between stages 9,900 36 (9,835) (37) (65) 1 — — Business activity in the year 37,356 19 2,864 24 — — 40,220 43 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 17,664 (9) 1,526 (23) 142 (3) 19,332 (35) Limit management and final repayments (36,362) (14) (4,639) (33) (245) — (41,246) (47) As at 30 June 2022 206,564 199 18,333 172 849 — 225,746 371 Measurement uncertainty Management has applied economic uncertainty and other adjustments to modelled ECL outputs. Economic uncertainty adjustments have been applied to customers and clients considered most vulnerable to rising costs and supply chain disruption. As a result, ECL is higher than would be the case if it were based on forecast economic scenarios alone. The measurement of modelled ECL involves complexity and judgement, including estimation of probabilities of default (PD), loss given default (LGD), a range of unbiased future economic scenarios, estimation of expected lives, estimation of exposures at default (EAD) and assessing significant increases in credit risk. The Barclays Bank Group uses a five-scenario model to calculate ECL. An external consensus forecast is assembled from key sources, including HM Treasury (short and medium term forecasts), Bloomberg (based on median of economic forecasts) and the Urban Land Institute (for US House Prices), which forms the Baseline scenario. In addition, two adverse scenarios (Downside 1 and Downside 2) and two favourable scenarios (Upside 1 and Upside 2) are derived, with associated probability weightings. The adverse scenarios are calibrated to a broadly similar severity to Barclays’ internal stress tests and stress scenarios provided by regulators whilst also considering IFRS 9 specific sensitivities and non-linearity. The favourable scenarios are designed to reflect plausible upside risks to the Baseline scenario which are broadly consistent with the economic narrative approved by the Senior Scenario Review Committee. All scenarios are regenerated at a minimum semi-annually. The scenarios include key economic variables, (including GDP, unemployment, House Price Index (HPI) and base rates in both the UK and US markets), and expanded variables using statistical models based on historical correlations. The upside and downside shocks are designed to evolve over a five-year stress horizon, with all five scenarios converging to a steady state after approximately seven years. Scenarios used to calculate the Barclays Bank Group’s ECL charge were refreshed in Q222. The current Baseline scenario reflects the latest consensus economic forecasts. Unemployment rates remain low, close to current levels. As inflation expectations drift higher, central banks tighten monetary policy sharply. In 2023, the UK Bank Rate reaches 2.75%, while the US Federal Funds Rate peaks at 3.25%. Rising borrowing charges and falling real wages subtract from growth through lower investment and household consumption. In the Downside 2 scenario, with inflation expectations rising, the central banks have to raise interest rates very sharply. The UK Bank Rate and the US Federal Funds Rate both reach 5.0% in Q223. Higher borrowing costs derail the economy and unemployment peaks in Q124 at 9.2% in the UK and 9.5% in the US. Given already stretched valuations, the sharp increase in mortgage servicing costs sees house prices decrease very sharply. In the Upside 2 scenario, supply disruptions are resolved, while the aggregate demand is supported by a release of household savings. GDP growth accelerates. Recovering labour force participation limits domestic inflationary pressures, while lower energy prices add some downward pressure on prices globally. The methodology for estimating probability weights used in calculating ECL involves simulating a range of future paths for UK and US GDP using historical data. The five scenarios are mapped against the distribution of these future paths, with the median centred around the Baseline such that scenarios further from the Baseline attract a lower weighting. A single set of five scenarios is used across all portfolios and all five weights are normalised to equate to 100%. The same scenarios and weights that are used in the ECL estimation are also used for Barclays’ internal planning purposes. The impacts across the portfolios are different because of the sensitivities of each of the portfolios to specific macroeconomic variables. For example, mortgages are highly sensitive to house prices; credit cards and unsecured consumer loans are highly sensitive to unemployment. The decrease in the Upside scenario weightings and increase in the Baseline weighting were driven by: (i) continued growth in UK/US GDP which resulted in a narrower range of future GDP paths; and (ii) generally less favourable GDP projections across scenarios, increasing the distance between Upside 2 and Baseline scenario paths. For further details see page 16. COVID-19 related expert judgements have been materially replaced by provisions for customers and clients considered most vulnerable to rising costs and supply chain disruption. The economic uncertainty adjustments of £0.7bn (FY21: £1.0bn) have been applied as overlays to the modelled ECL output. These adjustments consist of a customer uncertainty provision of £0.6bn (FY21: £0.9bn) and a model uncertainty provision of £0.1bn (FY21: £0.1bn). For further details, see pages 11 to 12. The tables below show the key consensus macroeconomic variables used in the scenarios (five-year annual paths), the probability weights applied to each scenario and the macroeconomic variables by scenario using ‘specific bases’, i.e. the most extreme position of each variable in the context of the scenario, for example, the highest unemployment for downside scenarios and the lowest unemployment for upside scenarios. The five-year average table provides additional transparency. Baseline average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 3.9 1.7 1.6 1.6 1.6 UK unemployment 2 4.0 4.1 3.9 3.9 3.9 UK HPI 3 4.3 1.0 2.2 2.5 2.8 UK bank rate 1.5 2.7 2.4 2.1 2.0 US GDP 1 3.3 2.2 2.1 2.1 2.1 US unemployment 4 3.6 3.5 3.5 3.5 3.5 US HPI 5 4.1 3.4 3.4 3.4 3.4 US federal funds rate 1.5 3.2 2.9 2.7 2.5 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 4.9 2.3 1.9 1.7 UK unemployment 2 4.8 4.7 4.5 4.3 4.2 UK HPI 3 4.7 1.0 1.9 1.9 2.3 UK bank rate 0.1 0.8 1.0 1.0 0.8 US GDP 1 5.5 3.9 2.6 2.4 2.4 US unemployment 4 5.5 4.2 3.6 3.6 3.6 US HPI 5 11.8 4.5 5.2 4.9 5.0 US federal funds rate 0.2 0.3 0.9 1.2 1.3 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 3.1 (4.8) (0.4) 4.3 3.6 UK unemployment 2 5.2 8.4 8.6 6.8 5.9 UK HPI 3 0.2 (26.2) (3.6) 17.9 10.2 UK bank rate 1.8 4.7 4.3 2.6 2.3 US GDP 1 2.4 (4.1) (0.2) 3.4 2.7 US unemployment 4 4.6 8.0 9.0 7.1 5.8 US HPI 5 (0.2) (11.7) (0.2) 5.5 3.5 US federal funds rate 1.8 4.8 4.6 3.6 3.0 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 0.2 (4.0) 2.8 4.3 UK unemployment 2 4.8 7.2 9.0 7.6 6.3 UK HPI 3 4.7 (14.3) (21.8) 11.9 15.2 UK bank rate 0.1 2.2 3.9 3.1 2.2 US GDP 1 5.5 (0.8) (3.5) 2.5 3.2 US unemployment 4 5.5 6.4 9.1 8.1 6.4 US HPI 5 11.8 (6.6) (9.0) 5.9 6.7 US federal funds rate 0.2 2.1 3.4 2.6 2.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 1 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 3.5 (1.6) 0.6 3.0 2.6 UK unemployment 2 4.6 6.2 6.2 5.3 4.9 UK HPI 3 2.3 (13.2) (0.8) 10.0 6.5 UK bank rate 1.6 3.8 3.4 2.4 2.0 US GDP 1 2.7 (1.0) 1.1 2.9 2.5 US unemployment 4 4.1 5.7 6.2 5.3 4.6 US HPI 5 1.9 (4.4) 1.6 4.4 3.4 US federal funds rate 1.7 3.9 3.8 3.2 2.8 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 2.8 (0.7) 2.3 2.9 UK unemployment 2 4.8 6.2 6.8 6.0 5.3 UK HPI 3 4.7 (6.8) (10.5) 6.9 8.6 UK bank rate 0.1 1.6 2.7 2.3 1.6 US GDP 1 5.5 1.6 (0.4) 2.4 2.7 US unemployment 4 5.5 5.4 6.6 6.1 5.2 US HPI 5 11.8 (1.2) (2.1) 4.8 5.2 US federal funds rate 0.2 1.3 2.3 2.1 1.8 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Upside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 5.0 5.2 3.1 2.4 2.0 UK unemployment 2 3.8 3.7 3.6 3.6 3.6 UK HPI 3 6.5 11.2 6.2 4.7 3.7 UK bank rate 1.2 1.5 1.4 1.3 1.3 US GDP 1 4.0 4.9 3.6 3.4 3.4 US unemployment 4 3.4 3.0 3.1 3.1 3.1 US HPI 5 5.4 5.5 4.6 4.5 4.5 US federal funds rate 1.1 2.2 1.9 1.7 1.5 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 7.2 4.0 2.7 2.1 UK unemployment 2 4.8 4.5 4.1 4.0 4.0 UK HPI 3 4.7 8.5 9.0 5.2 4.2 UK bank rate 0.1 0.2 0.5 0.5 0.3 US GDP 1 5.5 5.3 4.1 3.5 3.4 US unemployment 4 5.5 3.9 3.4 3.3 3.3 US HPI 5 11.8 10.6 8.5 7.2 6.6 US federal funds rate 0.2 0.3 0.4 0.7 1.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Upside 1 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 4.5 3.5 2.4 2.0 1.8 UK unemployment 2 3.9 3.8 3.8 3.8 3.8 UK HPI 3 5.4 6.3 4.1 3.6 3.2 UK bank rate 1.3 2.0 1.6 1.5 1.5 US GDP 1 3.7 3.7 3.0 2.9 2.9 US unemployment 4 3.5 3.2 3.3 3.3 3.3 US HPI 5 4.7 4.4 4.0 3.9 3.9 US federal funds rate 1.3 2.4 2.2 1.9 1.8 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 6.0 3.1 2.3 1.9 UK unemployment 2 4.8 4.6 4.3 4.2 4.1 UK HPI 3 4.7 5.0 5.0 3.9 3.3 UK bank rate 0.1 0.6 0.8 0.8 0.5 US GDP 1 5.5 4.6 3.4 2.9 2.9 US unemployment 4 5.5 4.0 3.5 3.5 3.5 US HPI 5 11.8 8.3 7.0 6.0 5.7 US federal funds rate 0.2 0.3 0.6 1.0 1.1 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Scenario probability weighting Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 30 June 2022 Scenario probability weighting 14.0 25.6 37.8 15.2 7.4 As at 31 December 2021 Scenario probability weighting 20.9 27.2 30.1 14.8 7.0 Specific bases show the most extreme position of each variable in the context of the scenario, for example, the highest unemployment for downside scenarios, average unemployment for baseline scenarios and lowest unemployment for upside scenarios. GDP and HPI downside and upside scenario data represents the lowest and highest points relative to the start point in the 20 quarter period. Macroeconomic variables (specific bases) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2022 % % % % % UK GDP 2 16.8 12.8 2.1 (1.1) (5.9) UK unemployment 3 3.6 3.8 4.0 6.6 9.2 UK HPI 4 36.7 24.8 2.6 (13.6) (30.8) UK bank rate 3 0.8 0.8 2.1 4.0 5.0 US GDP 2 20.2 16.1 2.4 (0.5) (5.0) US unemployment 3 3.0 3.2 3.5 6.5 9.5 US HPI 4 27.0 22.9 3.5 (2.6) (13.4) US federal funds rate 3 0.3 0.3 2.6 4.1 5.0 As at 31 December 2021 UK GDP 2 21.4 18.3 3.4 (1.6) (1.6) UK unemployment 3 4.0 4.1 4.5 7.0 9.2 UK HPI 4 35.7 23.8 2.4 (12.7) (29.9) UK bank rate 3 0.1 0.1 0.7 2.8 4.0 US GDP 2 22.8 19.6 3.4 1.5 (1.3) US unemployment 3 3.3 3.5 4.1 6.8 9.5 US HPI 4 53.3 45.2 6.2 2.2 (5.0) US federal funds rate 3 0.1 0.1 0.8 2.3 3.5 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 20 quarter period starts from Q122 (2021: Q121). 2 Maximum growth relative to Q421 (2021: Q420), based on 20 quarter period in Upside scenarios; 5-year yearly average Compound Annual Growth Rate (CAGR) in Baseline; minimum growth relative to Q421 (2021: Q420), based on 20 quarter period in Downside scenarios. 3 Lowest quarter in 20 quarter period in Upside scenarios; 5-year average in Baseline; highest quarter 20 quarter period in Downside scenarios.. 4 Maximum growth relative to Q421 (2021: Q420), based on 20 quarter period in Upside scenarios; 5-year quarter end CAGR in Baseline; minimum growth relative to Q421 (2021: Q420), based on 20 quarter period in Downside scenarios. Average basis represents the average quarterly value of variables in the 20 quarter period with GDP and HPI based on yearly average and quarterly CAGRs respectively. Macroeconomic variables (5-year averages) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2022 % % % % % UK GDP 2 3.5 2.8 2.1 1.6 1.1 UK unemployment 3 3.7 3.8 4.0 5.5 7.0 UK HPI 4 6.4 4.5 2.6 0.6 (1.5) UK bank rate 3 1.3 1.6 2.1 2.7 3.1 US GDP 2 3.9 3.2 2.4 1.6 0.8 US unemployment 3 3.1 3.3 3.5 5.2 6.9 US HPI 4 4.9 4.2 3.5 1.4 (0.8) US federal funds rate 3 1.7 1.9 2.6 3.1 3.6 As at 31 December 2021 UK GDP 2 4.4 3.9 3.4 2.7 1.8 UK unemployment 3 4.3 4.4 4.5 5.8 7.0 UK HPI 4 6.3 4.4 2.4 0.3 (2.0) UK bank rate 3 0.3 0.5 0.7 1.7 2.3 US GDP 2 4.4 3.9 3.4 2.4 1.3 US unemployment 3 3.9 4.0 4.1 5.7 7.1 US HPI 4 8.9 7.7 6.2 3.6 1.4 US federal funds rate 3 0.5 0.6 0.8 1.5 2.1 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HPI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. . 2 5-year yearly average CAGR, starting 2021 (2021: 2020). 3 5-year average. Period based on 20 quarters from Q122 (2021: Q121). 4 5-year quarter end CAGR, starting Q421 (2021: Q420). |
Basis of preparation
Basis of preparation | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of initial application of standards or interpretations [abstract] | |
Basis of preparation | Basis of preparation These condensed consolidated interim financial statements (the financial statements) for the six months ended 30 June 2022 have been prepared in accordance with (a) the Disclosure Guidance and Transparency Rules (DTR) of the UK’s Financial Conduct Authority (FCA), and (b) (i) UK adopted IAS 34, Interim Financial Reporting (ii) IAS 34, Interim Financial Reporting, as published by the International Accounting Standards Board (IASB), and (iii) IAS 34, Interim Financial Reporting as adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the European Union (EU). UK adopted IAS 34 and EU adopted IAS 34 are currently the same and were the same as at 30 June 2022. The condensed consolidated interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2021. The annual financial statements for the year ended 31 December 2021 were prepared in accordance the requirements of the Companies Act 2006 and in accordance with (i) UK-adopted international accounting standards (ii) International Financial Reporting Standards (IFRS) and interpretations (IFRICs) as issued by the IASB and (iii) IFRS adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the EU . UK adopted IFRS and EU adopted IFRS are currently the same and were the same as at 31 December 2021. The accounting policies and methods of computation used in these condensed consolidated interim financial statements are the same as those used in the Barclays Bank PLC Annual Report on Form 20-F for the financial year ended 31 December 2021, as amended (the Annual Report 2021). 1. Going concern The financial statements are prepared on a going concern basis, as the Directors are satisfied that the Barclays Bank Group and parent company have the resources to continue in business for a period of at least 12 months from approval of the interim financial statements. In making this assessment, the Directors have considered a wide range of information relating to present and future conditions which includes a review of a working capital report (WCR). The WCR is used by the Directors to assess the future performance of the Barclays Bank Group and that it has the resources in place that are required to meet its ongoing regulatory requirements. The WCR includes an assessment of the impact of internally generated stress testing scenarios on the liquidity and capital requirements forecasts. The stress tests used were based upon an assessment of reasonably possible downside economic scenarios that the Barclays Bank Group could experience. The WCR indicated that the Barclays Bank Group had sufficient capital in place to support its future business requirements and remained above its regulatory minimum requirements in the internal stress scenarios. 2. Other disclosures The Credit risk disclosures on pages 7 to 18 form part of these interim financial statements. Restatement of financial statements The comparatives in these condensed consolidated interim financial statements for the six months ended 30 June 2022 (the financial statements) have been restated to reflect both a provision and contingent liability disclosure in respect of the impact of an over-issuance of securities (Over-issuance of Securities) in excess of the maximum aggregate offering price registered under Barclays Bank PLC’s shelf registration statement on Form F-3, as declared effective by the SEC in August 2019 (2019 F-3) and Barclays Bank PLC’s predecessor shelf registration statement on Form F-3 filed in 2018 (Predecessor Shelf). Due to a historic SEC settlement order, at the time the 2019 F-3 was filed and the Predecessor Shelf was amended, Barclays Bank PLC had ceased to be a “well-known seasoned issuer” (or WKSI) and had become an “ineligible issuer”, as defined in Rule 405 under the Securities Act of 1933, as amended (Securities Act), thus being required to register upfront a certain amount of securities with the SEC. In March 2022, Barclays Bank PLC became aware that it had issued securities in the US materially in excess of the amount it had registered with the SEC under the 2019 F-3 and subsequently became aware that securities had also been issued in excess of the amount it had registered with the SEC under the Predecessor Shelf. The securities that were issued in this period comprise structured notes and exchange traded notes (ETNs). As such, certain offers and sales of these securities were not made in compliance with the Securities Act, giving rise to rights of rescission for certain purchasers of the securities. Under Section 12(a)(1) of the Securities Act, certain purchasers of unregistered securities have a right to recover, upon the tender of such security, the consideration paid for such security with interest, less the amount of any income received, or damages if the purchaser no longer owns the security (the Rescission Price). As a result, Barclays Bank PLC has elected to make a rescission offer to eligible purchasers of the relevant affected securities at the Rescission Price (the Rescission Offer). A proportion of the expected costs associated with the rights of rescission of certain investors are attributable to Barclays Bank PLC’s financial statements for the year ended 31 December 2021. Accordingly, the comparatives in these financial statements have been restated. The restatement impacts the consolidated income statement, the parent company income statement, the consolidated statement of comprehensive income, the parent company statement of comprehensive income, the consolidated balance sheet, the parent company balance sheet, the consolidated statement of changes in equity, the parent company statement of changes in equity, the consolidated cash flow statement, and the parent company cash flow statement for the year ended 31 December 2021, as well as half yearly financial information that is presented within this document. There was no material effect on Barclays Bank PLC’s previously reported financial statements for the years ended 31 December 2020 and 2019. The table below reflects each of the consolidated financial statement line items that were affected by the restatement: For the half year ended 30 June 2021 Impact on the consolidated income statement As reported £m Restatement £m As restated £m Litigation and conduct (87) (77) (164) Operating expenses (5,146) (77) (5,223) Profit before tax 3,334 (77) 3,257 Taxation (611) 17 (594) Profit after tax 2,723 (60) 2,663 For the half year ended 30 June 2021 Impact on the consolidated statement of comprehensive income As reported £m Restatement £m As restated £m Profit after tax 2,723 (60) 2,663 Total comprehensive income for the year 1,092 (60) 1,032 For the half year ended 30 June 2021 Impact on the consolidated cash flow statement As reported £m Restatement £m As restated £m Profit before tax 3,334 (77) 3,257 Adjustment for non-cash items 5,001 77 5,078 For the year ended 31 December 2021 Impact on the consolidated income statement As reported £m Restatement £m As restated £m Litigation and conduct (154) (220) (374) Operating expenses (10,039) (220) (10,259) Profit before tax 5,638 (220) 5,418 Taxation (880) 50 (830) Profit after tax 4,758 (170) 4,588 For the year ended 31 December 2021 Impact on the consolidated balance sheet As reported £m Restatement £m As restated £m Liabilities Current tax liabilities 738 (50) 688 Provisions 890 220 1,110 Total liabilities 1,005,291 170 1,005,461 Equity Retained earnings 43,585 (170) 43,415 Total equity 56,487 (170) 56,317 The table below reflects each of the line items of the parent company financial statements that were affected by the restatement: For the year ended 31 December 2021 Impact on the parent company balance sheet As reported £m Restatement £m As restated £m Liabilities Current tax liabilities 392 (50) 342 Provisions 699 220 919 Total liabilities 1,011,809 170 1,011,979 Equity Retained earnings 37,350 (170) 37,180 Total equity 52,862 (170) 52,692 The financial impact of the restatement has been reflected in Notes 2, 4, 8 and 17. |
Segmental reporting
Segmental reporting | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of operating segments [abstract] | |
Segmental reporting | Segmental reporting Analysis of results by business Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.22 £m £m £m £m Total income 8,086 1,992 (88) 9,990 Credit impairment (charge)/release (31) (278) 16 (293) Net operating income/(expense) 8,055 1,714 (72) 9,697 Operating expenses (3,912) (1,285) (62) (5,259) Litigation and conduct (1,632) (200) (1) (1,833) Total operating expenses (5,544) (1,485) (63) (7,092) Other net income 2 — — — — Profit/(loss) before tax 2,511 229 (135) 2,605 As at 30.06.22 £bn £bn £bn £bn Total assets 1,179.5 80.4 12.8 1,272.7 Restated 1 Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.21 £m £m £m £m Total income 6,632 1,649 (92) 8,189 Credit impairment release 260 22 6 288 Net operating income/(expense) 6,892 1,671 (86) 8,477 Operating expenses (3,617) (1,126) (316) (5,059) Litigation and conduct (79) (82) (3) (164) Total operating expenses (3,696) (1,208) (319) (5,223) Other net income 2 3 — — 3 Profit/(loss) before tax 3,199 463 (405) 3,257 As at 31.12.21 £bn £bn £bn £bn Total assets 986.2 64.4 11.2 1,061.8 1 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. 2 Other net income represents the share of post-tax results of associates and joint ventures and profit (or loss) on disposal of subsidiaries, associates and joint ventures. Split of income by geographic region 1 Half year ended 30.06.22 Half year ended 30.06.21 £m £m United Kingdom 4,674 2,698 Europe 1,310 1,213 Americas 3,276 3,676 Africa and Middle East 31 20 Asia 699 582 Total 9,990 8,189 1 The geographical analysis is based on the location of the office where the transactions are recorded. |
Net fee and commission income
Net fee and commission income | 6 Months Ended |
Jun. 30, 2022 | |
Fee and commission income (expense) [abstract] | |
Net fee and commission income | Net fee and commission income Fee and commission income is disaggregated below and includes a total for fees in scope of IFRS 15, Revenue from Contracts with Customers: Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.22 £m £m £m £m Fee type Transactional 216 1,229 — 1,445 Advisory 440 72 — 512 Brokerage and execution 734 28 — 762 Underwriting and syndication 1,101 — — 1,101 Other 30 78 11 119 Total revenue from contracts with customers 2,521 1,407 11 3,939 Other non-contract fee income 67 2 — 69 Fee and commission income 2,588 1,409 11 4,008 Fee and commission expense 1 (461) (707) (1) (1,169) Net fee and commission income 2,127 702 10 2,839 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.21 £m £m £m £m Fee type Transactional 184 984 — 1,168 Advisory 399 61 — 460 Brokerage and execution 527 26 — 553 Underwriting and syndication 1,715 — — 1,715 Other 25 76 11 112 Total revenue from contracts with customers 2,850 1,147 11 4,008 Other non-contract fee income 59 3 — 62 Fee and commission income 2,909 1,150 11 4,070 Fee and commission expense 1 (369) (496) (5) (870) Net fee and commission income 2,540 654 6 3,200 Note 1. Barclays Bank Group has corrected the presentation of the scheme fees incurred when Barclays acts as an “acquirer” as part of the payment transaction cycle. From 2022 onwards, the scheme fees reported under "Consumer, Cards and Payments" are presented within fees and commission income under “Transactional” fee type, which had previously been recognised in fees and commission expense. The reclassification into Fee and Commission income is a reduction of £94m for H122. The comparatives have not been restated as the effect is not considered material although the effect would have been a reduction of H121: £81m with no impact on Net fee and commission income. There is no impact on Net assets or Cash flows reported. Transactional fees are service charges on deposit accounts, cash management services and transactional processing fees. These include interchange and merchant fee income generated from credit and bank card usage. Advisory fees are generated from wealth management services and investment banking advisory services related to mergers, acquisitions and financial restructurings. Brokerage and execution fees are earned for executing client transactions with various exchanges and over-the-counter markets and assisting clients in clearing transactions. Underwriting and syndication fees are earned for the distribution of client equity or debt securities, and the arrangement and administration of a loan syndication. These include commitment fees to provide loan financing. |
Tax
Tax | 6 Months Ended |
Jun. 30, 2022 | |
Major components of tax expense (income) [abstract] | |
Tax | Tax The tax charge for H122 was £476m (restated 1 H121: £594m), representing an effective tax rate (ETR) of 18.3% (restated H121: 18.2%). The ETR for H122 includes a charge recognised for the re-measurement of the Barclays Bank Group’s UK deferred tax assets (DTAs) due to the enactment of legislation in Q122 which will result in the UK banking surcharge rate being reduced from 8% to 3% effective from 1 April 2023. The ETR excluding the impact of this downward re-measurement of UK DTAs was 11.2% which includes a 5.7% benefit relating to adjustments in respect of prior years. The H121 ETR included a benefit recognised for the re-measurement of the Barclays Bank Group’s UK DTAs as a result of the enactment of legislation to increase the UK corporation tax rate to 25% effective from 1 April 2023. The re-measurement of UK DTAs has resulted in the Barclays Bank Group’s UK DTAs decreasing by £100m with a tax charge in the income statement of £183m and a tax credit within other comprehensive income of £83m. In October 2021, the OECD and G20 Inclusive Framework on Base Erosion and Profit Shifting announced plans to introduce a global minimum tax rate of 15%. The model rules were released by the OECD in December 2021 with further guidance published in March 2022. Draft legislation published by the UK government on 20 July 2022 to implement the global minimum tax regime is expected to apply for accounting periods beginning on or after 31 December 2023. The Barclays Bank Group is reviewing the published OECD model rules and guidance and will review further guidance as well as new legislation to be released by governments implementing this new tax regime to assess the potential impact of new legislation. In the USA, the proposed Build Back Better Act was passed by the House of Representatives in 2021 but it was not passed by the Senate and it is uncertain whether various proposals contained in the Act will progress further. The Act included proposals to implement material changes to international tax provisions, including amendments to the Base Erosion and Anti-Abuse Tax and the imposition of an alternative minimum tax based on accounting profits. It is unclear at this time whether any of these proposals could have a significant impact on the Barclays Bank Group if enacted. The Barclays Bank Group will continue to monitor developments and assess the potential impact of any future legislative changes ultimately enacted. 1. 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Basis of preparation on page 29 for more details. As at 30.06.22 As at 31.12.21 Deferred tax assets and liabilities £m £m USA 1,530 2,006 UK 1,084 576 Other territories 438 399 Deferred tax assets 3,052 2,981 Deferred tax liabilities — (6) Analysis of deferred tax assets Temporary differences 1,911 1,785 Tax losses 1,141 1,196 Deferred tax assets 3,052 2,981 |
Dividends on ordinary shares
Dividends on ordinary shares | 6 Months Ended |
Jun. 30, 2022 | |
Dividends on ordinary shares [Abstract] | |
Dividends on ordinary shares | Dividends on ordinary shares Half year ended 30.06.22 Half year ended 30.06.21 Dividends paid during the period £m £m Ordinary shares 200 694 Preference shares 15 13 Total 215 707 |
Fair value of financial instrum
Fair value of financial instruments | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of fair value measurement of assets [abstract] | |
Fair value of financial instruments | Fair value of financial instruments This section should be read in conjunction with Note 16, Fair value of financial instruments of the Barclays Bank PLC Annual Report 2021, which provides more detail about accounting policies adopted, valuation methodologies used in calculating fair value and the valuation control framework which governs oversight of valuations. There have been no changes in the accounting policies adopted or the valuation methodologies used. Valuation The following table shows the Barclays Bank Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Valuation technique using Quoted market prices Observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Total As at 30.06.22 £m £m £m £m Trading portfolio assets 58,340 64,300 4,256 126,896 Financial assets at fair value through the income statement 1,037 203,230 6,163 210,430 Derivative financial instruments 11,653 328,870 3,873 344,396 Financial assets at fair value through other comprehensive income 15,993 27,785 36 43,814 Investment property — — 5 5 Total assets 87,023 624,185 14,333 725,541 Trading portfolio liabilities (47,118) (28,680) (82) (75,880) Financial liabilities designated at fair value (193) (255,155) (439) (255,787) Derivative financial instruments (12,674) (304,473) (4,379) (321,526) Total liabilities (59,985) (588,308) (4,900) (653,193) As at 31.12.21 Trading portfolio assets 80,836 63,754 2,281 146,871 Financial assets at fair value through the income statement 4,953 177,194 6,079 188,226 Derivative financial instruments 6,150 252,131 4,010 262,291 Financial assets at fair value through other comprehensive income 16,070 29,800 38 45,908 Investment property — — 7 7 Total assets 108,009 522,879 12,415 643,303 Trading portfolio liabilities (26,701) (26,563) (27) (53,291) Financial liabilities designated at fair value (174) (250,553) (404) (251,131) Derivative financial instruments (6,571) (243,893) (6,059) (256,523) Total liabilities (33,446) (521,009) (6,490) (560,945) The following table shows the Barclays Bank Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: As at 30.06.22 As at 31.12.21 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 1,573 (1,849) 1,091 (1,351) Foreign exchange derivatives 786 (560) 376 (374) Credit derivatives 234 (615) 323 (709) Equity derivatives 1,280 (1,355) 2,220 (3,625) Corporate debt 1,171 (13) 1,205 (21) Reverse repurchase and repurchase agreements 178 (188) 13 (172) Non-asset backed loans 6,435 — 3,743 — Asset backed securities 291 — 558 — Equity cash products 422 (3) 393 — Private equity investments 123 — 148 — Other 1 1,840 (317) 2,345 (238) Total 14,333 (4,900) 12,415 (6,490) 1. Other includes commercial real estate loans, fund and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. Assets and liabilities reclassified between Level 1 and Level 2 During the period there were no material transfers between Level 1 and Level 2 (year ended December 2021: no material transfers between Level 1 and Level 2). Level 3 movement analysis The following table summarises the movements in the balances of Level 3 assets and liabilities during the period. The table shows gains and losses and includes amounts for all financial assets and liabilities that are held at fair value transferred to and from Level 3 during the period. Transfers have been reflected as if they had taken place at the beginning of the period. Asset and liability moves between Level 2 and Level 3 are primarily due to i) an increase or decrease in observable market activity related to an input or ii) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.22 As at 01.01.22 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 389 90 (144) — (17) 54 — — 43 (11) 404 Non-asset backed loans 758 2,448 (459) — — 11 — — 50 (113) 2,695 Asset backed securities 454 72 (80) — (297) (20) — — 100 (66) 163 Equity cash products 303 21 (56) — — 24 — — 52 (17) 327 Other 377 326 (42) — (5) 56 — — 39 (84) 667 Trading portfolio assets 2,281 2,957 (781) — (319) 125 — — 284 (291) 4,256 Non-asset backed loans 2,985 1,848 (757) — (315) (76) — — 52 — 3,737 Equity cash products 84 — — — — 3 2 — — — 89 Private equity investments 148 19 (60) — — 7 11 — 3 (4) 124 Other 2,862 4,817 (5,579) — (155) 9 179 — 99 (19) 2,213 Financial assets at fair value through the income statement 6,079 6,684 (6,396) — (470) (57) 192 — 154 (23) 6,163 Asset backed securities 38 — — — — — — (2) — — 36 Financial assets at fair value through other comprehensive income 38 — — — — — — (2) — — 36 Investment property 7 — (1) — — — (1) — — — 5 Trading portfolio liabilities (27) (35) 3 — — (29) — — — 6 (82) Financial liabilities designated at fair value (404) (5) — (13) 47 (22) 2 — (81) 37 (439) Interest rate derivatives (260) 25 — — (4) (305) (9) — 271 6 (276) Foreign exchange derivatives 2 — — — (9) 273 — — (65) 25 226 Credit derivatives (386) (36) 5 — 60 (99) — — 20 55 (381) Equity derivatives (1,405) (83) — — 170 980 — — (9) 272 (75) Net derivative financial instruments 1 (2,049) (94) 5 — 217 849 (9) — 217 358 (506) Total 5,925 9,507 (7,170) (13) (525) 866 184 (2) 574 87 9,433 1. Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £3,873m and derivative financial liabilities were £4,379m. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.21 As at 01.01.21 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 305 (87) — — 25 — — 40 (11) 423 Non-asset backed loans 709 620 (131) — (84) 13 — — 124 (106) 1,145 Asset backed securities 686 112 (294) — — (10) — — 43 (48) 489 Equity cash products 214 13 (17) — — 32 — — 29 (9) 262 Other 103 21 — — (51) (1) — — 162 (1) 233 Trading portfolio assets 1,863 1,071 (529) — (135) 59 — — 398 (175) 2,552 Non-asset backed loans 2,280 696 (299) — (388) 10 — — 69 (47) 2,321 Equity cash products 320 166 (194) — — (171) 18 — — — 139 Private equity investments 88 22 (7) — (7) (1) 3 — — — 98 Other 1,704 2,296 (2,389) — (160) (19) 1 — 16 — 1,449 Financial assets at fair value through the income statement 4,392 3,180 (2,889) — (555) (181) 22 — 85 (47) 4,007 Non-asset backed loans 106 — — — — — — — — (106) — Asset backed securities 47 — — — (5) — — 1 — — 43 Financial assets at fair value through other comprehensive income 153 — — — (5) — — 1 — (106) 43 Investment property 10 — (2) — — — — — — — 8 Trading portfolio liabilities (28) (3) 14 — — (7) — — — 7 (17) Financial liabilities designated at fair value (341) — — — 98 7 — — (78) 18 (296) Interest rate derivatives (2) 9 — — 33 (121) 4 — 21 (296) (352) Foreign exchange derivatives 1 — — — 58 (6) — — 3 (34) 22 Credit derivatives (155) (118) 2 — (5) 12 (1) — 1 (1) (265) Equity derivatives (1,615) (315) (1) — (32) (221) — — 28 808 (1,348) Net derivative financial instruments 1 (1,771) (424) 1 — 54 (336) 3 — 53 477 (1,943) Total 4,278 3,824 (3,405) — (543) (458) 25 1 458 174 4,354 1. Derivative financial instruments are presented on a net basis. On a gross basis, derivative financial assets were £3,656m and derivative financial liabilities were £5,599m. Unrealised gains and losses on Level 3 financial assets and liabilities The following table discloses the unrealised gains and losses recognised in the period arising on Level 3 financial assets and liabilities held at the period end. Half year ended 30.06.22 Half year ended 30.06.21 Income statement Other compre-hensive income Total Income statement Other compre-hensive income Total Trading income Other income Trading income Other income £m £m £m £m £m £m £m £m Trading portfolio assets 121 — — 121 35 — — 35 Financial assets at fair value through the income statement 16 9 — 25 (67) 35 — (32) Financial assets at fair value through other comprehensive income — — (2) (2) — — — — Investment properties — (1) — (1) — — — — Trading portfolio liabilities (35) — — (35) (6) — — (6) Financial liabilities designated at fair value (14) — — (14) 7 — — 7 Net derivative financial instruments 862 (1) — 861 (367) — — (367) Total 950 7 (2) 955 (398) 35 — (363) Valuation techniques and sensitivity analysis Sensitivity analysis is performed on products with significant unobservable inputs (Level 3) to generate a range of reasonably possible alternative valuations. The sensitivity methodologies applied take account of the nature of valuation techniques used, as well as the availability and reliability of observable proxy and historical data and the impact of using alternative models. Sensitivity analysis of valuations using unobservable inputs As at 30.06.22 As at 31.12.21 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income Statement Equity Income statement Equity Income Statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 75 — (108) — 51 — (79) — Foreign exchange derivatives 15 — (22) — 20 — (28) — Credit derivatives 111 — (115) — 112 — (103) — Equity derivatives 107 — (112) — 181 — (190) — Corporate debt 36 — (35) — 38 — (28) — Non-asset backed loans 233 — (260) — 99 — (150) — Equity cash products 56 — (112) — 25 — (42) — Private equity investments 9 — (9) — 10 — (11) — Other 1 27 — (36) — 19 — (20) — Total 669 — (809) — 555 — (651) — 1 Other includes commercial real estate loans, fund and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. The effect of stressing unobservable inputs to a range of reasonably possible alternatives, alongside considering the impact of using alternative models, would be to increase fair values by up to £669m (December 2021: £555m) or to decrease fair values by up to £809m (December 2021: £651m) with substantially all the potential effect impacting profit and loss rather than reserves. Significant unobservable inputs The valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 are consistent with those described within Note 16, Fair value of financial instruments in the Barclays Bank PLC Annual Report 2021. Fair value adjustments Key balance sheet valuation adjustments are quantified below: As at 30.06.22 As at 31.12.21 £m £m Exit price adjustments derived from market bid-offer spreads (531) (498) Uncollateralised derivative funding (82) (127) Derivative credit valuation adjustments (388) (212) Derivative debit valuation adjustments 208 91 • Exit price adjustments derived from market bid-offer spreads increased by £33m to £531m as a result of movements in market bid offer spreads. • Uncollateralised derivative funding decreased by £45m to £82m as a result of reduction in uncollateralised funding exposure due to increases in interest rates which offset the impact of wider funding spreads. • Derivative credit valuation adjustments decreased by £176m to £388m as a result of widening input counterparty credit spreads. • Derivative debit valuation adjustments decreased by £117m to £208m as a result of widening in input own credit spreads. Portfolio exemption The Barclays Bank Group uses the portfolio exemption in IFRS 13, Fair Value Measurement to measure the fair value of groups of financial assets and liabilities. Instruments are measured using the price that would be received to sell a net long position (i.e. an asset) for a particular risk exposure or to transfer a net short position (i.e. a liability) for a particular risk exposure in an orderly transaction between market participants at the balance sheet date under current market conditions. Accordingly, the Barclays Bank Group measures the fair value of the group of financial assets and liabilities consistently with how market participants would price the net risk exposure at the measurement date. Unrecognised gains as a result of the use of valuation models using unobservable inputs The amount that has yet to be recognised in income that relates to the difference between the transaction price (the fair value at initial recognition) and the amount that would have arisen had valuation models using unobservable inputs been used on initial recognition, less amounts subsequently recognised, is £106m (December 2021: £122m) for financial instruments measured at fair value and £27m (December 2021: £28m) for financial instruments carried at amortised cost. There are additions and FX gains of £19m (December 2021: £59m) and amortisation and releases of £35m (December 2021: £40m) for financial instruments measured at fair value and amortisation and releases of £1m (December 2021: £2m) offset by additions of £nil (December 2021: £nil) for financial instruments carried at amortised cost. Third party credit enhancements Structured and brokered certificates of deposit issued by the Barclays Bank Group are insured up to $250,000 per depositor by the Federal Deposit Insurance Corporation (FDIC) in the United States. The FDIC is funded by premiums that the Barclays Bank Group and other banks pay for deposit insurance coverage. The carrying value of these issued certificates of deposit that are designated under the IFRS 9 fair value option includes this third party credit enhancement. The on-balance sheet value of these brokered certificates of deposit amounted to £3,065m (December 2021: £790m). Comparison of carrying amounts and fair values for assets and liabilities not held at fair value Valuation methodologies employed in calculating the fair value of financial assets and liabilities measured at amortised cost are consistent with those described within Note 16, Fair value of financial instruments in the Barclays Bank PLC Annual Report 2021. The following table summarises the fair value of financial assets and liabilities measured at amortised cost on the Barclays Bank Group’s balance sheet: As at 30.06.22 As at 31.12.21 Carrying amount Fair value Carrying amount Fair value Financial assets £m £m £m £m Loans and advances at amortised cost 180,098 180,103 145,259 145,665 Reverse repurchase agreements and other similar secured lending 1,060 1,060 3,177 3,177 Financial liabilities Deposits at amortised cost (311,465) (311,455) (262,828) (262,843) Repurchase agreements and other similar secured borrowing (12,805) (12,807) (12,769) (12,776) Debt securities in issue (68,656) (68,504) (48,388) (48,350) Subordinated liabilities (32,241) (32,230) (32,185) (33,598) |
Subordinated liabilities
Subordinated liabilities | 6 Months Ended |
Jun. 30, 2022 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Subordinated liabilities Half year ended 30.06.22 Year ended 31.12.21 £m £m Opening balance 32,185 32,005 Issuances 4,803 9,099 Redemptions (4,221) (7,241) Other (526) (1,678) Closing balance 32,241 32,185 Designated at fair value (Note 6) 580 483 Total subordinated liabilities 32,821 32,668 Issuances of £4,803m comprise £4,544m of intra-group loans from Barclays PLC and £128m USD Floating Rate Notes, £89m ZAR Floating Rate Notes and £42m EUR Floating Rate Notes issued externally by Barclays Bank PLC subsidiaries. Redemptions of £4,221m comprise £3,087m of intra-group loans from Barclays PLC, £1,060m notes issued externally by Barclays Bank PLC and £74m USD Floating Rate Notes issued externally by a Barclays Bank PLC subsidiary. £1,060m notes issued externally by Barclays Bank PLC comprise £838m EUR 6.625% Fixed Rate Subordinated Notes, £147m USD 6.86% Callable Perpetual Core Tier One Notes, £42m EUR Subordinated Floating Rate Notes, £21m GBP Undated Floating Rate Primary Capital Notes and £12m GBP 6% Callable Perpetual Core Tier One Notes. Other movements predominantly comprise foreign exchange movements and fair value hedge adjustments. |
Provisions
Provisions | 6 Months Ended |
Jun. 30, 2022 | |
Provisions [abstract] | |
Provisions | Provisions Restated 1 As at 30.06.22 As at 31.12.21 £m £m Customer redress 1,629 266 Legal, competition and regulatory matters 406 211 Redundancy and restructuring 23 46 Undrawn contractually committed facilities and guarantees 487 499 Onerous contracts — 2 Sundry provisions 100 86 Total 2,645 1,110 1. 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. Over-issuance of Securities As at 30 June 2022, Barclays Bank PLC has recognised a balance sheet provision of £1,757m (December 2021: £220m) in relation to the Over-issuance of Securities (see Basis of preparation on page 29 for more information), out of which £1,592m (December 2021: £220m) is due to the over-issuance of structured notes (within customer redress), and £165m (December 2021: £nil) is in relation to liabilities that could be incurred arising out of ongoing discussions in respect of a potential SEC resolution (within legal, competition and regulatory matters). The amount of the provision in relation to the rescission rights of investors in over-issued structured notes is determined by (among other things) the market value of the structured notes subject to the Rescission Offer, participation rates in such Rescission Offer, prevailing interest rates, and movements in foreign exchange rates. The majority of the structured notes subject to the Rescission Offer provide an equity linked return to investors. As such, the value of these notes is highly sensitive to movements in the price of individual securities and a range of indices. The increase in the provision of £1,372m predominantly reflects a reduction in the market value of the structured notes and additional accrued interest that would be payable to investors on rescission. The US equity markets have been volatile during the first half of 2022, with significant reductions in the value of US equity indices such as the S&P 500 from the year end 2021 levels which has led to a reduction in the market value of the structured notes, and increased the size of the provision. The provision does not include the impact of market hedges that have been entered into subsequent to the year-end and were initiated from the end of the first quarter of 2022 to reduce the net volatility to the income statement. When determining these market hedges, consideration was given to changes in the rescission costs which would arise from volatility in the market along with the positioning of the Markets business. The structured notes also accrue interest on a monthly basis (at current prevailing interest rates and participation rate assumptions this is c£34m a month) until the Rescission Price has been paid. The provision also assumes that not all structured note investors whose securities are out of the money will accept the Rescission Offer. If all investors were to accept the Rescission Offer, the provision would increase by c£60m. The remaining increase in the provision of £165m results from Barclays Bank PLC’s estimates of the potential SEC resolution. |
Retirement benefits
Retirement benefits | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of defined benefit plans [abstract] | |
Retirement benefits | Retirement benefits As at 30 June 2022, the Barclays Bank Group’s IAS 19 net pension surplus across all schemes was £5bn (December 2021: £3.6bn). The UK Retirement Fund (UKRF), which is the Barclays Bank Group’s main scheme, had an IAS 19 net pension surplus of £5.2bn (December 2021: £3.8bn). The movement for the UKRF was driven by an overall increase in AA corporate bond yields (used for discounting future liabilities), a reduction in long-term expected price inflation assumption and the payment of deficit reduction contributions. These movements were partially offset by the fall in the value of UKRF's assets and the impact of high recent inflation on the liabilities. UKRF funding valuations The latest annual update as at 30 September 2021 showed the funding position had improved to a surplus of £0.6bn from a deficit of £0.9bn shown as at 30 September 2020. The improvement was mainly due to £0.7bn of deficit reduction contributions and favourable asset returns, partially offset by higher expected long term price inflation. The deficit recovery plan agreed at the last triennial valuation requires deficit reduction contributions from Barclays Bank PLC of £294m in 2022 and £286m in 2023. The deficit reduction contributions are in addition to the regular contributions to meet the Group’s share of the cost of benefits accruing over each year. £147m of the 2022 deficit reduction contributions were paid in April, with the remaining £147m for 2022 due in September. The next triennial actuarial valuation of the UKRF is due to be completed in 2023 with an effective date of 30 September 2022. |
Called up share capital
Called up share capital | 6 Months Ended |
Jun. 30, 2022 | |
Equity [abstract] | |
Called up share capital | Called up share capital Ordinary shares As at 30 June 2022 the issued ordinary share capital of Barclays Bank PLC comprised 2,342m (December 2021: 2,342m) ordinary shares of £1 each. Preference shares As at 30 June 2022 the issued preference share capital of Barclays Bank PLC of £6m (December 2021: £6m) comprised 1,000 Sterling Preference Shares of £1.00 each (December 2021: 1000); 31,856 Euro Preference Shares of €100 each (December 2021: 31,856); and 58,133 US Dollar Preference shares of $100 each (December 2021: 58,133). There were no issuances or redemptions of ordinary or preference shares in the six months to 30 June 2022. |
Other equity instruments
Other equity instruments | 6 Months Ended |
Jun. 30, 2022 | |
Miscellaneous components of equity [abstract] | |
Other equity instruments | Other equity instruments Other equity instruments of £9,794m (December 2021: £9,693m) are AT1 securities issued to Barclays PLC. Barclays PLC uses funds from market issuances to purchase AT1 securities from Barclays Bank PLC. There was one issuance and one redemption in the six months to 30 June 2022. The AT1 securities are perpetual securities with no fixed maturity and are structured to qualify as AT1 instruments under prevailing capital rules applicable as at the relevant issue date. AT1 securities are undated and are redeemable, at the option of Barclays Bank PLC, in whole on (i) the initial call date, or on any fifth anniversary after the initial call date or (ii) any day falling in a named period ending on the initial reset date, or on any fifth anniversary after the initial reset date. In addition, the AT1 securities are redeemable, at the option of Barclays Bank PLC, in whole in the event of certain changes in the tax or regulatory treatment of the securities. Any redemptions require the prior consent of the PRA. |
Other reserves
Other reserves | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | Other reserves As at 30.06.22 As at 31.12.21 £m £m Currency translation reserve 4,589 2,581 Fair value through other comprehensive income reserve (917) (118) Cash flow hedging reserve (3,492) (618) Own credit reserve (103) (960) Other reserves (24) (24) Total 53 861 Currency translation reserve The currency translation reserve represents the cumulative gains and losses on the retranslation of the Barclays Bank Group’s net investment in foreign operations, net of the effects of hedging. As at 30 June 2022, there was a credit balance of £4,589m (December 2021: £2,581m credit) in the currency translation reserve. The £2,008m credit movement principally reflects the weakening of GBP against USD during the period. Fair value through other comprehensive income reserve The fair value through other comprehensive income reserve represents the fair value changes of fair value through other comprehensive income investments since initial recognition. As at 30 June 2022, there was a debit balance of £917m (December 2021: £118m debit) in the fair value through other comprehensive income reserve. The loss of £799m is principally driven by a £1,083m loss from the decrease in fair value of bonds due to increasing bond yields which was partially offset by a tax credit of £284m. Cash flow hedging reserve The cash flow hedging reserve represents the cumulative gains and losses on effective cash flow hedging instruments that will be recycled to the income statement when the hedged transactions affect profit or loss. As at 30 June 2022, there was a debit balance of £3,492m (December 2021: £618m debit) in the cash flow hedging reserve. The decrease of £2,874m principally reflects a £3,908m decrease in the fair value of interest rate swaps held for hedging purposes as major interest rate forward curves increased. This is partially offset by a tax credit of £1,032m. Own credit reserve The own credit reserve reflects the cumulative own credit gains and losses on financial liabilities at fair value. Amounts in the own credit reserve are not recycled to profit or loss in future periods. As at 30 June 2022, there was a debit balance of £103m (December 2021: £960m debit) in the own credit reserve. The movement of £857m principally reflects a £1,258m gain from the widening of Barclays funding spreads partially offset by a tax charge of £403m. Other reserves As at 30 June 2022, there was a debit balance of £24m (December 2021: £24m debit) in other reserves relating to redeemed ordinary and preference shares issued by Barclays Bank Group. |
Contingent liabilities and comm
Contingent liabilities and commitments | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | Contingent liabilities and commitments As at 30.06.22 As at 31.12.21 Contingent liabilities and financial guarantees £m £m Guarantees and letters of credit pledged as collateral security 16,743 15,759 Performance guarantees, acceptances and endorsements 7,532 7,987 Total 24,275 23,746 Commitments Documentary credits and other short-term trade related transactions 1,888 1,584 Standby facilities, credit lines and other commitments 334,483 282,867 Total 336,371 284,451 Further details on contingent liabilities, where it is not practicable to disclose an estimate of the potential financial effect on the Barclays Bank Group relating to legal and competition and regulatory matters can be found in Note 14. |
Legal, competition and regulato
Legal, competition and regulatory matters | 6 Months Ended |
Jun. 30, 2022 | |
Legal, competition and regulatory matters | |
Legal, competition and regulatory matters | Legal, competition and regulatory matters The Barclays Bank Group faces legal, competition and regulatory challenges, many of which are beyond our control. The extent of the impact of these matters cannot always be predicted but may materially impact our operations, financial results, condition and prospects. Matters arising from a set of similar circumstances can give rise to either a contingent liability or a provision, or both, depending on the relevant facts and circumstances. The recognition of provisions in relation to such matters involves critical accounting estimates and judgments in accordance with the relevant accounting policies applicable to Note 8, Provisions. We have not disclosed an estimate of the potential financial impact or effect on the Barclays Bank Group of contingent liabilities where it is not currently practicable to do so. Various matters detailed in this note seek damages of an unspecified amount. While certain matters specify the damages claimed, such claimed amounts do not necessarily reflect the Barclays Bank Group’s potential financial exposure in respect of those matters. Investigations into certain advisory services agreements FCA proceedings In 2008, Barclays Bank PLC and Qatar Holdings LLC entered into two advisory service agreements (the Agreements). The Financial Conduct Authority (FCA) conducted an investigation into whether the Agreements may have related to Barclays PLC’s capital raisings in June and November 2008 (the Capital Raisings) and therefore should have been disclosed in the announcements or public documents relating to the Capital Raisings. In 2013, the FCA issued warning notices (the Notices) finding that Barclays PLC and Barclays Bank PLC acted recklessly and in breach of certain disclosure-related listing rules, and that Barclays PLC was also in breach of Listing Principle 3. The financial penalty provided in the Notices is £50m. Barclays PLC and Barclays Bank PLC continue to contest the findings. Following the conclusion of the Serious Fraud Office (SFO) proceedings against certain former Barclays executives resulting in their acquittals, the FCA proceedings, which were stayed, have resumed. A hearing took place before the Regulatory Decisions Committee in the first quarter of 2022 and a decision is expected in the second half of 2022. Investigations into LIBOR and other benchmarks and related civil actions Regulators and law enforcement agencies, including certain competition authorities, from a number of governments have conducted investigations relating to Barclays Bank PLC’s involvement in allegedly manipulating certain financial benchmarks, such as LIBOR. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Barclays Bank Group and other banks in relation to the alleged manipulation of LIBOR and/or other benchmarks. USD LIBOR civil actions The majority of the USD LIBOR cases, which have been filed in various US jurisdictions, have been consolidated for pre-trial purposes in the US District Court in the Southern District of New York (SDNY). The complaints are substantially similar and allege, among other things, that Barclays PLC, Barclays Bank PLC, BCI and other financial institutions individually and collectively violated provisions of the US Sherman Antitrust Act (Antitrust Act), the US Commodity Exchange Act (CEA), the US Racketeer Influenced and Corrupt Organizations Act (RICO), the Securities Exchange Act of 1934 and various state laws by manipulating USD LIBOR rates. Putative class actions and individual actions seek unspecified damages with the exception of one lawsuit, in which the plaintiffs are seeking no less than $100m in actual damages and additional punitive damages against all defendants, including Barclays Bank PLC. Some of the lawsuits also seek trebling of damages under the Antitrust Act and RICO. Barclays Bank PLC has previously settled certain claims. Two class action settlements, where Barclays Bank PLC has respectively paid $7.1m and $20m have received final court approval. Barclays Bank PLC also settled two further matters for $7.5m and $1.95m, respectively. Sterling LIBOR civil actions In 2016, two putative class actions filed in the SDNY against Barclays Bank PLC, BCI and other Sterling LIBOR panel banks alleging, among other things, that the defendants manipulated the Sterling LIBOR rate in violation of the Antitrust Act, CEA and RICO, were consolidated. The defendants’ motion to dismiss the claims was granted in 2018. The plaintiffs have appealed the dismissal. Japanese Yen LIBOR civil actions In 2012, a putative class action was filed in the SDNY against Barclays Bank PLC and other Japanese Yen LIBOR panel banks by a lead plaintiff involved in exchange-traded derivatives and members of the Japanese Bankers Association’s Euroyen Tokyo Interbank Offered Rate (Euroyen TIBOR) panel. The complaint alleges, among other things, manipulation of the Euroyen TIBOR and Yen LIBOR rates and breaches of the CEA and the Antitrust Act. In 2014, the court dismissed the plaintiff’s antitrust claims, and, in 2020, the court dismissed the plaintiff’s remaining CEA claims. The plaintiff has appealed the lower court’s dismissal of such claims. In 2015, a second putative class action, making similar allegations to the above class action, was filed in the SDNY against Barclays PLC, Barclays Bank PLC and BCI. Barclays and the plaintiffs have reached a settlement of $17.75m for both actions, which is subject to court approval. SIBOR/SOR civil action In 2016, a putative class action was filed in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants, alleging manipulation of the Singapore Interbank Offered Rate (SIBOR) and Singapore Swap Offer Rate (SOR). The plaintiffs and remaining defendants (which includes Barclays Bank PLC) have reached a joint settlement to resolve this matter for $91m, which has received preliminary court approval. A final court approval hearing has been scheduled for November 2022. The financial impact of Barclays’ share of the joint settlement is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. ICE LIBOR civil actions In 2019, several putative class actions were filed in the SDNY against a panel of banks, including Barclays PLC, Barclays Bank PLC, BCI, other financial institution defendants and Intercontinental Exchange Inc. and certain of its affiliates (ICE), asserting antitrust claims that defendants manipulated USD LIBOR through defendants’ submissions to ICE. These actions have been consolidated. The defendants’ motion to dismiss was granted in 2020 and the plaintiffs appealed. In February 2022, the dismissal was affirmed on appeal. The plaintiffs have not sought U.S. Supreme Court review. This matter is now concluded. In August 2020, an ICE LIBOR-related action was filed by a group of individual plaintiffs in the US District Court for the Northern District of California on behalf of individual borrowers and consumers of loans and credit cards with variable interest rates linked to USD ICE LIBOR. The plaintiffs’ motion seeking, among other things, preliminary and permanent injunctions to enjoin the defendants from continuing to set LIBOR or enforce any financial instrument that relies in whole or in part on USD LIBOR was denied. The defendants have moved to dismiss the case. Non-US benchmarks civil actions There remains one claim, issued in 2017 against Barclays Bank PLC and other banks in the UK in connection with alleged manipulation of LIBOR. Proceedings have also been brought in a number of other jurisdictions in Europe, Argentina and Israel relating to alleged manipulation of LIBOR and EURIBOR. Additional proceedings in other jurisdictions may be brought in the future. Credit Default Swap civil action A putative antitrust class action is pending in New Mexico federal court against Barclays Bank PLC, BCI and various other financial institutions. The plaintiffs, the New Mexico State Investment Council and certain New Mexico pension funds, allege that the defendants conspired to manipulate the benchmark price used to value Credit Default Swap (CDS) contracts at settlement (i.e. the CDS final auction price). The plaintiffs allege violations of US antitrust laws and the CEA, and unjust enrichment under state law. The defendants have moved to dismiss the case. Foreign Exchange investigations and related civil actions In 2015, the Barclays Bank Group reached settlements totalling approximately $2.38bn with various US federal and state authorities and the FCA in relation to investigations into certain sales and trading practices in the Foreign Exchange market. The European Commission announced two settlements in May 2019 and the Barclays Bank Group paid penalties totalling approximately €210m. In June 2019, the Swiss Competition Commission announced two settlements and the Barclays Bank Group paid penalties totalling approximately CHF27m. In December 2021, the European Commission announced a final settlement which required the Barclays Bank Group to pay penalties totalling approximately €54m, which amount has been provided for in previous periods. The financial impact of any ongoing investigations is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Barclays Bank Group and other banks in relation to alleged manipulation of Foreign Exchange markets. FX opt out civil action In 2018, Barclays Bank PLC and BCI settled a consolidated action filed in the SDNY, alleging manipulation of Foreign Exchange markets (Consolidated FX Action), for a total amount of $384m. Also in 2018, a group of plaintiffs who opted out of the Consolidated FX Action filed a complaint in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants. Some of the plaintiffs’ claims were dismissed in 2020. Retail basis civil action In 2015, a putative class action was filed against several international banks, including Barclays PLC and BCI, on behalf of a proposed class of individuals who exchanged currencies on a retail basis at bank branches (Retail Basis Claims). The SDNY has ruled that the Retail Basis Claims are not covered by the settlement agreement in the Consolidated FX Action. The Court subsequently dismissed all Retail Basis Claims against the Barclays Bank Group and all other defendants. The plaintiffs have filed an amended complaint. Non-US FX civil actions Legal proceedings have been brought or are threatened against Barclays PLC, Barclays Bank PLC, BCI and Barclays Execution Services Limited (BX) in connection with alleged manipulation of Foreign Exchange in the UK, a number of other jurisdictions in Europe, Israel, Brazil and Australia. Additional proceedings may be brought in the future. The above-mentioned proceedings include two purported class actions filed against Barclays PLC, Barclays Bank PLC, BX, BCI and other financial institutions in the UK Competition Appeal Tribunal (CAT) in 2019 following the settlements with the European Commission described above. The CAT refused to certify these claims in the first quarter of 2022 although the claimants are seeking permission to appeal. Also in 2019, a separate claim was filed in the UK in the High Court of Justice (High Court), and subsequently transferred to the CAT, by various banks and asset management firms against Barclays Bank PLC and other financial institutions alleging breaches of European and UK competition laws related to FX trading. Metals related civil actions A number of US civil complaints, each on behalf of a proposed class of plaintiffs, have been consolidated and transferred to the SDNY. The complaints allege that Barclays Bank PLC and other members of The London Gold Market Fixing Ltd. manipulated the prices of gold and gold derivative contracts in violation of the Antitrust Act and other federal laws. The parties have reached a joint settlement to resolve this matter for $50m, which has received preliminary court approval, with the final court approval hearing scheduled for August 2022. The financial impact of Barclays’ share of the joint settlement is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. A separate US civil complaint by a proposed class of plaintiffs against a number of banks, including Barclays Bank PLC, BCI and BX, alleging manipulation of the price of silver in violation of the CEA, the Antitrust Act and state antitrust and consumer protection laws, has been dismissed as against the Barclays entities. The plaintiffs have the option to seek the court’s permission to appeal. Civil actions have also been filed in Canadian courts against Barclays PLC, Barclays Bank PLC, Barclays Capital Canada Inc. and BCI on behalf of proposed classes of plaintiffs alleging manipulation of gold and silver prices. US residential mortgage related civil actions There are two pending US Residential Mortgage-Backed Securities (RMBS) related civil actions arising from unresolved repurchase requests submitted by Trustees for certain RMBS, alleging breaches of various loan-level representations and warranties (R&Ws) made by Barclays Bank PLC and/or a subsidiary acquired in 2007. In one action, the Barclays defendants’ motion for summary judgment was granted in June 2022 and the plaintiffs’ R&W breach claim was dismissed. The plaintiffs may appeal. The other repurchase action is pending. Barclays Bank PLC has reached settlements to resolve two other repurchase actions, which have received final court approval. Payment of the settlement amount of one of those repurchase actions was completed in the first quarter of 2022, and the other will be completed in the third quarter of 2022. The financial impact of the settlements is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. In 2020, a civil litigation claim was filed in the New Mexico First Judicial District Court by the State of New Mexico against six banks, including BCI, on behalf of two New Mexico state pension funds and the New Mexico State Investment Council relating to legacy RMBS purchases. As to BCI, the complaint alleges that the funds purchased approximately $22m in RMBS underwritten by BCI. The parties have reached a joint settlement to resolve this matter for $32.5m. The settlement was paid in April 2022. The financial impact of BCI’s share of the joint settlement is not material to the Barclays Bank Group’s operating results, cash flows or financial position. Government and agency securities civil actions Treasury auction securities civil actions Consolidated putative class action complaints filed in US federal court against Barclays Bank PLC, BCI and other financial institutions under the Antitrust Act and state common law allege that the defendants (i) conspired to manipulate the US Treasury securities market and/or (ii) conspired to prevent the creation of certain platforms by boycotting or threatening to boycott such trading platforms. The court dismissed the consolidated action in March 2021. The plaintiffs filed an amended complaint. The defendants’ motion to dismiss the amended complaint was granted in March 2022. The plaintiffs are appealing this decision. In addition, certain plaintiffs have filed a related, direct action against BCI and certain other financial institutions, alleging that defendants conspired to fix and manipulate the US Treasury securities market in violation of the Antitrust Act, the CEA and state common law. Supranational, Sovereign and Agency bonds civil actions Civil antitrust actions have been filed in the SDNY and Federal Court of Canada in Toronto against Barclays Bank PLC, BCI, BX, Barclays Capital Securities Limited and, with respect to the civil action filed in Canada only, Barclays Capital Canada, Inc. and other financial institutions alleging that the defendants conspired to fix prices and restrain competition in the market for US dollar-denominated Supranational, Sovereign and Agency bonds. In one of the actions filed in the SDNY, the court granted the defendants’ motion to dismiss the plaintiffs’ complaint. The dismissal was affirmed on appeal; however, the district court subsequently informed the parties of a potential conflict. The motion to dismiss were assigned to a new district court judge and the plaintiffs have moved to vacate the dismissal order. The plaintiffs have voluntarily dismissed the other SDNY action. In the Federal Court of Canada action, the plaintiffs reached settlements with a small number of banks in 2020 (not including Barclays Capital Canada, Inc.). The plaintiffs have commenced the class certification process. There is no court scheduled deadline and the action remains at an early stage. Variable Rate Demand Obligations civil actions Civil actions have been filed against Barclays Bank PLC and BCI and other financial institutions alleging the defendants conspired or colluded to artificially inflate interest rates set for Variable Rate Demand Obligations (VRDOs). VRDOs are municipal bonds with interest rates that reset on a periodic basis, most commonly weekly. Two actions in state court have been filed by private plaintiffs on behalf of the states of Illinois and California. Three putative class action complaints have been consolidated in the SDNY. In the consolidated SDNY class action, certain of the plaintiffs’ claims were dismissed in November 2020 and defendants’ motion for partial dismissal of the amended consolidated complaint was granted in part and denied in part in June 2022. In the California action, the plaintiffs’ claims were dismissed in June 2021. The plaintiffs have appealed the dismissal. Odd-lot corporate bonds antitrust class action In 2020, BCI, together with other financial institutions, were named as defendants in a putative class action. The complaint alleges a conspiracy to boycott developing electronic trading platforms for odd-lots and price fixing. The plaintiffs demand unspecified money damages. The defendants’ motion to dismiss was granted in 2021 and the plaintiffs have appealed the dismissal. The district court subsequently informed the parties of a potential conflict and the case was reassigned to a new district court judge. The plaintiffs have filed a motion seeking a ruling that would vacate the dismissal and allow the plaintiffs to file an amended complaint if the appeals court remands the case for further proceedings. Interest rate swap and credit default swap US civil actions Barclays PLC, Barclays Bank PLC and BCI, together with other financial institutions that act as market makers for interest rate swaps (IRS) are named as defendants in several antitrust class actions which were consolidated in the SDNY in 2016. The complaints allege the defendants conspired to prevent the development of exchanges for IRS and demand unspecified money damages. In 2018, trueEX LLC filed an antitrust class action in the SDNY against a number of financial institutions including Barclays PLC, Barclays Bank PLC and BCI based on similar allegations with respect to trueEX LLC’s development of an IRS platform. In 2017, Tera Group Inc. filed a separate civil antitrust action in the SDNY claiming that certain conduct alleged in the IRS cases also caused the plaintiff to suffer harm with respect to the Credit Default Swaps market. In 2018 and 2019, respectively, the court dismissed certain claims in both cases for unjust enrichment and tortious interference but denied motions to dismiss the federal and state antitrust claims, which remain pending. BDC Finance L.L.C. In 2008, BDC Finance L.L.C. (BDC) filed a complaint in the Supreme Court of the State of New York (NY Supreme Court), demanding damages of $298m, alleging that Barclays Bank PLC had breached a contract in connection with a portfolio of total return swaps governed by an ISDA Master Agreement (the Master Agreement). Following a trial, the court ruled in 2018 that Barclays Bank PLC was not a defaulting party, which was affirmed on appeal. In April 2021, the trial court entered judgement in favour of Barclays Bank PLC for $3.3m and as yet to be determined legal fees and costs. BDC appealed. In January 2022, the appellate court reversed the trial court’s summary judgment decision in favour of Barclays Bank PLC and remanded the case to the lower court for further proceedings, with the trial scheduled to commence in the fourth quarter of 2022. In 2011, BDC’s investment advisor, BDCM Fund Adviser, L.L.C. and its parent company, Black Diamond Capital Holdings, L.L.C. also sued Barclays Bank PLC and BCI in Connecticut State Court for unspecified damages allegedly resulting from Barclays Bank PLC’s conduct relating to the Master Agreement, asserting claims for violation of the Connecticut Unfair Trade Practices Act and tortious interference with business and prospective business relations. This case is currently stayed. Civil actions in respect of the US Anti-Terrorism Act There are a number of civil actions, on behalf of more than 4,000 plaintiffs, filed in US federal courts in the US District Court in the Eastern District of New York (EDNY) and SDNY against Barclays Bank PLC and a number of other banks. The complaints generally allege that Barclays Bank PLC and those banks engaged in a conspiracy to facilitate US dollar-denominated transactions for the Iranian Government and various Iranian banks, which in turn funded acts of terrorism that injured or killed the plaintiffs or the plaintiffs’ family members. The plaintiffs seek to recover damages for pain, suffering and mental anguish under the provisions of the US Anti-Terrorism Act, which allow for the trebling of any proven damages. The court granted the defendants’ motions to dismiss three out of the six actions in the EDNY. The plaintiffs have appealed in one action. The remaining actions are stayed pending a decision on the appeal. Out of the two actions in the SDNY, the court also granted the defendants’ motion to dismiss the first action which is stayed pending a decision on the EDNY appeal. The second SDNY action is stayed pending any appeal on the dismissal of the first. Shareholder derivative action In November 2020, a purported Barclays shareholder filed a putative derivative action in New York state court against BCI and a number of current and former members of the Board of Directors of Barclays PLC and senior executives or employees of the Barclays Bank Group. The shareholder filed the claim on behalf of nominal defendant Barclays PLC, alleging that the individual defendants harmed the company through breaches of their duties, including under the Companies Act 2006. The plaintiff seeks damages on behalf of Barclays PLC for the losses that Barclays PLC allegedly suffered as a result of these alleged breaches. An amended complaint was filed in April 2021, which BCI and certain other defendants moved to dismiss. The motion to dismiss was granted in April 2022. The plaintiffs are appealing the decision. Derivative transactions civil action In 2021, Vestia (a Dutch housing association) brought a claim against Barclays Bank PLC in the UK in the High Court in relation to a series of derivative transactions entered into with Barclays Bank PLC between 2008 and 2011, seeking damages of £329m. Barclays Bank PLC is defending the claim and has made a counterclaim. Timeshare loans, skilled person review and associated matters In August 2020, the FCA granted an application by Clydesdale Financial Services Limited (CFS), which trades as Barclays Partner Finance and houses Barclays’ point-of-sale finance business, for a validation order with respect to certain loans to customers brokered between April 2014 and April 2016 by Azure Services Limited (ASL), a timeshare operator, which did not, at the point of sale, hold the necessary broker licence. As a condition to the validation order, the FCA required CFS to undertake a skilled person review of the assessment of affordability processes for the loans brokered by ASL (ASL Loans) as well as CFS’ policies and procedures for assessing affordability and oversight of brokers more generally, and dictated a remediation methodology in the event that ASL Loans did not pass the affordability test. CFS voluntarily agreed to remediate the ASL Loans, in accordance with the FCA’s methodology and the remediation exercise is substantively complete. The remaining scope of the skilled person review is also complete. The skilled person made a number of observations, some of which were adverse, about both current and historic affordability practices as well as current oversight practices. CFS is not required to conduct a full back book review but, following a review of certain cohorts of loans to determine historic affordability and/or broker oversight practices that may have caused customer harm, where harm is identified, CFS’ intention is to remediate. To date CFS has identified a number of areas for remediation but the scoping exercise is ongoing. Separately, and notwithstanding this, CFS decided in March 2022 to extend the proactive remediation of ASL Loans beyond those brokered between April 2014 to April 2016 to include the full portfolio of ASL Loans brokered between 2006 and 2018. In the first quarter of 2022, a customer remediation provision of £181m has been recognised in relation to the remediation of the ASL Loans originated outside the April 2014 to April 2016 period. This provision represents the best estimate as at 30 June 2022. CFS continues to review complaints about other legacy partner finance loans, however, it is not currently possible to predict the outcome of this review or the financial impact on the Barclays Bank Group. Over-issuance of securities in the US Barclays Bank PLC maintains a US shelf registration statement with the Securities and Exchange Commission (SEC) in order to issue securities to US investors. In May 2017, Barclays Bank PLC was the subject of an SEC settlement order as a result of which it lost its status as a “well-known seasoned issuer” (or WKSI) and was required to register a specified amount of securities to be issued under any US shelf registration statements filed with the SEC. On 10 March 2022, executive management became aware that Barclays Bank PLC had issued securities materially in excess of the set amount under its 2019 US shelf registration statement (2019 F-3) and subsequently became aware that securities had also been issued in excess of the set amount under the predecessor US shelf registration statement (the Predecessor Shelf). The securities that have been over-issued comprise structured notes and exchange traded notes (ETNs). Securities issued in excess of the amount registered are considered to be “unregistered securities” for the purposes of US securities laws with certain purchasers of those securities having a right to recover, upon the tender of such security to, Barclays Bank PLC, the consideration paid for such security with interest, less the amount of any income received, or to recover damages from Barclays Bank PLC if the purchaser no longer owns the security and had sold the security at a loss (the Rescission Price). Barclays Bank PLC is expected to launch a rescission offer on 1 August 2022, by which Barclays Bank PLC will offer to repurchase the relevant affected securities for the rescission price (the Rescission Offer). Although the Rescission Offer is expected to reduce liability with respect to potential private civil claims, it will not necessarily prevent such claims from being asserted against Barclays Bank PLC and/or its affiliates, including claims under applicable US federal securities laws. Further, the Rescission Offer does not bar the SEC and other regulators from pursuing enforcement actions against Barclays Bank PLC and its affiliates, which are expected to result in fines, penalties and/or other sanctions. The Barclays Bank Group is engaged with, and responding to inquiries and requests for information from, various regulators, including the SEC. The SEC’s investigation into this matter is at an advanced stage and the Barclays Bank Group has had preliminary discussions with the staff of the SEC’s Division of Enforcement about resolving this matter. As at 30 June 2022, Barclays Bank PLC has recognised a balance sheet provision of £1,757m (December 2021: £220m) in relation to this matter, out of which £1,592m (December 2021: £220m) relates to the over-issuance of structured notes and £165m (December 2021: £nil) relates to liabilities that could be incurred arising out of ongoing discussions in respect of a potential SEC resolution. A contingent liability exists in relation to the over-issuance of ETNs due to evidentiary challenges and the high level of trading in the securities. A contingent liability also exists in relation to any potential civil claims or enforcement actions taken against Barclays Bank PLC and/or its affiliates, but Barclays Bank PLC is unable to assess the likelihood of liabilities that may arise out of such claims or actions. Any liabilities, claims or actions in connection with the over-issuance of securities under its 2019 F-3 and the Predecessor Shelf could have an adverse effect on Barclays Bank PLC’s and the Barclays Bank Group’s business, financial condition, results of operations and reputation as a frequent issuer in the securities markets. Investigation into the use of unapproved communications platforms In July 2022, Barclays Bank PLC and BCI reached an agreement in principle with the staff of the SEC’s Division of Enforcement and the staff of the Commodity Futures Trading Commission (CFTC) in connection with investigations by the SEC and the CFTC of Barclays Bank PLC, BCI and other financial institutions as part of a financial industry sweep regarding compliance with record-keeping obligations in connection with business-related communications sent over unapproved electronic messaging platforms. The SEC and the CFTC found that Barclays Bank PLC and BCI failed to comply with their respective record keeping rules, where such communications were sent or received by employees over electronic messaging channels that had not been approved by the bank for business use by employees. The proposed resolutions will include Barclays Bank PLC and BCI paying a combined $125m civil monetary penalty to the SEC and a $75m civil monetary penalty to the CFTC. There will also be non-financial components to the settlements which have yet to be finalised and agreed with the SEC and CFTC. Subject to final agreement of the terms of the settlements and related documentation, as well as the SEC’s and CFTC’s approval, the civil monetary penalties are expected to be paid during the third quarter of 2022. HM Revenue & Customs (HMRC) assessments concerning UK Value Added Tax In 2018, HMRC issued notices that have the effect of removing certain overseas subsidiaries that have operations in the UK from Barclays’ UK VAT group, in which group supplies between members are generally free from VAT. The notices have retrospective effect and correspond to assessments of £181m (inclusive of interest), of which Barclays would expect to attribute an amount of approximately £128m to Barclays Bank UK PLC and £53m to Barclays Bank PLC. HMRC’s decision has been appealed to the First Tier Tribunal (Tax Chamber). Local authority civil actions concerning LIBOR Following settlement by Barclays Bank PLC of various governmental investigations concerning certain benchmark interest rate submissions referred to above in ‘Investigations into LIBOR and other benchmarks and related civil actions’, in the UK, certain local authorities brought claims in 2018 against Barclays Bank PLC and Barclays Bank UK PLC asserting that they entered into loans between 2006 and 2008 in reliance on misrepresentations made by Barclays Bank PLC in respect of its conduct in relation to LIBOR. Barclays Bank PLC and Barclays Bank UK PLC were successful in their applications to strike out the claims. The claims have been settled on terms such that the parties have agreed not to pursue these claims further and to bear their own costs. The financial impact of the settlements is not material to the Barclays Bank Group’s operating results, cash flows or financial position. General The Barclays Bank Group is engaged in various other legal, competition and regulatory matters in the UK, the US and a number of other overseas jurisdictions. It is subject to legal |
Related party transactions
Related party transactions | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of transactions between related parties [abstract] | |
Related party transactions | Related party transactions Related party transactions in the half year ended 30 June 2022 were similar in nature to those disclosed in the Barclays Bank PLC Annual Report 2021. Amounts included in the Barclays Bank Group’s financial statements with other Barclays Group companies are as follows: Half year ended 30.06.22 Half year ended 30.06.21 Parent Fellow subsidiaries Parent Fellow subsidiaries £m £m £m £m Total income (342) 12 (304) 10 Operating expenses (34) (1,647) (31) (1,560) As at 30.06.22 As at 31.12.21 Parent Fellow subsidiaries Parent Fellow subsidiaries £m £m £m £m Total assets 6,768 3,395 6,491 909 Total liabilities 35,140 4,626 32,141 3,962 Except for the above, no related party transactions that have taken place in the half year ended 30 June 2022 have materially affected the financial position or performance of the Barclays Bank Group during this period. |
Interest rate benchmark reform
Interest rate benchmark reform | 6 Months Ended |
Jun. 30, 2022 | |
Interest rate benchmark reform [Abstract] | |
Interest rate benchmark reform | Interest rate benchmark reform Following the financial crisis, the reform and replacement of benchmark interest rates such as LIBOR became a priority for global regulators. The FCA and other global regulators instructed market participants to prepare for the cessation of GBP, EUR, CHF, JPY LIBOR and the 1-week and 2-month USD settings of LIBOR after the end of 2021. The remaining USD LIBOR settings are scheduled to cease immediately after 30 June 2023. How the Barclays Group is managing the transition to alternative benchmark rates Barclays established a Group-wide LIBOR Transition Programme, further detail on the transition programme is available in the Barclays Bank PLC Annual Report 2021. This Programme oversaw transition for GBP, EUR, CHF and JPY LIBOR exposures and continues to work to transition the remaining residual of unremediated exposures from synthetic rates, in addition to overseeing USD LIBOR transition in preparation for the 30 June 2023 cessation. The majority of GBP, EUR, CHF and JPY exposures have now transitioned from LIBOR and good progress has been made with the unremediated exposures reported at year-end 2021. A small residual population of GBP, EUR and JPY contracts remain unremediated at the end of H1 2022. The majority of these have now reset onto GBP and JPY Synthetic LIBOR rates. We continue to work with clients to bilaterally transition these trades and have raised potential risks regarding note holder consent for securitised products and Local Authority consent for Public Finance Initiative (PFI) loan deals with our regulators. The Barclays Group-wide LIBOR Transition Programme has also commenced focus on the transition of USD LIBOR exposures impacted by the 30 June 2023 cessation timeline. As with GBP, EUR, CHF and JPY LIBOR, USD LIBOR transition approaches will vary by product and nature of counterparty. H122 saw focused efforts to transition uncommitted lending exposure with further wide scale client engagement for other products due to commence in H222. Both active conversion of exposures and inclusion of fallback provisions will be leveraged for bilateral derivative and non-derivatives products. For cleared derivatives, Barclays is working with central clearing counterparties (CCPs) on transition which is expected to follow a market wide, standardised approach to reform similar to the CCP-led conversions in 2021. The Barclays Bank Group met the Q121 Federal Reserve Bank of New York milestone to cease new use of US dollar LIBOR, with limited exceptions. The Barclays Bank Group has put in place controls so that any exceptions or exemptions are approved. |
Barclays Bank PLC parent conden
Barclays Bank PLC parent condensed balance sheet | 6 Months Ended |
Jun. 30, 2022 | |
Condensed Financial Information Disclosure [Abstract] | |
Barclays Bank PLC parent condensed balance sheet | Barclays Bank PLC parent condensed balance sheet Restated 1 As at 30.06.22 As at 31.12.21 Assets £m £m Cash and balances at central banks 195,796 144,964 Cash collateral and settlement balances 89,878 75,571 Loans and advances at amortised cost 247,192 199,782 Reverse repurchase agreements and other similar secured lending 3,873 4,982 Trading portfolio assets 84,976 96,724 Financial assets at fair value through the income statement 240,618 236,577 Derivative financial instruments 295,680 234,409 Financial assets at fair value through other comprehensive income 41,479 44,163 Investment in associates and joint ventures 12 12 Investment in subsidiaries 19,338 19,134 Goodwill and intangible assets 108 109 Property, plant and equipment 121 128 Current tax assets 1,286 671 Deferred tax assets 1,763 1,679 Retirement benefit assets 5,179 3,825 Other assets 2,495 1,941 Total assets 1,229,794 1,064,671 Liabilities Deposits at amortised cost 345,322 286,761 Cash collateral and settlement balances 83,284 56,419 Repurchase agreements and other similar secured borrowing 26,893 29,202 Debt securities in issue 50,638 32,585 Subordinated liabilities 31,694 31,875 Trading portfolio liabilities 55,518 50,116 Financial liabilities designated at fair value 284,345 291,062 Derivative financial instruments 288,032 227,991 Current tax liabilities 249 342 Deferred tax liabilities — 6 Retirement benefit liabilities 105 104 Other liabilities 6,147 4,597 Provisions 2,334 919 Total liabilities 1,174,561 1,011,979 Equity Called up share capital and share premium 2,348 2,348 Other equity instruments 14,500 14,400 Other reserves (2,877) (1,236) Retained earnings 41,262 37,180 Total equity 55,233 52,692 Total liabilities and equity 1,229,794 1,064,671 1. 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. Barclays Bank PLC considers the carrying value of its investment in subsidiaries to be fully recoverable. |
Credit Risk (Tables)
Credit Risk (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of credit risk exposure [abstract] | |
Disclosure of provision matrix | The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure, as expected credit loss (ECL) is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios, the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Stage 2 As at 30.06.22 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total 1 Gross exposure £m £m £m £m £m £m £m Home loans 10,461 314 11 170 495 1,016 11,972 Credit cards, unsecured loans and other retail lending 29,940 2,944 187 201 3,332 1,682 34,954 Wholesale loans 124,360 11,154 79 322 11,555 707 136,622 Total 164,761 14,412 277 693 15,382 3,405 183,548 Impairment allowance Home loans 10 14 1 1 16 343 369 Credit cards, unsecured loans and other retail lending 679 685 55 81 821 883 2,383 Wholesale loans 246 196 1 1 198 254 698 Total 935 895 57 83 1,035 1,480 3,450 Net exposure Home loans 10,451 300 10 169 479 673 11,603 Credit cards, unsecured loans and other retail lending 29,261 2,259 132 120 2,511 799 32,571 Wholesale loans 124,114 10,958 78 321 11,357 453 135,924 Total 163,826 13,517 220 610 14,347 1,925 180,098 Coverage ratio % % % % % % % Home loans 0.1 4.5 9.1 0.6 3.2 33.8 3.1 Credit cards, unsecured loans and other retail lending 2.3 23.3 29.4 40.3 24.6 52.5 6.8 Wholesale loans 0.2 1.8 1.3 0.3 1.7 35.9 0.5 Total 0.6 6.2 20.6 12.0 6.7 43.5 1.9 As at 31.12.21 Gross exposure £m £m £m £m £m £m £m Home loans 9,760 548 22 83 653 958 11,371 Credit cards, unsecured loans and other retail lending 24,011 2,402 198 182 2,782 1,469 28,262 Wholesale loans 95,242 12,275 301 386 12,962 921 109,125 Total 129,013 15,225 521 651 16,397 3,348 148,758 Impairment allowance Home loans 8 33 1 1 35 343 386 Credit cards, unsecured loans and other retail lending 605 677 39 75 791 906 2,302 Wholesale loans 183 188 3 2 193 435 811 Total 796 898 43 78 1,019 1,684 3,499 Net exposure Home loans 9,752 515 21 82 618 615 10,985 Credit cards, unsecured loans and other retail lending 23,406 1,725 159 107 1,991 563 25,960 Wholesale loans 95,059 12,087 298 384 12,769 486 108,314 Total 128,217 14,327 478 573 15,378 1,664 145,259 Coverage ratio % % % % % % % Home loans 0.1 6.0 4.5 1.2 5.4 35.8 3.4 Credit cards, unsecured loans and other retail lending 2.5 28.2 19.7 41.2 28.4 61.7 8.1 Wholesale loans 0.2 1.5 1.0 0.5 1.5 47.2 0.7 Total 0.6 5.9 8.3 12.0 6.2 50.3 2.4 1 Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £173.9bn (December 2021: £135.5bn) and impairment allowance of £138m (December 2021: £104m). This comprises £7m (December 2021: £4m) ECL on £172.1bn (December 2021: £135.3bn) Stage 1 assets, £2m (December 2021: £0m) on £1.7bn (December 2021: £65m) Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £129m (December 2021: £100m) on £133m (December 2021: £100m) Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £487m (December 2021:£499m). |
Disclosure of credit risk | The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in the Barclays Bank PLC Annual Report 2021. Transfers between stages in the tables have been reflected as if they had taken place at the beginning of the year. The movements are measured over a 6-month period. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2022 9,760 8 653 35 958 343 11,371 386 Transfers from Stage 1 to Stage 2 (219) — 219 — — — — — Transfers from Stage 2 to Stage 1 330 13 (330) (13) — — — — Transfers to Stage 3 (127) — (51) (3) 178 3 — — Transfers from Stage 3 14 — 21 2 (35) (2) — — Business activity in the period 1 1,185 2 — — — — 1,185 2 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 52 (13) 7 (4) 6 10 65 (7) Final repayments (534) — (24) (1) (81) (1) (639) (2) Disposals — — — — — — — — Write-offs 2 — — — — (10) (10) (10) (10) As at 30 June 2022 3 10,461 10 495 16 1,016 343 11,972 369 Credit cards, unsecured loans and other retail lending As at 1 January 2022 24,011 605 2,782 791 1,469 906 28,262 2,302 Transfers from Stage 1 to Stage 2 (1,293) (28) 1,293 28 — — — — Transfers from Stage 2 to Stage 1 944 199 (944) (199) — — — — Transfers to Stage 3 (356) (7) (270) (127) 626 134 — — Transfers from Stage 3 15 7 32 4 (47) (11) — — Business activity in the period 1 6,041 331 174 15 13 2 6,228 348 Refinements to models used for calculation 4 — 43 — 187 — 96 — 326 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 2,749 (453) 485 145 123 139 3,357 (169) Final repayments (2,019) (14) (193) (13) (112) (5) (2,324) (32) Disposals 5 (152) (4) (27) (10) (26) (14) (205) (28) Write-offs 2 — — — — (364) (364) (364) (364) As at 30 June 2022 3 29,940 679 3,332 821 1,682 883 34,954 2,383 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. Business activity reported within Credit cards, unsecured loans and other retail lending portfolio includes GAP portfolio acquisition in US cards of £2.7bn. 2 In H122, gross write-offs amounted to £560m (H121: £606m) and post write-off recoveries amounted to £20m (H121: £15m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £540m (H121: £591m). 3 Other financial assets subject to impairment excluded in the tables above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £173.9bn (December 2021: £135.5bn) and impairment allowance of £138m (December 2021: £104m). This comprises £7m ECL (December 2021: £4m) on £172.1bn Stage 1 assets (December 2021: £135.3bn), £2m (December 2021: £0m) on £1.7bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2021: £65m) and £129m (December 2021: £100m) on £133m Stage 3 other assets (December 2021: £100m). 4 Refinements to models used for calculation reported within Credit cards, unsecured loans and other retail lending portfolio include a £0.3bn movement in US cards. These reflect methodology changes made during the year. Barclays continually review the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. 5 The £0.2bn of disposals reported within Credit cards, unsecured loans and other retail lending portfolio relates to sale of NFL portfolio within US cards. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Wholesale loans As at 1 January 2022 95,242 183 12,962 193 921 435 109,125 811 Transfers from Stage 1 to Stage 2 (2,035) (4) 2,035 4 — — — — Transfers from Stage 2 to Stage 1 4,848 31 (4,848) (31) — — — — Transfers to Stage 3 (38) — (66) (1) 104 1 — — Transfers from Stage 3 32 — 1 — (33) — — — Business activity in the period 1 24,929 28 1,628 13 1 — 26,558 41 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 18,690 31 1,555 46 (10) 91 20,235 168 Final repayments (17,308) (23) (1,681) (26) (44) (40) (19,033) (89) Disposals 2 — — (31) — (46) (47) (77) (47) Write-offs 3 — — — — (186) (186) (186) (186) As at 30 June 2022 4 124,360 246 11,555 198 707 254 136,622 698 Reconciliation of ECL movement to impairment charge/(release) for the period £m Home loans (7) Credit cards, unsecured loans and other retail lending 473 Wholesale loans 120 ECL movement excluding assets derecognised due to disposals and write-offs 586 Recoveries and reimbursements 5 (31) Exchange and other adjustments 6 (245) Impairment release on loan commitments and other financial guarantees (40) Impairment charge on other financial assets 4 23 Income statement charge for the period 293 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under “Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes”. 2 The £0.1bn of disposals reported within Wholesale loans relate to debt sales undertaken during the year. 3 In H122, gross write-offs amounted to £560m (H121: £606m) and post write-off recoveries amounted to £20m (H121: £15m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £540m (H121: £591m). 4 Other financial assets subject to impairment excluded from the tables above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £173.9bn (December 2021: £135.5bn) and impairment allowance of £138m (December 2021: £104m). This comprises £7m ECL (December 2021: £4m) on £172.1bn Stage 1 assets (December 2021: £135.3bn), £2m (December 2021: £0m) on £1.7bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement assets (December 2021: £65m) and £129m (December 2021: £100m) on £133m Stage 3 other assets (December 2021: £100m). 5 Recoveries and reimbursements includes a net gain in relation to reimbursements from guarantee contracts held with third parties of £11m (H121 loss: £216m) and post write off recoveries of £20m (H121: £15m). 6 Exchange and other adjustments includes foreign exchange and interest and fees in suspense. Loan commitments and financial guarantees Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Home loans As at 1 January 2022 53 — — — 1 — 54 — Net transfers between stages — — — — — — — — Business activity in the year 2 — — — — — 2 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 2 — — — — — 2 — Limit management and final repayments (13) — — — — — (13) — As at 30 June 2022 44 — — — 1 — 45 — Credit cards, unsecured loans and other retail lending As at 1 January 2022 78,655 36 3,214 33 32 20 81,901 89 Net transfers between stages (645) 4 361 — 284 (4) — — Business activity in the year 26,149 1 195 — — — 26,344 1 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 10,050 24 (1,156) 1 (259) 2 8,635 27 Limit management and final repayments (3,012) — (156) — (4) (1) (3,172) (1) As at 30 June 2022 111,197 65 2,458 34 53 17 113,708 116 Wholesale loans As at 1 January 2022 178,006 167 28,417 241 1,017 2 207,440 410 Net transfers between stages 9,900 36 (9,835) (37) (65) 1 — — Business activity in the year 37,356 19 2,864 24 — — 40,220 43 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 17,664 (9) 1,526 (23) 142 (3) 19,332 (35) Limit management and final repayments (36,362) (14) (4,639) (33) (245) — (41,246) (47) As at 30 June 2022 206,564 199 18,333 172 849 — 225,746 371 |
Drivers of loan impairment charge | As at 30.06.22 As at 31.12.21 Management adjustments to impairment allowances Proportion of total impairment allowances Management adjustments to impairment allowances Proportion of total impairment allowances £m % £m % Home loans 5 1.4 34 8.8 Credit cards, unsecured loans and other retail lending 557 22.3 966 40.4 Wholesale loans 191 17.8 142 11.6 Total 753 19.1 1,142 28.6 Management adjustments to models for impairment allowance 1 Impairment allowance pre management adjustments 2 Economic uncertainty adjustments Other adjustments Total adjustments Total impairment allowance 3 (a) (b) (a+b) As at 30.06.22 £m £m £m £m £m Home loans 364 5 — 5 369 Credit cards, unsecured loans and other retail lending 1,938 416 141 557 2,495 Wholesale loans 882 293 (102) 191 1,073 Total 3,184 714 39 753 3,937 As at 31.12.21 Home loans 352 34 — 34 386 Credit cards, unsecured loans and other retail lending 1,425 771 195 966 2,391 Wholesale loans 1,079 244 (102) 142 1,221 Total 2,856 1,049 93 1,142 3,998 1 Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance. 2 Includes £2.7bn (December 2021: £2.2bn) of modelled ECL, £0.3bn (December 2021: £0.5bn) of individually assessed impairments and £0.2bn (December 2021: £0.2bn) ECL from non-modelled exposures. 3 Total impairment allowance consists of ECL stock on drawn and undrawn exposure. |
Macroeconomic variables used in the calculation of ECL and the respective scenario probability weighting | Baseline average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 3.9 1.7 1.6 1.6 1.6 UK unemployment 2 4.0 4.1 3.9 3.9 3.9 UK HPI 3 4.3 1.0 2.2 2.5 2.8 UK bank rate 1.5 2.7 2.4 2.1 2.0 US GDP 1 3.3 2.2 2.1 2.1 2.1 US unemployment 4 3.6 3.5 3.5 3.5 3.5 US HPI 5 4.1 3.4 3.4 3.4 3.4 US federal funds rate 1.5 3.2 2.9 2.7 2.5 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 4.9 2.3 1.9 1.7 UK unemployment 2 4.8 4.7 4.5 4.3 4.2 UK HPI 3 4.7 1.0 1.9 1.9 2.3 UK bank rate 0.1 0.8 1.0 1.0 0.8 US GDP 1 5.5 3.9 2.6 2.4 2.4 US unemployment 4 5.5 4.2 3.6 3.6 3.6 US HPI 5 11.8 4.5 5.2 4.9 5.0 US federal funds rate 0.2 0.3 0.9 1.2 1.3 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 3.1 (4.8) (0.4) 4.3 3.6 UK unemployment 2 5.2 8.4 8.6 6.8 5.9 UK HPI 3 0.2 (26.2) (3.6) 17.9 10.2 UK bank rate 1.8 4.7 4.3 2.6 2.3 US GDP 1 2.4 (4.1) (0.2) 3.4 2.7 US unemployment 4 4.6 8.0 9.0 7.1 5.8 US HPI 5 (0.2) (11.7) (0.2) 5.5 3.5 US federal funds rate 1.8 4.8 4.6 3.6 3.0 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 0.2 (4.0) 2.8 4.3 UK unemployment 2 4.8 7.2 9.0 7.6 6.3 UK HPI 3 4.7 (14.3) (21.8) 11.9 15.2 UK bank rate 0.1 2.2 3.9 3.1 2.2 US GDP 1 5.5 (0.8) (3.5) 2.5 3.2 US unemployment 4 5.5 6.4 9.1 8.1 6.4 US HPI 5 11.8 (6.6) (9.0) 5.9 6.7 US federal funds rate 0.2 2.1 3.4 2.6 2.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 1 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 3.5 (1.6) 0.6 3.0 2.6 UK unemployment 2 4.6 6.2 6.2 5.3 4.9 UK HPI 3 2.3 (13.2) (0.8) 10.0 6.5 UK bank rate 1.6 3.8 3.4 2.4 2.0 US GDP 1 2.7 (1.0) 1.1 2.9 2.5 US unemployment 4 4.1 5.7 6.2 5.3 4.6 US HPI 5 1.9 (4.4) 1.6 4.4 3.4 US federal funds rate 1.7 3.9 3.8 3.2 2.8 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 2.8 (0.7) 2.3 2.9 UK unemployment 2 4.8 6.2 6.8 6.0 5.3 UK HPI 3 4.7 (6.8) (10.5) 6.9 8.6 UK bank rate 0.1 1.6 2.7 2.3 1.6 US GDP 1 5.5 1.6 (0.4) 2.4 2.7 US unemployment 4 5.5 5.4 6.6 6.1 5.2 US HPI 5 11.8 (1.2) (2.1) 4.8 5.2 US federal funds rate 0.2 1.3 2.3 2.1 1.8 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Upside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 5.0 5.2 3.1 2.4 2.0 UK unemployment 2 3.8 3.7 3.6 3.6 3.6 UK HPI 3 6.5 11.2 6.2 4.7 3.7 UK bank rate 1.2 1.5 1.4 1.3 1.3 US GDP 1 4.0 4.9 3.6 3.4 3.4 US unemployment 4 3.4 3.0 3.1 3.1 3.1 US HPI 5 5.4 5.5 4.6 4.5 4.5 US federal funds rate 1.1 2.2 1.9 1.7 1.5 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 7.2 4.0 2.7 2.1 UK unemployment 2 4.8 4.5 4.1 4.0 4.0 UK HPI 3 4.7 8.5 9.0 5.2 4.2 UK bank rate 0.1 0.2 0.5 0.5 0.3 US GDP 1 5.5 5.3 4.1 3.5 3.4 US unemployment 4 5.5 3.9 3.4 3.3 3.3 US HPI 5 11.8 10.6 8.5 7.2 6.6 US federal funds rate 0.2 0.3 0.4 0.7 1.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Upside 1 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30 June 2022 % % % % % UK GDP 1 4.5 3.5 2.4 2.0 1.8 UK unemployment 2 3.9 3.8 3.8 3.8 3.8 UK HPI 3 5.4 6.3 4.1 3.6 3.2 UK bank rate 1.3 2.0 1.6 1.5 1.5 US GDP 1 3.7 3.7 3.0 2.9 2.9 US unemployment 4 3.5 3.2 3.3 3.3 3.3 US HPI 5 4.7 4.4 4.0 3.9 3.9 US federal funds rate 1.3 2.4 2.2 1.9 1.8 2021 2022 2023 2024 2025 As at 31 December 2021 % % % % % UK GDP 1 6.2 6.0 3.1 2.3 1.9 UK unemployment 2 4.8 4.6 4.3 4.2 4.1 UK HPI 3 4.7 5.0 5.0 3.9 3.3 UK bank rate 0.1 0.6 0.8 0.8 0.5 US GDP 1 5.5 4.6 3.4 2.9 2.9 US unemployment 4 5.5 4.0 3.5 3.5 3.5 US HPI 5 11.8 8.3 7.0 6.0 5.7 US federal funds rate 0.2 0.3 0.6 1.0 1.1 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Scenario probability weighting Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 30 June 2022 Scenario probability weighting 14.0 25.6 37.8 15.2 7.4 As at 31 December 2021 Scenario probability weighting 20.9 27.2 30.1 14.8 7.0 Specific bases show the most extreme position of each variable in the context of the scenario, for example, the highest unemployment for downside scenarios, average unemployment for baseline scenarios and lowest unemployment for upside scenarios. GDP and HPI downside and upside scenario data represents the lowest and highest points relative to the start point in the 20 quarter period. Macroeconomic variables (specific bases) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2022 % % % % % UK GDP 2 16.8 12.8 2.1 (1.1) (5.9) UK unemployment 3 3.6 3.8 4.0 6.6 9.2 UK HPI 4 36.7 24.8 2.6 (13.6) (30.8) UK bank rate 3 0.8 0.8 2.1 4.0 5.0 US GDP 2 20.2 16.1 2.4 (0.5) (5.0) US unemployment 3 3.0 3.2 3.5 6.5 9.5 US HPI 4 27.0 22.9 3.5 (2.6) (13.4) US federal funds rate 3 0.3 0.3 2.6 4.1 5.0 As at 31 December 2021 UK GDP 2 21.4 18.3 3.4 (1.6) (1.6) UK unemployment 3 4.0 4.1 4.5 7.0 9.2 UK HPI 4 35.7 23.8 2.4 (12.7) (29.9) UK bank rate 3 0.1 0.1 0.7 2.8 4.0 US GDP 2 22.8 19.6 3.4 1.5 (1.3) US unemployment 3 3.3 3.5 4.1 6.8 9.5 US HPI 4 53.3 45.2 6.2 2.2 (5.0) US federal funds rate 3 0.1 0.1 0.8 2.3 3.5 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 20 quarter period starts from Q122 (2021: Q121). 2 Maximum growth relative to Q421 (2021: Q420), based on 20 quarter period in Upside scenarios; 5-year yearly average Compound Annual Growth Rate (CAGR) in Baseline; minimum growth relative to Q421 (2021: Q420), based on 20 quarter period in Downside scenarios. 3 Lowest quarter in 20 quarter period in Upside scenarios; 5-year average in Baseline; highest quarter 20 quarter period in Downside scenarios.. 4 Maximum growth relative to Q421 (2021: Q420), based on 20 quarter period in Upside scenarios; 5-year quarter end CAGR in Baseline; minimum growth relative to Q421 (2021: Q420), based on 20 quarter period in Downside scenarios. Average basis represents the average quarterly value of variables in the 20 quarter period with GDP and HPI based on yearly average and quarterly CAGRs respectively. Macroeconomic variables (5-year averages) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2022 % % % % % UK GDP 2 3.5 2.8 2.1 1.6 1.1 UK unemployment 3 3.7 3.8 4.0 5.5 7.0 UK HPI 4 6.4 4.5 2.6 0.6 (1.5) UK bank rate 3 1.3 1.6 2.1 2.7 3.1 US GDP 2 3.9 3.2 2.4 1.6 0.8 US unemployment 3 3.1 3.3 3.5 5.2 6.9 US HPI 4 4.9 4.2 3.5 1.4 (0.8) US federal funds rate 3 1.7 1.9 2.6 3.1 3.6 As at 31 December 2021 UK GDP 2 4.4 3.9 3.4 2.7 1.8 UK unemployment 3 4.3 4.4 4.5 5.8 7.0 UK HPI 4 6.3 4.4 2.4 0.3 (2.0) UK bank rate 3 0.3 0.5 0.7 1.7 2.3 US GDP 2 4.4 3.9 3.4 2.4 1.3 US unemployment 3 3.9 4.0 4.1 5.7 7.1 US HPI 4 8.9 7.7 6.2 3.6 1.4 US federal funds rate 3 0.5 0.6 0.8 1.5 2.1 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HPI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. . 2 5-year yearly average CAGR, starting 2021 (2021: 2020). 3 5-year average. Period based on 20 quarters from Q122 (2021: Q121). 4 5-year quarter end CAGR, starting Q421 (2021: Q420). |
Basis of preparation (Tables)
Basis of preparation (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of initial application of standards or interpretations [abstract] | |
Financial statement line items affected by the restatement | The table below reflects each of the consolidated financial statement line items that were affected by the restatement: For the half year ended 30 June 2021 Impact on the consolidated income statement As reported £m Restatement £m As restated £m Litigation and conduct (87) (77) (164) Operating expenses (5,146) (77) (5,223) Profit before tax 3,334 (77) 3,257 Taxation (611) 17 (594) Profit after tax 2,723 (60) 2,663 For the half year ended 30 June 2021 Impact on the consolidated statement of comprehensive income As reported £m Restatement £m As restated £m Profit after tax 2,723 (60) 2,663 Total comprehensive income for the year 1,092 (60) 1,032 For the half year ended 30 June 2021 Impact on the consolidated cash flow statement As reported £m Restatement £m As restated £m Profit before tax 3,334 (77) 3,257 Adjustment for non-cash items 5,001 77 5,078 For the year ended 31 December 2021 Impact on the consolidated income statement As reported £m Restatement £m As restated £m Litigation and conduct (154) (220) (374) Operating expenses (10,039) (220) (10,259) Profit before tax 5,638 (220) 5,418 Taxation (880) 50 (830) Profit after tax 4,758 (170) 4,588 For the year ended 31 December 2021 Impact on the consolidated balance sheet As reported £m Restatement £m As restated £m Liabilities Current tax liabilities 738 (50) 688 Provisions 890 220 1,110 Total liabilities 1,005,291 170 1,005,461 Equity Retained earnings 43,585 (170) 43,415 Total equity 56,487 (170) 56,317 The table below reflects each of the line items of the parent company financial statements that were affected by the restatement: For the year ended 31 December 2021 Impact on the parent company balance sheet As reported £m Restatement £m As restated £m Liabilities Current tax liabilities 392 (50) 342 Provisions 699 220 919 Total liabilities 1,011,809 170 1,011,979 Equity Retained earnings 37,350 (170) 37,180 Total equity 52,862 (170) 52,692 |
Segmental reporting (Tables)
Segmental reporting (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of operating segments [abstract] | |
Analysis of results by business | Analysis of results by business Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.22 £m £m £m £m Total income 8,086 1,992 (88) 9,990 Credit impairment (charge)/release (31) (278) 16 (293) Net operating income/(expense) 8,055 1,714 (72) 9,697 Operating expenses (3,912) (1,285) (62) (5,259) Litigation and conduct (1,632) (200) (1) (1,833) Total operating expenses (5,544) (1,485) (63) (7,092) Other net income 2 — — — — Profit/(loss) before tax 2,511 229 (135) 2,605 As at 30.06.22 £bn £bn £bn £bn Total assets 1,179.5 80.4 12.8 1,272.7 Restated 1 Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.21 £m £m £m £m Total income 6,632 1,649 (92) 8,189 Credit impairment release 260 22 6 288 Net operating income/(expense) 6,892 1,671 (86) 8,477 Operating expenses (3,617) (1,126) (316) (5,059) Litigation and conduct (79) (82) (3) (164) Total operating expenses (3,696) (1,208) (319) (5,223) Other net income 2 3 — — 3 Profit/(loss) before tax 3,199 463 (405) 3,257 As at 31.12.21 £bn £bn £bn £bn Total assets 986.2 64.4 11.2 1,061.8 1 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. 2 Other net income represents the share of post-tax results of associates and joint ventures and profit (or loss) on disposal of subsidiaries, associates and joint ventures. |
Split of income by geographic region | Split of income by geographic region 1 Half year ended 30.06.22 Half year ended 30.06.21 £m £m United Kingdom 4,674 2,698 Europe 1,310 1,213 Americas 3,276 3,676 Africa and Middle East 31 20 Asia 699 582 Total 9,990 8,189 1 The geographical analysis is based on the location of the office where the transactions are recorded. |
Net fee and commission income (
Net fee and commission income (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Fee and commission income (expense) [abstract] | |
Total fees in scope of IFRS 15 revenues from contracts with customers | Fee and commission income is disaggregated below and includes a total for fees in scope of IFRS 15, Revenue from Contracts with Customers: Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.22 £m £m £m £m Fee type Transactional 216 1,229 — 1,445 Advisory 440 72 — 512 Brokerage and execution 734 28 — 762 Underwriting and syndication 1,101 — — 1,101 Other 30 78 11 119 Total revenue from contracts with customers 2,521 1,407 11 3,939 Other non-contract fee income 67 2 — 69 Fee and commission income 2,588 1,409 11 4,008 Fee and commission expense 1 (461) (707) (1) (1,169) Net fee and commission income 2,127 702 10 2,839 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.21 £m £m £m £m Fee type Transactional 184 984 — 1,168 Advisory 399 61 — 460 Brokerage and execution 527 26 — 553 Underwriting and syndication 1,715 — — 1,715 Other 25 76 11 112 Total revenue from contracts with customers 2,850 1,147 11 4,008 Other non-contract fee income 59 3 — 62 Fee and commission income 2,909 1,150 11 4,070 Fee and commission expense 1 (369) (496) (5) (870) Net fee and commission income 2,540 654 6 3,200 Note 1. Barclays Bank Group has corrected the presentation of the scheme fees incurred when Barclays acts as an “acquirer” as part of the payment transaction cycle. From 2022 onwards, the scheme fees reported under "Consumer, Cards and Payments" are presented within fees and commission income under “Transactional” fee type, which had previously been recognised in fees and commission expense. The reclassification into Fee and Commission income is a reduction of £94m for H122. The comparatives have not been restated as the effect is not considered material although the effect would have been a reduction of H121: £81m with no impact on Net fee and commission income. There is no impact on Net assets or Cash flows reported. |
Tax (Tables)
Tax (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Major components of tax expense (income) [abstract] | |
Disclosure of deferred taxes | As at 30.06.22 As at 31.12.21 Deferred tax assets and liabilities £m £m USA 1,530 2,006 UK 1,084 576 Other territories 438 399 Deferred tax assets 3,052 2,981 Deferred tax liabilities — (6) Analysis of deferred tax assets Temporary differences 1,911 1,785 Tax losses 1,141 1,196 Deferred tax assets 3,052 2,981 |
Dividends on ordinary shares (T
Dividends on ordinary shares (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Dividends on ordinary shares [Abstract] | |
Dividends on ordinary shares | Half year ended 30.06.22 Half year ended 30.06.21 Dividends paid during the period £m £m Ordinary shares 200 694 Preference shares 15 13 Total 215 707 |
Fair value of financial instr_2
Fair value of financial instruments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of fair value measurement of assets [abstract] | |
Assets and liabilities held at fair value disaggregated by valuation technique (fair value hierarchy) | The following table shows the Barclays Bank Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Valuation technique using Quoted market prices Observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Total As at 30.06.22 £m £m £m £m Trading portfolio assets 58,340 64,300 4,256 126,896 Financial assets at fair value through the income statement 1,037 203,230 6,163 210,430 Derivative financial instruments 11,653 328,870 3,873 344,396 Financial assets at fair value through other comprehensive income 15,993 27,785 36 43,814 Investment property — — 5 5 Total assets 87,023 624,185 14,333 725,541 Trading portfolio liabilities (47,118) (28,680) (82) (75,880) Financial liabilities designated at fair value (193) (255,155) (439) (255,787) Derivative financial instruments (12,674) (304,473) (4,379) (321,526) Total liabilities (59,985) (588,308) (4,900) (653,193) As at 31.12.21 Trading portfolio assets 80,836 63,754 2,281 146,871 Financial assets at fair value through the income statement 4,953 177,194 6,079 188,226 Derivative financial instruments 6,150 252,131 4,010 262,291 Financial assets at fair value through other comprehensive income 16,070 29,800 38 45,908 Investment property — — 7 7 Total assets 108,009 522,879 12,415 643,303 Trading portfolio liabilities (26,701) (26,563) (27) (53,291) Financial liabilities designated at fair value (174) (250,553) (404) (251,131) Derivative financial instruments (6,571) (243,893) (6,059) (256,523) Total liabilities (33,446) (521,009) (6,490) (560,945) The following table shows the Barclays Bank Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: As at 30.06.22 As at 31.12.21 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 1,573 (1,849) 1,091 (1,351) Foreign exchange derivatives 786 (560) 376 (374) Credit derivatives 234 (615) 323 (709) Equity derivatives 1,280 (1,355) 2,220 (3,625) Corporate debt 1,171 (13) 1,205 (21) Reverse repurchase and repurchase agreements 178 (188) 13 (172) Non-asset backed loans 6,435 — 3,743 — Asset backed securities 291 — 558 — Equity cash products 422 (3) 393 — Private equity investments 123 — 148 — Other 1 1,840 (317) 2,345 (238) Total 14,333 (4,900) 12,415 (6,490) 1. Other includes commercial real estate loans, fund and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. |
Analysis of movements in Level 3 assets and liabilities | Level 3 movement analysis The following table summarises the movements in the balances of Level 3 assets and liabilities during the period. The table shows gains and losses and includes amounts for all financial assets and liabilities that are held at fair value transferred to and from Level 3 during the period. Transfers have been reflected as if they had taken place at the beginning of the period. Asset and liability moves between Level 2 and Level 3 are primarily due to i) an increase or decrease in observable market activity related to an input or ii) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.22 As at 01.01.22 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 389 90 (144) — (17) 54 — — 43 (11) 404 Non-asset backed loans 758 2,448 (459) — — 11 — — 50 (113) 2,695 Asset backed securities 454 72 (80) — (297) (20) — — 100 (66) 163 Equity cash products 303 21 (56) — — 24 — — 52 (17) 327 Other 377 326 (42) — (5) 56 — — 39 (84) 667 Trading portfolio assets 2,281 2,957 (781) — (319) 125 — — 284 (291) 4,256 Non-asset backed loans 2,985 1,848 (757) — (315) (76) — — 52 — 3,737 Equity cash products 84 — — — — 3 2 — — — 89 Private equity investments 148 19 (60) — — 7 11 — 3 (4) 124 Other 2,862 4,817 (5,579) — (155) 9 179 — 99 (19) 2,213 Financial assets at fair value through the income statement 6,079 6,684 (6,396) — (470) (57) 192 — 154 (23) 6,163 Asset backed securities 38 — — — — — — (2) — — 36 Financial assets at fair value through other comprehensive income 38 — — — — — — (2) — — 36 Investment property 7 — (1) — — — (1) — — — 5 Trading portfolio liabilities (27) (35) 3 — — (29) — — — 6 (82) Financial liabilities designated at fair value (404) (5) — (13) 47 (22) 2 — (81) 37 (439) Interest rate derivatives (260) 25 — — (4) (305) (9) — 271 6 (276) Foreign exchange derivatives 2 — — — (9) 273 — — (65) 25 226 Credit derivatives (386) (36) 5 — 60 (99) — — 20 55 (381) Equity derivatives (1,405) (83) — — 170 980 — — (9) 272 (75) Net derivative financial instruments 1 (2,049) (94) 5 — 217 849 (9) — 217 358 (506) Total 5,925 9,507 (7,170) (13) (525) 866 184 (2) 574 87 9,433 1. Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £3,873m and derivative financial liabilities were £4,379m. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.21 As at 01.01.21 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 305 (87) — — 25 — — 40 (11) 423 Non-asset backed loans 709 620 (131) — (84) 13 — — 124 (106) 1,145 Asset backed securities 686 112 (294) — — (10) — — 43 (48) 489 Equity cash products 214 13 (17) — — 32 — — 29 (9) 262 Other 103 21 — — (51) (1) — — 162 (1) 233 Trading portfolio assets 1,863 1,071 (529) — (135) 59 — — 398 (175) 2,552 Non-asset backed loans 2,280 696 (299) — (388) 10 — — 69 (47) 2,321 Equity cash products 320 166 (194) — — (171) 18 — — — 139 Private equity investments 88 22 (7) — (7) (1) 3 — — — 98 Other 1,704 2,296 (2,389) — (160) (19) 1 — 16 — 1,449 Financial assets at fair value through the income statement 4,392 3,180 (2,889) — (555) (181) 22 — 85 (47) 4,007 Non-asset backed loans 106 — — — — — — — — (106) — Asset backed securities 47 — — — (5) — — 1 — — 43 Financial assets at fair value through other comprehensive income 153 — — — (5) — — 1 — (106) 43 Investment property 10 — (2) — — — — — — — 8 Trading portfolio liabilities (28) (3) 14 — — (7) — — — 7 (17) Financial liabilities designated at fair value (341) — — — 98 7 — — (78) 18 (296) Interest rate derivatives (2) 9 — — 33 (121) 4 — 21 (296) (352) Foreign exchange derivatives 1 — — — 58 (6) — — 3 (34) 22 Credit derivatives (155) (118) 2 — (5) 12 (1) — 1 (1) (265) Equity derivatives (1,615) (315) (1) — (32) (221) — — 28 808 (1,348) Net derivative financial instruments 1 (1,771) (424) 1 — 54 (336) 3 — 53 477 (1,943) Total 4,278 3,824 (3,405) — (543) (458) 25 1 458 174 4,354 1. Derivative financial instruments are presented on a net basis. On a gross basis, derivative financial assets were £3,656m and derivative financial liabilities were £5,599m. |
Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | Unrealised gains and losses on Level 3 financial assets and liabilities The following table discloses the unrealised gains and losses recognised in the period arising on Level 3 financial assets and liabilities held at the period end. Half year ended 30.06.22 Half year ended 30.06.21 Income statement Other compre-hensive income Total Income statement Other compre-hensive income Total Trading income Other income Trading income Other income £m £m £m £m £m £m £m £m Trading portfolio assets 121 — — 121 35 — — 35 Financial assets at fair value through the income statement 16 9 — 25 (67) 35 — (32) Financial assets at fair value through other comprehensive income — — (2) (2) — — — — Investment properties — (1) — (1) — — — — Trading portfolio liabilities (35) — — (35) (6) — — (6) Financial liabilities designated at fair value (14) — — (14) 7 — — 7 Net derivative financial instruments 862 (1) — 861 (367) — — (367) Total 950 7 (2) 955 (398) 35 — (363) |
Sensitivity analysis of valuations using unobservable inputs | Sensitivity analysis of valuations using unobservable inputs As at 30.06.22 As at 31.12.21 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income Statement Equity Income statement Equity Income Statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 75 — (108) — 51 — (79) — Foreign exchange derivatives 15 — (22) — 20 — (28) — Credit derivatives 111 — (115) — 112 — (103) — Equity derivatives 107 — (112) — 181 — (190) — Corporate debt 36 — (35) — 38 — (28) — Non-asset backed loans 233 — (260) — 99 — (150) — Equity cash products 56 — (112) — 25 — (42) — Private equity investments 9 — (9) — 10 — (11) — Other 1 27 — (36) — 19 — (20) — Total 669 — (809) — 555 — (651) — 1 Other includes commercial real estate loans, fund and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. |
Fair value adjustments | Fair value adjustments Key balance sheet valuation adjustments are quantified below: As at 30.06.22 As at 31.12.21 £m £m Exit price adjustments derived from market bid-offer spreads (531) (498) Uncollateralised derivative funding (82) (127) Derivative credit valuation adjustments (388) (212) Derivative debit valuation adjustments 208 91 |
Comparison of carrying amounts and fair values for assets and liabilities not held at fair value | The following table summarises the fair value of financial assets and liabilities measured at amortised cost on the Barclays Bank Group’s balance sheet: As at 30.06.22 As at 31.12.21 Carrying amount Fair value Carrying amount Fair value Financial assets £m £m £m £m Loans and advances at amortised cost 180,098 180,103 145,259 145,665 Reverse repurchase agreements and other similar secured lending 1,060 1,060 3,177 3,177 Financial liabilities Deposits at amortised cost (311,465) (311,455) (262,828) (262,843) Repurchase agreements and other similar secured borrowing (12,805) (12,807) (12,769) (12,776) Debt securities in issue (68,656) (68,504) (48,388) (48,350) Subordinated liabilities (32,241) (32,230) (32,185) (33,598) |
Subordinated Liabilities (Table
Subordinated Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Half year ended 30.06.22 Year ended 31.12.21 £m £m Opening balance 32,185 32,005 Issuances 4,803 9,099 Redemptions (4,221) (7,241) Other (526) (1,678) Closing balance 32,241 32,185 Designated at fair value (Note 6) 580 483 Total subordinated liabilities 32,821 32,668 |
Provisions (Tables)
Provisions (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Provisions [abstract] | |
Provisions | Restated 1 As at 30.06.22 As at 31.12.21 £m £m Customer redress 1,629 266 Legal, competition and regulatory matters 406 211 Redundancy and restructuring 23 46 Undrawn contractually committed facilities and guarantees 487 499 Onerous contracts — 2 Sundry provisions 100 86 Total 2,645 1,110 1. 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Other reserves (Tables)
Other reserves (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | As at 30.06.22 As at 31.12.21 £m £m Currency translation reserve 4,589 2,581 Fair value through other comprehensive income reserve (917) (118) Cash flow hedging reserve (3,492) (618) Own credit reserve (103) (960) Other reserves (24) (24) Total 53 861 |
Contingent liabilities and co_2
Contingent liabilities and commitments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of contingent liabilities [abstract] | |
Disclosure of contingent liabilities and commitments | As at 30.06.22 As at 31.12.21 Contingent liabilities and financial guarantees £m £m Guarantees and letters of credit pledged as collateral security 16,743 15,759 Performance guarantees, acceptances and endorsements 7,532 7,987 Total 24,275 23,746 Commitments Documentary credits and other short-term trade related transactions 1,888 1,584 Standby facilities, credit lines and other commitments 334,483 282,867 Total 336,371 284,451 |
Related party transactions (Tab
Related party transactions (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of transactions between related parties [abstract] | |
Disclosure of transactions between related parties | Amounts included in the Barclays Bank Group’s financial statements with other Barclays Group companies are as follows: Half year ended 30.06.22 Half year ended 30.06.21 Parent Fellow subsidiaries Parent Fellow subsidiaries £m £m £m £m Total income (342) 12 (304) 10 Operating expenses (34) (1,647) (31) (1,560) As at 30.06.22 As at 31.12.21 Parent Fellow subsidiaries Parent Fellow subsidiaries £m £m £m £m Total assets 6,768 3,395 6,491 909 Total liabilities 35,140 4,626 32,141 3,962 |
Barclays Bank PLC parent cond_2
Barclays Bank PLC parent condensed balance sheet (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Condensed Financial Information Disclosure [Abstract] | |
Barclays Bank PLC condensed balance sheet | Restated 1 As at 30.06.22 As at 31.12.21 Assets £m £m Cash and balances at central banks 195,796 144,964 Cash collateral and settlement balances 89,878 75,571 Loans and advances at amortised cost 247,192 199,782 Reverse repurchase agreements and other similar secured lending 3,873 4,982 Trading portfolio assets 84,976 96,724 Financial assets at fair value through the income statement 240,618 236,577 Derivative financial instruments 295,680 234,409 Financial assets at fair value through other comprehensive income 41,479 44,163 Investment in associates and joint ventures 12 12 Investment in subsidiaries 19,338 19,134 Goodwill and intangible assets 108 109 Property, plant and equipment 121 128 Current tax assets 1,286 671 Deferred tax assets 1,763 1,679 Retirement benefit assets 5,179 3,825 Other assets 2,495 1,941 Total assets 1,229,794 1,064,671 Liabilities Deposits at amortised cost 345,322 286,761 Cash collateral and settlement balances 83,284 56,419 Repurchase agreements and other similar secured borrowing 26,893 29,202 Debt securities in issue 50,638 32,585 Subordinated liabilities 31,694 31,875 Trading portfolio liabilities 55,518 50,116 Financial liabilities designated at fair value 284,345 291,062 Derivative financial instruments 288,032 227,991 Current tax liabilities 249 342 Deferred tax liabilities — 6 Retirement benefit liabilities 105 104 Other liabilities 6,147 4,597 Provisions 2,334 919 Total liabilities 1,174,561 1,011,979 Equity Called up share capital and share premium 2,348 2,348 Other equity instruments 14,500 14,400 Other reserves (2,877) (1,236) Retained earnings 41,262 37,180 Total equity 55,233 52,692 Total liabilities and equity 1,229,794 1,064,671 1. 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Credit Risk - Loans and advance
Credit Risk - Loans and advances at amortised cost by product (Details) £ in Millions | Dec. 31, 2022 GBP (£) | Jun. 30, 2022 GBP (£) | Dec. 31, 2021 GBP (£) | |
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Provisions | £ 2,645 | £ 1,110 | [1] | |
Management adjustments to impairment allowances | £ 753 | £ 1,142 | ||
Proportion of total impairment allowances | 19.10% | 28.60% | ||
Provision for credit commitments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Provisions | £ 487 | £ 499 | ||
Loans and advances | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Management adjustments to impairment allowances | 753 | 1,142 | ||
Loans and advances | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 180,098 | £ 145,259 | ||
Coverage ratio | 0.019 | 0.024 | ||
Loans and advances | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 183,548 | £ 148,758 | ||
Loans and advances | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (3,450) | (3,499) | ||
Loans and advances | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 163,826 | £ 128,217 | ||
Coverage ratio | 0.006 | 0.006 | ||
Loans and advances | Stage 1 | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 164,761 | £ 129,013 | ||
Loans and advances | Stage 1 | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (935) | (796) | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 14,347 | £ 15,378 | ||
Coverage ratio | 0.067 | 0.062 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 13,517 | £ 14,327 | ||
Coverage ratio | 0.062 | 0.059 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 220 | £ 478 | ||
Coverage ratio | 0.206 | 0.083 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 610 | £ 573 | ||
Coverage ratio | 0.120 | 0.120 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 15,382 | £ 16,397 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 14,412 | 15,225 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 277 | 521 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 693 | 651 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1,035) | (1,019) | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (895) | (898) | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (57) | (43) | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (83) | (78) | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,925 | £ 1,664 | ||
Coverage ratio | 0.435 | 0.503 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 3,405 | £ 3,348 | ||
Loans and advances | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1,480) | (1,684) | ||
Home loans | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ 5 | £ 34 | ||
Proportion of total impairment allowances | 1.40% | 8.80% | ||
Home loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 11,603 | £ 10,985 | ||
Coverage ratio | 0.031 | 0.034 | ||
Home loans | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 11,972 | £ 11,371 | ||
Home loans | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (369) | (386) | ||
Home loans | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 10,451 | £ 9,752 | ||
Coverage ratio | 0.001 | 0.001 | ||
Home loans | Stage 1 | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 10,461 | £ 9,760 | ||
Home loans | Stage 1 | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (10) | (8) | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 479 | £ 618 | ||
Coverage ratio | 0.032 | 0.054 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 300 | £ 515 | ||
Coverage ratio | 0.045 | 0.060 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 10 | £ 21 | ||
Coverage ratio | 0.091 | 0.045 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 169 | £ 82 | ||
Coverage ratio | 0.006 | 0.012 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 495 | £ 653 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 314 | 548 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 11 | 22 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 170 | 83 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (16) | (35) | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (14) | (33) | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1) | (1) | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1) | (1) | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 673 | £ 615 | ||
Coverage ratio | 0.338 | 0.358 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,016 | £ 958 | ||
Home loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (343) | (343) | ||
Credit cards, unsecured loans and other retail lending | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ 557 | £ 966 | ||
Proportion of total impairment allowances | 22.30% | 40.40% | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 32,571 | £ 25,960 | ||
Coverage ratio | 0.068 | 0.081 | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 34,954 | £ 28,262 | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2,383) | (2,302) | ||
Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 29,261 | £ 23,406 | ||
Coverage ratio | 0.023 | 0.025 | ||
Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 29,940 | £ 24,011 | ||
Credit cards, unsecured loans and other retail lending | Stage 1 | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (679) | (605) | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 2,511 | £ 1,991 | ||
Coverage ratio | 0.246 | 0.284 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 2,259 | £ 1,725 | ||
Coverage ratio | 0.233 | 0.282 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 132 | £ 159 | ||
Coverage ratio | 0.294 | 0.197 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 120 | £ 107 | ||
Coverage ratio | 0.403 | 0.412 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 3,332 | £ 2,782 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 2,944 | 2,402 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 187 | 198 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 201 | 182 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (821) | (791) | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (685) | (677) | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (55) | (39) | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (81) | (75) | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 799 | £ 563 | ||
Coverage ratio | 0.525 | 0.617 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 1,682 | £ 1,469 | ||
Credit cards, unsecured loans and other retail lending | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (883) | (906) | ||
Wholesale loans | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Management adjustments to impairment allowances | £ 191 | £ 142 | ||
Proportion of total impairment allowances | 17.80% | 11.60% | ||
Wholesale loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 135,924 | £ 108,314 | ||
Coverage ratio | 0.005 | 0.007 | ||
Wholesale loans | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 136,622 | £ 109,125 | ||
Wholesale loans | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (698) | (811) | ||
Wholesale loans | Stage 1 | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 124,114 | £ 95,059 | ||
Coverage ratio | 0.002 | 0.002 | ||
Wholesale loans | Stage 1 | Financial assets at amortised cost | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 124,360 | £ 95,242 | ||
Wholesale loans | Stage 1 | Financial assets at amortised cost | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (246) | (183) | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 11,357 | £ 12,769 | ||
Coverage ratio | 0.017 | 0.015 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 10,958 | £ 12,087 | ||
Coverage ratio | 0.018 | 0.015 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 78 | £ 298 | ||
Coverage ratio | 0.013 | 0.010 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 321 | £ 384 | ||
Coverage ratio | 0.003 | 0.005 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 11,555 | £ 12,962 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 11,154 | 12,275 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 79 | 301 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Gross exposure | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 322 | 386 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (198) | (193) | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (196) | (188) | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | Not later than 30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1) | (3) | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 2 | Impairment allowance | >30 days past due | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1) | (2) | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 453 | £ 486 | ||
Coverage ratio | 0.359 | 0.472 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 707 | £ 921 | ||
Wholesale loans | Lifetime expected credit losses | Financial assets at amortised cost | Stage 3 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (254) | (435) | ||
Impairment charge on other financial assets4 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 173,900 | 135,500 | ||
Impairment charge on other financial assets4 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (138) | (104) | ||
Impairment charge on other financial assets4 | Stage 1 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 172,100 | 135,300 | ||
Impairment charge on other financial assets4 | Stage 1 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (7) | (4) | ||
Impairment charge on other financial assets4 | Stage 1 | Impairment allowance | Provision for credit commitments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (7) | (4) | ||
Impairment charge on other financial assets4 | Lifetime expected credit losses | Stage 3 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 129 | 100 | ||
Impairment charge on other financial assets4 | Lifetime expected credit losses | Stage 3 | Gross exposure | Provision for credit commitments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 100 | 133 | ||
Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 1,700 | 65 | ||
Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2) | 0 | ||
Other assets | Lifetime expected credit losses | Stage 3 | Gross exposure | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 129 | 100 | ||
Other assets | Lifetime expected credit losses | Stage 3 | Gross exposure | Provision for credit commitments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 133 | 100 | ||
Other assets | Lifetime expected credit losses | Stage 3 | Impairment allowance | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ (129) | £ (100) | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Credit Risk - Movement in impai
Credit Risk - Movement in impairment allowance on loans and advances at amortised cost - incl ECL recon (Details) - GBP (£) £ in Millions | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Income statement charge for the period | £ 293 | £ (288) | [1] | |
Loans and advances | ||||
Loans and advances at amortised cost | ||||
Opening balance | 3,998 | |||
Ending balance | 3,937 | |||
Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 386 | |||
Ending balance | 369 | |||
Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 2,391 | |||
Ending balance | 2,495 | |||
Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 1,221 | |||
Ending balance | 1,073 | |||
Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 45 | £ 54 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 2 | |||
Limit management and final repayments | (13) | |||
Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 8,635 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 113,708 | 81,901 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 26,344 | |||
Limit management and final repayments | (3,172) | |||
Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 19,332 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 225,746 | 207,440 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 40,220 | |||
Limit management and final repayments | (41,246) | |||
Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 0 | 0 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 27 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 116 | 89 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 1 | |||
Limit management and final repayments | (1) | |||
Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (35) | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 371 | 410 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 43 | |||
Limit management and final repayments | (47) | |||
Impairment allowance | Impairment release on loan commitments and other financial guarantees | ||||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Income statement charge for the period | (40) | |||
Impairment allowance | Impairment charge on other financial assets4 | ||||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Income statement charge for the period | 23 | |||
Financial assets at amortised cost | Loans and advances | ||||
Loans and advances at amortised cost | ||||
Disposals | 0 | |||
Write-offs | 560 | £ 606 | ||
Financial assets at amortised cost | Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 11,371 | |||
Business activity in the year | 1,185 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (65) | |||
Final repayments | 639 | |||
Disposals | 0 | |||
Write-offs | 10 | |||
Ending balance | 11,972 | |||
Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 28,262 | |||
Business activity in the year | 6,228 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (3,357) | |||
Final repayments | 2,324 | |||
Disposals | 205 | |||
Write-offs | 364 | |||
Ending balance | 34,954 | |||
Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 109,125 | |||
Business activity in the year | 26,558 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (20,235) | |||
Final repayments | 19,033 | |||
Disposals | 77 | |||
Write-offs | 186 | |||
Ending balance | 136,622 | |||
Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Loans and advances | ||||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
ECL movement excluding assets derecognised due to disposals and write-offs | 586 | |||
Recoveries and reimbursements | (31) | |||
Exchange and other adjustments | (245) | |||
Financial assets at amortised cost | Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 386 | |||
Business activity in the year | 2 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (7) | |||
Final repayments | (2) | |||
Disposals | 0 | |||
Write-offs | (10) | |||
Ending balance | 369 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
ECL movement excluding assets derecognised due to disposals and write-offs | (7) | |||
Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 2,302 | |||
Business activity in the year | 348 | |||
Refinements to models used for calculation | 326 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (169) | |||
Final repayments | (32) | |||
Disposals | (28) | |||
Write-offs | (364) | |||
Ending balance | 2,383 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
ECL movement excluding assets derecognised due to disposals and write-offs | 473 | |||
Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 811 | |||
Business activity in the year | 41 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 168 | |||
Final repayments | (89) | |||
Disposals | (47) | |||
Write-offs | (186) | |||
Ending balance | 698 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
ECL movement excluding assets derecognised due to disposals and write-offs | 120 | |||
Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Stage 1 | Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 44 | 53 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 2 | |||
Limit management and final repayments | (13) | |||
Stage 1 | Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 10,050 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 111,197 | 78,655 | ||
Net transfers between stages | (645) | |||
Business activity in the year | 26,149 | |||
Limit management and final repayments | (3,012) | |||
Stage 1 | Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 17,664 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 206,564 | 178,006 | ||
Net transfers between stages | 9,900 | |||
Business activity in the year | 37,356 | |||
Limit management and final repayments | (36,362) | |||
Stage 1 | Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 0 | 0 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Stage 1 | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 24 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 65 | 36 | ||
Net transfers between stages | 4 | |||
Business activity in the year | 1 | |||
Limit management and final repayments | 0 | |||
Stage 1 | Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (9) | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 199 | 167 | ||
Net transfers between stages | 36 | |||
Business activity in the year | 19 | |||
Limit management and final repayments | (14) | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 9,760 | |||
Business activity in the year | 1,185 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (52) | |||
Final repayments | 534 | |||
Disposals | 0 | |||
Write-offs | 0 | |||
Ending balance | 10,461 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (219) | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 330 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (127) | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 14 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 24,011 | |||
Business activity in the year | 6,041 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (2,749) | |||
Final repayments | 2,019 | |||
Disposals | 152 | |||
Write-offs | 0 | |||
Ending balance | 29,940 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (1,293) | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 944 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (356) | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 15 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 95,242 | |||
Business activity in the year | 24,929 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (18,690) | |||
Final repayments | 17,308 | |||
Disposals | 0 | |||
Write-offs | 0 | |||
Ending balance | 124,360 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (2,035) | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 4,848 | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (38) | |||
Stage 1 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 32 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 8 | |||
Business activity in the year | 2 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (13) | |||
Final repayments | 0 | |||
Disposals | 0 | |||
Write-offs | 0 | |||
Ending balance | 10 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 13 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 605 | |||
Business activity in the year | 331 | |||
Refinements to models used for calculation | 43 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (453) | |||
Final repayments | (14) | |||
Disposals | (4) | |||
Write-offs | 0 | |||
Ending balance | 679 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (28) | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 199 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (7) | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 7 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 183 | |||
Business activity in the year | 28 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 31 | |||
Final repayments | (23) | |||
Disposals | 0 | |||
Write-offs | 0 | |||
Ending balance | 246 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (4) | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 31 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Stage 1 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 2 | Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 0 | 0 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Lifetime expected credit losses | Stage 2 | Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,156) | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 2,458 | 3,214 | ||
Net transfers between stages | 361 | |||
Business activity in the year | 195 | |||
Limit management and final repayments | (156) | |||
Lifetime expected credit losses | Stage 2 | Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,526 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 18,333 | 28,417 | ||
Net transfers between stages | (9,835) | |||
Business activity in the year | 2,864 | |||
Limit management and final repayments | (4,639) | |||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 0 | 0 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 34 | 33 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (23) | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 172 | 241 | ||
Net transfers between stages | (37) | |||
Business activity in the year | 24 | |||
Limit management and final repayments | (33) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 653 | |||
Business activity in the year | 0 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (7) | |||
Final repayments | 24 | |||
Disposals | 0 | |||
Write-offs | 0 | |||
Ending balance | 495 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 219 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (330) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (51) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 21 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 2,782 | |||
Business activity in the year | 174 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (485) | |||
Final repayments | 193 | |||
Disposals | 27 | |||
Write-offs | 0 | |||
Ending balance | 3,332 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 1,293 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (944) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (270) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 32 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 12,962 | |||
Business activity in the year | 1,628 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,555) | |||
Final repayments | 1,681 | |||
Disposals | 31 | |||
Write-offs | 0 | |||
Ending balance | 11,555 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 2,035 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (4,848) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (66) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 1 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 35 | |||
Business activity in the year | 0 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) | |||
Final repayments | (1) | |||
Disposals | 0 | |||
Write-offs | 0 | |||
Ending balance | 16 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (13) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (3) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 2 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 791 | |||
Business activity in the year | 15 | |||
Refinements to models used for calculation | 187 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 145 | |||
Final repayments | (13) | |||
Disposals | (10) | |||
Write-offs | 0 | |||
Ending balance | 821 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 28 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (199) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (127) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 4 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 193 | |||
Business activity in the year | 13 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 46 | |||
Final repayments | (26) | |||
Disposals | 0 | |||
Write-offs | 0 | |||
Ending balance | 198 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 4 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (31) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (1) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 1 | 1 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Lifetime expected credit losses | Stage 3 | Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (259) | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 53 | 32 | ||
Net transfers between stages | 284 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | (4) | |||
Lifetime expected credit losses | Stage 3 | Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 142 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 849 | 1,017 | ||
Net transfers between stages | (65) | |||
Business activity in the year | 0 | |||
Limit management and final repayments | (245) | |||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 0 | 0 | ||
Net transfers between stages | 0 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 17 | 20 | ||
Net transfers between stages | (4) | |||
Business activity in the year | 0 | |||
Limit management and final repayments | (1) | |||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (3) | |||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||||
Exposure to credit risk on loan commitments and financial guarantee contracts | 0 | £ 2 | ||
Net transfers between stages | 1 | |||
Business activity in the year | 0 | |||
Limit management and final repayments | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 958 | |||
Business activity in the year | 0 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (6) | |||
Final repayments | 81 | |||
Disposals | 0 | |||
Write-offs | 10 | |||
Ending balance | 1,016 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 178 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (35) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 1,469 | |||
Business activity in the year | 13 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (123) | |||
Final repayments | 112 | |||
Disposals | 26 | |||
Write-offs | 364 | |||
Ending balance | 1,682 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 626 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (47) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 921 | |||
Business activity in the year | 1 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 10 | |||
Final repayments | 44 | |||
Disposals | 46 | |||
Write-offs | 186 | |||
Ending balance | 707 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 104 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Gross exposure | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (33) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Home loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 343 | |||
Business activity in the year | 0 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 10 | |||
Final repayments | (1) | |||
Write-offs | (10) | |||
Ending balance | 343 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 3 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Home loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (2) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||||
Loans and advances at amortised cost | ||||
Opening balance | 906 | |||
Business activity in the year | 2 | |||
Refinements to models used for calculation | 96 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 139 | |||
Final repayments | (5) | |||
Disposals | (14) | |||
Write-offs | (364) | |||
Ending balance | 883 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 134 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | (11) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | ||||
Loans and advances at amortised cost | ||||
Opening balance | 435 | |||
Business activity in the year | 0 | |||
Refinements to models used for calculation | 0 | |||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 91 | |||
Final repayments | (40) | |||
Disposals | (47) | |||
Write-offs | (186) | |||
Ending balance | 254 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 0 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers to Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | 1 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost | Impairment allowance | Wholesale loans | Transfers from Stage 3 | ||||
Loans and advances at amortised cost | ||||
Increase (decrease) through transfers, financial assets | £ 0 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Credit Risk - Management adjust
Credit Risk - Management adjustments to models for impairment charge (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 753 | £ 1,142 |
Proportion of total impairment allowances | 19.10% | 28.60% |
Loans and advances | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 753 | £ 1,142 |
Impairment allowance | 3,937 | 3,998 |
Loans and advances | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Impairment allowance pre management adjustments | 3,184 | 2,856 |
Loans and advances | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 714 | 1,049 |
Loans and advances | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 39 | 93 |
Loans and advances | Modelled ECL | ||
Disclosure of financial assets [line items] | ||
Impairment allowance | 2,700 | 2,200 |
Loans and advances | Individually assessed impairments | ||
Disclosure of financial assets [line items] | ||
Impairment allowance | 300 | 500 |
Loans and advances | Non-modelled ECL | ||
Disclosure of financial assets [line items] | ||
Impairment allowance | 200 | 200 |
Home loans | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 5 | £ 34 |
Proportion of total impairment allowances | 1.40% | 8.80% |
Impairment allowance | £ 369 | £ 386 |
Home loans | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Impairment allowance pre management adjustments | 364 | 352 |
Home loans | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 5 | 34 |
Home loans | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 0 | 0 |
Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 557 | £ 966 |
Proportion of total impairment allowances | 22.30% | 40.40% |
Impairment allowance | £ 2,495 | £ 2,391 |
Credit cards, unsecured loans and other retail lending | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Impairment allowance pre management adjustments | 1,938 | 1,425 |
Credit cards, unsecured loans and other retail lending | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 416 | 771 |
Credit cards, unsecured loans and other retail lending | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 141 | 195 |
Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 191 | £ 142 |
Proportion of total impairment allowances | 17.80% | 11.60% |
Impairment allowance | £ 1,073 | £ 1,221 |
Wholesale loans | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Impairment allowance pre management adjustments | 882 | 1,079 |
Wholesale loans | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 293 | 244 |
Wholesale loans | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ (102) | £ (102) |
Credit Risk - Movement in gross
Credit Risk - Movement in gross exposure for loans and advances at amortised cost - footnotes narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2022 | |
Financial guarantee contracts | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Post write-off recoveries | £ 20 | £ 15 | ||
Net release in ECL | 11 | 216 | ||
Home loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 11,603 | 10,985 | ||
Home loans | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 10,451 | 9,752 | ||
Home loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 479 | 618 | ||
Home loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 673 | 615 | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 32,571 | 25,960 | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 29,261 | 23,406 | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 2,511 | 1,991 | ||
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 799 | 563 | ||
Wholesale loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 135,924 | 108,314 | ||
Wholesale loans | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 124,114 | 95,059 | ||
Wholesale loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 11,357 | 12,769 | ||
Wholesale loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 453 | 486 | ||
Loans and advances | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Gross write-offs | 560 | £ 606 | ||
Post write-off recoveries | 20 | 15 | ||
Net write-offs | 540 | £ 591 | ||
Financial assets | 180,098 | 145,259 | ||
Loans and advances | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 163,826 | 128,217 | ||
Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 14,347 | 15,378 | ||
Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 1,925 | 1,664 | ||
Impairment allowance | Home loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 2 | |||
Gross write-offs | (10) | |||
Financial assets | (369) | (386) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Home loans | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 2 | |||
Gross write-offs | 0 | |||
Financial assets | (10) | (8) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Home loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 0 | |||
Gross write-offs | 0 | |||
Financial assets | (16) | (35) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Home loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 0 | |||
Gross write-offs | (10) | |||
Financial assets | (343) | (343) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 348 | |||
Gross write-offs | (364) | |||
Financial assets | (2,383) | (2,302) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | (326) | |||
Impairment allowance | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 331 | |||
Gross write-offs | 0 | |||
Financial assets | (679) | (605) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | (43) | |||
Impairment allowance | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 15 | |||
Gross write-offs | 0 | |||
Financial assets | (821) | (791) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | (187) | |||
Impairment allowance | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 2 | |||
Gross write-offs | (364) | |||
Financial assets | (883) | (906) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | (96) | |||
Impairment allowance | Wholesale loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 41 | |||
Gross write-offs | (186) | |||
Financial assets | (698) | (811) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Wholesale loans | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 28 | |||
Gross write-offs | 0 | |||
Financial assets | (246) | (183) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Wholesale loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 13 | |||
Gross write-offs | 0 | |||
Financial assets | (198) | (193) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Wholesale loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 0 | |||
Gross write-offs | (186) | |||
Financial assets | (254) | (435) | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Impairment allowance | Loans and advances | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (3,450) | (3,499) | ||
Impairment allowance | Loans and advances | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (935) | (796) | ||
Impairment allowance | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1,035) | (1,019) | ||
Impairment allowance | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (1,480) | (1,684) | ||
Impairment allowance | Impairment charge on other financial assets4 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (138) | (104) | ||
Impairment allowance | Impairment charge on other financial assets4 | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (7) | (4) | ||
Impairment allowance | Impairment charge on other financial assets4 | Stage 1 | Provision for credit commitments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (7) | (4) | ||
Impairment allowance | Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (2) | 0 | ||
Impairment allowance | Other assets | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | (129) | (100) | ||
Gross exposure | US cards | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 2,700 | |||
Gross exposure | Home loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 1,185 | |||
Gross write-offs | 10 | |||
Financial assets | 11,972 | 11,371 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Home loans | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 1,185 | |||
Gross write-offs | 0 | |||
Financial assets | 10,461 | 9,760 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Home loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 0 | |||
Gross write-offs | 0 | |||
Financial assets | 495 | 653 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Home loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 0 | |||
Gross write-offs | 10 | |||
Financial assets | 1,016 | 958 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 6,228 | |||
Gross write-offs | 364 | |||
Financial assets | 34,954 | 28,262 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Decrease through disposal, financial assets | 200 | |||
Gross exposure | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 6,041 | |||
Gross write-offs | 0 | |||
Financial assets | 29,940 | 24,011 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 174 | |||
Gross write-offs | 0 | |||
Financial assets | 3,332 | 2,782 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 13 | |||
Gross write-offs | 364 | |||
Financial assets | 1,682 | 1,469 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Wholesale loans | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 26,558 | |||
Gross write-offs | 186 | |||
Financial assets | 136,622 | 109,125 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Wholesale loans | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 24,929 | |||
Gross write-offs | 0 | |||
Financial assets | 124,360 | 95,242 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Wholesale loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 1,628 | |||
Gross write-offs | 0 | |||
Financial assets | 11,555 | 12,962 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Wholesale loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Business activity in the year | 1 | |||
Gross write-offs | 186 | |||
Financial assets | 707 | 921 | ||
Increase (decrease) through changes in models or risk parameters, financial assets | 0 | |||
Gross exposure | Loans and advances | Financial assets at amortised cost | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 183,548 | 148,758 | ||
Gross exposure | Loans and advances | Financial assets at amortised cost | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 164,761 | 129,013 | ||
Gross exposure | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 15,382 | 16,397 | ||
Gross exposure | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 3,405 | 3,348 | ||
Gross exposure | Impairment charge on other financial assets4 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 173,900 | 135,500 | ||
Gross exposure | Impairment charge on other financial assets4 | Stage 1 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 172,100 | 135,300 | ||
Gross exposure | Impairment charge on other financial assets4 | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 129 | 100 | ||
Gross exposure | Impairment charge on other financial assets4 | Lifetime expected credit losses | Stage 3 | Provision for credit commitments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 133 | £ 100 | ||
Gross exposure | Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 1,700 | 65 | ||
Gross exposure | Other assets | Lifetime expected credit losses | Stage 3 | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | 129 | 100 | ||
Gross exposure | Other assets | Lifetime expected credit losses | Stage 3 | Provision for credit commitments | ||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||
Financial assets | £ 133 | £ 100 |
Credit Risk - Movement in gro_2
Credit Risk - Movement in gross exposure for loan commitment and financial guarantees (Details) £ in Millions | 6 Months Ended |
Jun. 30, 2022 GBP (£) | |
Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | £ 54 |
Net transfers between stages | 0 |
Business activity in the year | 2 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 |
Limit management and final repayments | (13) |
Ending balance | 45 |
Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 81,901 |
Net transfers between stages | 0 |
Business activity in the year | 26,344 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 8,635 |
Limit management and final repayments | (3,172) |
Ending balance | 113,708 |
Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 207,440 |
Net transfers between stages | 0 |
Business activity in the year | 40,220 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 19,332 |
Limit management and final repayments | (41,246) |
Ending balance | 225,746 |
Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 89 |
Net transfers between stages | 0 |
Business activity in the year | 1 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 27 |
Limit management and final repayments | (1) |
Ending balance | 116 |
Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 410 |
Net transfers between stages | 0 |
Business activity in the year | 43 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (35) |
Limit management and final repayments | (47) |
Ending balance | 371 |
Stage 1 | Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 53 |
Net transfers between stages | 0 |
Business activity in the year | 2 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 |
Limit management and final repayments | (13) |
Ending balance | 44 |
Stage 1 | Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 78,655 |
Net transfers between stages | (645) |
Business activity in the year | 26,149 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 10,050 |
Limit management and final repayments | (3,012) |
Ending balance | 111,197 |
Stage 1 | Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 178,006 |
Net transfers between stages | 9,900 |
Business activity in the year | 37,356 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 17,664 |
Limit management and final repayments | (36,362) |
Ending balance | 206,564 |
Stage 1 | Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Stage 1 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 36 |
Net transfers between stages | 4 |
Business activity in the year | 1 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 24 |
Limit management and final repayments | 0 |
Ending balance | 65 |
Stage 1 | Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 167 |
Net transfers between stages | 36 |
Business activity in the year | 19 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (9) |
Limit management and final repayments | (14) |
Ending balance | 199 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 3,214 |
Net transfers between stages | 361 |
Business activity in the year | 195 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,156) |
Limit management and final repayments | (156) |
Ending balance | 2,458 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 28,417 |
Net transfers between stages | (9,835) |
Business activity in the year | 2,864 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,526 |
Limit management and final repayments | (4,639) |
Ending balance | 18,333 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 33 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1 |
Limit management and final repayments | 0 |
Ending balance | 34 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 241 |
Net transfers between stages | (37) |
Business activity in the year | 24 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (23) |
Limit management and final repayments | (33) |
Ending balance | 172 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 1 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 1 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 32 |
Net transfers between stages | 284 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (259) |
Limit management and final repayments | (4) |
Ending balance | 53 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 1,017 |
Net transfers between stages | (65) |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 142 |
Limit management and final repayments | (245) |
Ending balance | 849 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 20 |
Net transfers between stages | (4) |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 |
Limit management and final repayments | (1) |
Ending balance | 17 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 2 |
Net transfers between stages | 1 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (3) |
Limit management and final repayments | 0 |
Ending balance | £ 0 |
Credit Risk - Economic uncertai
Credit Risk - Economic uncertainty adjustments (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Covid-19 Related Uncertainty Adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 700 | £ 1,000 |
Covid-19 Related Uncertainty Adjustments | Customers | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 600 | 900 |
Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 2,495 | 2,391 |
Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 1,073 | 1,221 |
Wholesale loans | Covid-19 Related Uncertainty Adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 200 | 200 |
Loans and advances | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 3,937 | 3,998 |
Loans and advances | Covid-19 Related Uncertainty Adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 900 | |
Loans and advances | Covid-19 Related Uncertainty Adjustments | Customers | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 600 | 100 |
USA | Credit cards, unsecured loans and other retail lending | Covid-19 Related Uncertainty Adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 400 | 600 |
Model Uncertainty Risk | Covid-19 Related Uncertainty Adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 100 | £ 100 |
Credit Risk - Measurement uncer
Credit Risk - Measurement uncertainty, narrative (Details) £ in Billions | 6 Months Ended | |
Jun. 30, 2022 GBP (£) economic_scenario | Dec. 31, 2021 GBP (£) | |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios, percentage | 100% | |
Covid-19 Related Uncertainty Adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 0.7 | £ 1 |
Covid-19 Related Uncertainty Adjustments | Customers | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 0.6 | 0.9 |
Credit risk | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 5 | |
Stress horizon period | 5 years | |
Term at which scenario converges to steady state | 7 years | |
Credit risk | Downside Scenario | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic variables to calculate ECL | economic_scenario | 2 | |
Credit risk | Upside Scenario | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 2 | |
Model Uncertainty Risk | Covid-19 Related Uncertainty Adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | £ | £ 0.1 | £ 0.1 |
UK | Downside 2 | Not later than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Bank rate | 2.75% | |
UK | Downside 2 | Later than three months and not later than six months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Bank rate | 5% | |
UK | Downside 2 | Later than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.20% | |
USA | Downside 2 | Not later than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Federal funds rate | 3.25% | |
USA | Downside 2 | Later than three months and not later than six months | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Federal funds rate | 5% | |
USA | Downside 2 | Later than one year | Unemployment | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.50% |
Credit Risk - Measurement unc_2
Credit Risk - Measurement uncertainty - Average macroeconomic variables used in the calculation of ECL (Details) | Jun. 30, 2022 | Dec. 31, 2021 |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 37.80% | 30.10% |
Baseline | GDP | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 6.20% |
Baseline | GDP | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 5.50% |
Baseline | GDP | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 4.90% |
Baseline | GDP | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 3.90% |
Baseline | GDP | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 2.30% |
Baseline | GDP | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.60% |
Baseline | GDP | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 1.90% |
Baseline | GDP | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.40% |
Baseline | GDP | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 1.70% |
Baseline | GDP | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.40% |
Baseline | Unemployment | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 4.80% |
Baseline | Unemployment | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.50% |
Baseline | Unemployment | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.70% |
Baseline | Unemployment | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.20% |
Baseline | Unemployment | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.50% |
Baseline | Unemployment | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.60% |
Baseline | Unemployment | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.30% |
Baseline | Unemployment | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.60% |
Baseline | Unemployment | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.20% |
Baseline | Unemployment | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.60% |
Baseline | HPI | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 4.70% |
Baseline | HPI | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 11.80% |
Baseline | HPI | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1% | 1% |
Baseline | HPI | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.50% |
Baseline | HPI | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 1.90% |
Baseline | HPI | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5.20% |
Baseline | HPI | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 1.90% |
Baseline | HPI | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.90% |
Baseline | HPI | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2.30% |
Baseline | HPI | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5% |
Baseline | Bank rate | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.10% |
Baseline | Bank rate | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 0.80% |
Baseline | Bank rate | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 1% |
Baseline | Bank rate | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 1% |
Baseline | Bank rate | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 0.80% |
Baseline | Federal funds rate | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.20% |
Baseline | Federal funds rate | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 0.30% |
Baseline | Federal funds rate | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 0.90% |
Baseline | Federal funds rate | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 1.20% |
Baseline | Federal funds rate | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 1.30% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.40% | 7% |
Downside 2 | GDP | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 6.20% |
Downside 2 | GDP | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 5.50% |
Downside 2 | GDP | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.80%) | 0.20% |
Downside 2 | GDP | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.10%) | (0.80%) |
Downside 2 | GDP | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.40%) | (4.00%) |
Downside 2 | GDP | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.20%) | (3.50%) |
Downside 2 | GDP | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 2.80% |
Downside 2 | GDP | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 2.50% |
Downside 2 | GDP | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4.30% |
Downside 2 | GDP | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 3.20% |
Downside 2 | Unemployment | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 4.80% |
Downside 2 | Unemployment | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 5.50% |
Downside 2 | Unemployment | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.40% | 7.20% |
Downside 2 | Unemployment | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8% | 6.40% |
Downside 2 | Unemployment | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.60% | 9% |
Downside 2 | Unemployment | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9% | 9.10% |
Downside 2 | Unemployment | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.80% | 7.60% |
Downside 2 | Unemployment | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.10% | 8.10% |
Downside 2 | Unemployment | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.90% | 6.30% |
Downside 2 | Unemployment | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.80% | 6.40% |
Downside 2 | HPI | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 4.70% |
Downside 2 | HPI | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.20%) | 11.80% |
Downside 2 | HPI | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (26.20%) | (14.30%) |
Downside 2 | HPI | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (11.70%) | (6.60%) |
Downside 2 | HPI | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (3.60%) | (21.80%) |
Downside 2 | HPI | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.20%) | (9.00%) |
Downside 2 | HPI | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 17.90% | 11.90% |
Downside 2 | HPI | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 5.90% |
Downside 2 | HPI | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 10.20% | 15.20% |
Downside 2 | HPI | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.70% |
Downside 2 | Bank rate | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 0.10% |
Downside 2 | Bank rate | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 2.20% |
Downside 2 | Bank rate | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 3.90% |
Downside 2 | Bank rate | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 3.10% |
Downside 2 | Bank rate | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 2.20% |
Downside 2 | Federal funds rate | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 0.20% |
Downside 2 | Federal funds rate | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 2.10% |
Downside 2 | Federal funds rate | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 3.40% |
Downside 2 | Federal funds rate | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 2.60% |
Downside 2 | Federal funds rate | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 2% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 15.20% | 14.80% |
Downside 1 | GDP | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.20% |
Downside 1 | GDP | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 5.50% |
Downside 1 | GDP | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.60%) | 2.80% |
Downside 1 | GDP | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.00%) | 1.60% |
Downside 1 | GDP | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | (0.70%) |
Downside 1 | GDP | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | (0.40%) |
Downside 1 | GDP | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 2.30% |
Downside 1 | GDP | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 2.40% |
Downside 1 | GDP | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 2.90% |
Downside 1 | GDP | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.70% |
Downside 1 | Unemployment | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 4.80% |
Downside 1 | Unemployment | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 5.50% |
Downside 1 | Unemployment | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 6.20% |
Downside 1 | Unemployment | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 5.40% |
Downside 1 | Unemployment | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 6.80% |
Downside 1 | Unemployment | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 6.60% |
Downside 1 | Unemployment | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 6% |
Downside 1 | Unemployment | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 6.10% |
Downside 1 | Unemployment | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 5.30% |
Downside 1 | Unemployment | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 5.20% |
Downside 1 | HPI | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 4.70% |
Downside 1 | HPI | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 11.80% |
Downside 1 | HPI | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (13.20%) | (6.80%) |
Downside 1 | HPI | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.40%) | (1.20%) |
Downside 1 | HPI | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.80%) | (10.50%) |
Downside 1 | HPI | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | (2.10%) |
Downside 1 | HPI | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 10% | 6.90% |
Downside 1 | HPI | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 4.80% |
Downside 1 | HPI | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 8.60% |
Downside 1 | HPI | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5.20% |
Downside 1 | Bank rate | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.10% |
Downside 1 | Bank rate | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 1.60% |
Downside 1 | Bank rate | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 2.70% |
Downside 1 | Bank rate | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.30% |
Downside 1 | Bank rate | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 1.60% |
Downside 1 | Federal funds rate | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.20% |
Downside 1 | Federal funds rate | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 1.30% |
Downside 1 | Federal funds rate | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 2.30% |
Downside 1 | Federal funds rate | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 2.10% |
Downside 1 | Federal funds rate | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 1.80% |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 14% | 20.90% |
Upside 2 | GDP | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | 6.20% |
Upside 2 | GDP | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 5.50% |
Upside 2 | GDP | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 7.20% |
Upside 2 | GDP | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 5.30% |
Upside 2 | GDP | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 4% |
Upside 2 | GDP | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4.10% |
Upside 2 | GDP | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.70% |
Upside 2 | GDP | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.50% |
Upside 2 | GDP | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.10% |
Upside 2 | GDP | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.40% |
Upside 2 | Unemployment | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.80% |
Upside 2 | Unemployment | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5.50% |
Upside 2 | Unemployment | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.50% |
Upside 2 | Unemployment | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.90% |
Upside 2 | Unemployment | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4.10% |
Upside 2 | Unemployment | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.40% |
Upside 2 | Unemployment | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4% |
Upside 2 | Unemployment | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.30% |
Upside 2 | Unemployment | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4% |
Upside 2 | Unemployment | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.30% |
Upside 2 | HPI | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 4.70% |
Upside 2 | HPI | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.40% | 11.80% |
Upside 2 | HPI | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.20% | 8.50% |
Upside 2 | HPI | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 10.60% |
Upside 2 | HPI | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 9% |
Upside 2 | HPI | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 8.50% |
Upside 2 | HPI | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 5.20% |
Upside 2 | HPI | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 7.20% |
Upside 2 | HPI | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.20% |
Upside 2 | HPI | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.60% |
Upside 2 | Bank rate | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.20% | 0.10% |
Upside 2 | Bank rate | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.20% |
Upside 2 | Bank rate | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.40% | 0.50% |
Upside 2 | Bank rate | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.50% |
Upside 2 | Bank rate | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.30% |
Upside 2 | Federal funds rate | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | 0.20% |
Upside 2 | Federal funds rate | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 0.30% |
Upside 2 | Federal funds rate | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 0.40% |
Upside 2 | Federal funds rate | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.70% |
Upside 2 | Federal funds rate | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 1% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 25.60% | 27.20% |
Upside 1 | GDP | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.20% |
Upside 1 | GDP | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 5.50% |
Upside 1 | GDP | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6% |
Upside 1 | GDP | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.60% |
Upside 1 | GDP | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.10% |
Upside 1 | GDP | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.40% |
Upside 1 | GDP | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.30% |
Upside 1 | GDP | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 2.90% |
Upside 1 | GDP | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 1.90% |
Upside 1 | GDP | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 2.90% |
Upside 1 | Unemployment | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.80% |
Upside 1 | Unemployment | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 5.50% |
Upside 1 | Unemployment | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.60% |
Upside 1 | Unemployment | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 4% |
Upside 1 | Unemployment | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.30% |
Upside 1 | Unemployment | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.50% |
Upside 1 | Unemployment | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.20% |
Upside 1 | Unemployment | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.50% |
Upside 1 | Unemployment | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.10% |
Upside 1 | Unemployment | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.50% |
Upside 1 | HPI | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.40% | 4.70% |
Upside 1 | HPI | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 11.80% |
Upside 1 | HPI | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.30% | 5% |
Upside 1 | HPI | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 8.30% |
Upside 1 | HPI | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 5% |
Upside 1 | HPI | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 7% |
Upside 1 | HPI | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.90% |
Upside 1 | HPI | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 6% |
Upside 1 | HPI | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.30% |
Upside 1 | HPI | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 5.70% |
Upside 1 | Bank rate | Not later than one year | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.10% |
Upside 1 | Bank rate | One to two years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 0.60% |
Upside 1 | Bank rate | Two to three years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.80% |
Upside 1 | Bank rate | Three to four years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.80% |
Upside 1 | Bank rate | Four to five years | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.50% |
Upside 1 | Federal funds rate | Not later than one year | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.20% |
Upside 1 | Federal funds rate | One to two years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 0.30% |
Upside 1 | Federal funds rate | Two to three years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 0.60% |
Upside 1 | Federal funds rate | Three to four years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 1% |
Upside 1 | Federal funds rate | Four to five years | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 1.10% |
Credit Risk - Measurement unc_3
Credit Risk - Measurement uncertainty - Scenario probability weighting (Details) | Jun. 30, 2022 | Dec. 31, 2021 |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 14% | 20.90% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 25.60% | 27.20% |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 37.80% | 30.10% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 15.20% | 14.80% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.40% | 7% |
Credit Risk - Measurement unc_4
Credit Risk - Measurement uncertainty - Macroeconomic variables (specific bases and 5-year averages) (Details) | Jun. 30, 2022 | Dec. 31, 2021 |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 14% | 20.90% |
Upside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 16.80% | 21.40% |
Upside 2 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.40% |
Upside 2 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 20.20% | 22.80% |
Upside 2 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.40% |
Upside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4% |
Upside 2 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.30% |
Upside 2 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.30% |
Upside 2 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.90% |
Upside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 36.70% | 35.70% |
Upside 2 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.40% | 6.30% |
Upside 2 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 27% | 53.30% |
Upside 2 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 8.90% |
Upside 2 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Upside 2 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.30% |
Upside 2 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.10% |
Upside 2 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.50% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 25.60% | 27.20% |
Upside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 12.80% | 18.30% |
Upside 1 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 3.90% |
Upside 1 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 16.10% | 19.60% |
Upside 1 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.90% |
Upside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.10% |
Upside 1 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.40% |
Upside 1 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.50% |
Upside 1 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4% |
Upside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 24.80% | 23.80% |
Upside 1 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 4.40% |
Upside 1 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 22.90% | 45.20% |
Upside 1 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 7.70% |
Upside 1 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Upside 1 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.50% |
Upside 1 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.10% |
Upside 1 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 0.60% |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 37.80% | 30.10% |
Baseline | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 3.40% |
Baseline | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 3.40% |
Baseline | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.40% |
Baseline | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.40% |
Baseline | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 4.50% |
Baseline | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 4.50% |
Baseline | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.10% |
Baseline | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.10% |
Baseline | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 2.40% |
Baseline | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 2.40% |
Baseline | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.20% |
Baseline | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.20% |
Baseline | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.70% |
Baseline | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.70% |
Baseline | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 0.80% |
Baseline | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 0.80% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 15.20% | 14.80% |
Downside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.10%) | (1.60%) |
Downside 1 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 2.70% |
Downside 1 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.50%) | 1.50% |
Downside 1 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 2.40% |
Downside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.60% | 7% |
Downside 1 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 5.80% |
Downside 1 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 6.80% |
Downside 1 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 5.70% |
Downside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (13.60%) | (12.70%) |
Downside 1 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.30% |
Downside 1 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.60%) | 2.20% |
Downside 1 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.40% | 3.60% |
Downside 1 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 2.80% |
Downside 1 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 1.70% |
Downside 1 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 2.30% |
Downside 1 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 1.50% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.40% | 7% |
Downside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (5.90%) | (1.60%) |
Downside 2 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | 1.80% |
Downside 2 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (5.00%) | (1.30%) |
Downside 2 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 1.30% |
Downside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.20% | 9.20% |
Downside 2 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7% | 7% |
Downside 2 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.50% | 9.50% |
Downside 2 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.90% | 7.10% |
Downside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (30.80%) | (29.90%) |
Downside 2 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.50%) | (2.00%) |
Downside 2 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (13.40%) | (5.00%) |
Downside 2 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.80%) | 1.40% |
Downside 2 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | 4% |
Downside 2 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 2.30% |
Downside 2 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | 3.50% |
Downside 2 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 2.10% |
Basis of preparation (Details)
Basis of preparation (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||||||||
Jun. 30, 2022 | Dec. 30, 2021 | [2] | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | [3] | ||||
Disclosure of retrospective restatement [line items] | ||||||||||
Litigation and conduct | £ (1,833) | £ (164) | [1] | £ (374) | ||||||
Operating expenses | (7,092) | (5,223) | [1] | (10,259) | ||||||
Profit before tax | 2,605 | 3,257 | [1] | 5,418 | ||||||
Taxation | (476) | (594) | [1] | (830) | ||||||
Profit after tax | 2,129 | [2] | £ 1,925 | 2,663 | [3] | 4,588 | ||||
Total comprehensive income for the year | 2,409 | [2] | £ 1,871 | 1,032 | [3] | |||||
Adjustment for non-cash items | 5,078 | |||||||||
Current tax liabilities | 449 | 688 | [4] | |||||||
Provisions | 2,645 | 1,110 | [4] | |||||||
Total liabilities | 1,213,829 | 1,005,461 | [4] | |||||||
Retained earnings | 46,721 | 43,415 | [4] | |||||||
Total equity | £ 58,916 | [2] | 53,636 | [3] | 56,317 | [2] | £ 53,710 | |||
Barclays PLC | ||||||||||
Disclosure of retrospective restatement [line items] | ||||||||||
Current tax liabilities | 342 | |||||||||
Provisions | 919 | |||||||||
Total liabilities | 1,011,979 | |||||||||
Retained earnings | 37,180 | |||||||||
Total equity | 52,692 | |||||||||
Previously stated | ||||||||||
Disclosure of retrospective restatement [line items] | ||||||||||
Litigation and conduct | (87) | (154) | ||||||||
Operating expenses | (5,146) | (10,039) | ||||||||
Profit before tax | 3,334 | 5,638 | ||||||||
Taxation | (611) | (880) | ||||||||
Profit after tax | 2,723 | 4,758 | ||||||||
Total comprehensive income for the year | 1,092 | |||||||||
Adjustment for non-cash items | 5,001 | |||||||||
Current tax liabilities | 738 | |||||||||
Provisions | 890 | |||||||||
Total liabilities | 1,005,291 | |||||||||
Retained earnings | 43,585 | |||||||||
Total equity | 56,487 | |||||||||
Previously stated | Barclays PLC | ||||||||||
Disclosure of retrospective restatement [line items] | ||||||||||
Current tax liabilities | 392 | |||||||||
Provisions | 699 | |||||||||
Total liabilities | 1,011,809 | |||||||||
Retained earnings | 37,350 | |||||||||
Total equity | 52,862 | |||||||||
Increase (decrease) due to corrections of prior period errors | ||||||||||
Disclosure of retrospective restatement [line items] | ||||||||||
Litigation and conduct | (77) | (220) | ||||||||
Operating expenses | (77) | (220) | ||||||||
Profit before tax | (77) | (220) | ||||||||
Taxation | 17 | 50 | ||||||||
Profit after tax | (60) | (170) | ||||||||
Total comprehensive income for the year | (60) | |||||||||
Adjustment for non-cash items | £ 77 | |||||||||
Current tax liabilities | (50) | |||||||||
Provisions | 220 | |||||||||
Total liabilities | 170 | |||||||||
Retained earnings | (170) | |||||||||
Total equity | (170) | |||||||||
Increase (decrease) due to corrections of prior period errors | Barclays PLC | ||||||||||
Disclosure of retrospective restatement [line items] | ||||||||||
Current tax liabilities | (50) | |||||||||
Provisions | 220 | |||||||||
Total liabilities | 170 | |||||||||
Retained earnings | (170) | |||||||||
Total equity | £ (170) | |||||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[3]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[4]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Segmental reporting - Analysis
Segmental reporting - Analysis of results by business (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |||
Disclosure of operating segments [line items] | |||||
Total income | £ 9,990 | £ 8,189 | [1] | ||
Credit impairment (charge)/release | (293) | 288 | [1] | ||
Net operating income | 9,697 | 8,477 | [1] | ||
Operating expenses | (5,259) | (5,059) | |||
Litigation and conduct | (1,833) | (164) | |||
Operating expenses | (7,092) | (5,223) | [1] | £ (10,259) | |
Other net income | 0 | 3 | |||
Profit before tax | 2,605 | 3,257 | [1] | 5,418 | |
Total assets | 1,272,745 | 1,061,778 | [2] | ||
Operating segments | Corporate and Investment Bank | |||||
Disclosure of operating segments [line items] | |||||
Total income | 8,086 | 6,632 | |||
Credit impairment (charge)/release | (31) | 260 | |||
Net operating income | 8,055 | 6,892 | |||
Operating expenses | (3,912) | (3,617) | |||
Litigation and conduct | (1,632) | (79) | |||
Operating expenses | (5,544) | (3,696) | |||
Other net income | 0 | 3 | |||
Profit before tax | 2,511 | 3,199 | |||
Total assets | 1,179,500 | 986,200 | |||
Operating segments | Consumer, Cards and Payments | |||||
Disclosure of operating segments [line items] | |||||
Total income | 1,992 | 1,649 | |||
Credit impairment (charge)/release | (278) | 22 | |||
Net operating income | 1,714 | 1,671 | |||
Operating expenses | (1,285) | (1,126) | |||
Litigation and conduct | (200) | (82) | |||
Operating expenses | (1,485) | (1,208) | |||
Other net income | 0 | 0 | |||
Profit before tax | 229 | 463 | |||
Total assets | 80,400 | 64,400 | |||
Head Office | |||||
Disclosure of operating segments [line items] | |||||
Total income | (88) | (92) | |||
Credit impairment (charge)/release | 16 | 6 | |||
Net operating income | (72) | (86) | |||
Operating expenses | (62) | (316) | |||
Litigation and conduct | (1) | (3) | |||
Operating expenses | (63) | (319) | |||
Other net income | 0 | 0 | |||
Profit before tax | (135) | £ (405) | |||
Total assets | £ 12,800 | £ 11,200 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Segmental reporting - Split of
Segmental reporting - Split of income by geographic region (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Disclosure of operating segments [line items] | |||
Total income | £ 9,990 | £ 8,189 | [1] |
United Kingdom | |||
Disclosure of operating segments [line items] | |||
Total income | 4,674 | 2,698 | |
Europe | |||
Disclosure of operating segments [line items] | |||
Total income | 1,310 | 1,213 | |
Americas | |||
Disclosure of operating segments [line items] | |||
Total income | 3,276 | 3,676 | |
Africa and Middle East | |||
Disclosure of operating segments [line items] | |||
Total income | 31 | 20 | |
Asia | |||
Disclosure of operating segments [line items] | |||
Total income | £ 699 | £ 582 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Net fee and commission income_2
Net fee and commission income (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | £ 3,939 | £ 4,008 | ||
Other non-contract fee income | 69 | 62 | ||
Fee and commission income | 4,008 | 4,070 | [1] | |
Fee and commission expense | (1,169) | (870) | [1] | |
Net fee and commission income | 2,839 | 3,200 | [1] | |
Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,445 | 1,168 | ||
Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 512 | 460 | ||
Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 762 | 553 | ||
Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,101 | 1,715 | ||
Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 119 | 112 | ||
Operating segments | Corporate and Investment Bank | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 2,521 | 2,850 | ||
Other non-contract fee income | 67 | 59 | ||
Fee and commission income | 2,588 | 2,909 | ||
Fee and commission expense | (461) | (369) | ||
Net fee and commission income | 2,127 | 2,540 | ||
Operating segments | Corporate and Investment Bank | Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 216 | 184 | ||
Operating segments | Corporate and Investment Bank | Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 440 | 399 | ||
Operating segments | Corporate and Investment Bank | Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 734 | 527 | ||
Operating segments | Corporate and Investment Bank | Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,101 | 1,715 | ||
Operating segments | Corporate and Investment Bank | Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 30 | 25 | ||
Operating segments | Consumer, Cards and Payments | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,407 | 1,147 | ||
Other non-contract fee income | 2 | 3 | ||
Fee and commission income | 1,409 | 1,150 | ||
Fee and commission expense | (707) | (496) | ||
Net fee and commission income | 702 | 654 | ||
Reclassification into fees and commission income | 94 | £ 81 | ||
Operating segments | Consumer, Cards and Payments | Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 1,229 | 984 | ||
Operating segments | Consumer, Cards and Payments | Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 72 | 61 | ||
Operating segments | Consumer, Cards and Payments | Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 28 | 26 | ||
Operating segments | Consumer, Cards and Payments | Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | ||
Operating segments | Consumer, Cards and Payments | Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 78 | 76 | ||
Head Office | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 11 | 11 | ||
Other non-contract fee income | 0 | 0 | ||
Fee and commission income | 11 | 11 | ||
Fee and commission expense | (1) | (5) | ||
Net fee and commission income | 10 | 6 | ||
Head Office | Transactional | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | ||
Head Office | Advisory | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | ||
Head Office | Brokerage and execution | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | ||
Head Office | Underwriting and syndication | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | 0 | 0 | ||
Head Office | Other | ||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||
Total revenue from contracts with customers | £ 11 | £ 11 | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Tax - Narrative (Details)
Tax - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | ||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Tax charge | £ 476 | £ 594 | [1] | £ 830 |
Average effective tax rate | 18.30% | 18.20% | ||
Tax rate effect of foreign tax rates | 11.20% | |||
Average effective tax rate, benefit regarding prior period adjustments | 5.70% | |||
UK | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Increase (decrease) relating to tax rate changes or imposition of new taxes, deferred tax liability (asset) | £ 100 | |||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes | 183 | |||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes, other comprehensive income | £ 83 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Tax - Deferred tax assets and l
Tax - Deferred tax assets and liabilities (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Net deferred tax assets and liabilities [abstract] | |||
Deferred tax assets | £ 3,052 | £ 2,981 | [1] |
Deferred tax liabilities | 0 | (6) | [1] |
Temporary differences | |||
Net deferred tax assets and liabilities [abstract] | |||
Deferred tax assets | 1,911 | 1,785 | |
Tax losses | |||
Net deferred tax assets and liabilities [abstract] | |||
Deferred tax assets | 1,141 | 1,196 | |
USA | |||
Net deferred tax assets and liabilities [abstract] | |||
Deferred tax assets | 1,530 | 2,006 | |
Other territories | |||
Net deferred tax assets and liabilities [abstract] | |||
Deferred tax assets | 438 | 399 | |
Deferred tax liabilities | |||
Net deferred tax assets and liabilities [abstract] | |||
Deferred tax assets | 1,084 | 576 | |
Deferred tax liabilities | £ 0 | £ (6) | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Dividends on ordinary shares (D
Dividends on ordinary shares (Details) - GBP (£) £ in Millions | 6 Months Ended | |||||
Jun. 30, 2022 | Dec. 30, 2021 | [1] | Jun. 30, 2021 | |||
Dividends on ordinary shares [Abstract] | ||||||
Ordinary shares | £ 200 | [1] | £ 781 | £ 694 | [2] | |
Preference shares | 15 | [1] | £ 27 | 13 | [2] | |
Total | £ 215 | £ 707 | ||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Fair value of financial instr_3
Fair value of financial instruments - Assets and liabilities held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | £ 126,896 | £ 146,871 | [1] |
Financial assets at fair value through the income statement | 210,430 | 188,226 | [1] |
Derivative financial instruments | 344,396 | 262,291 | [1] |
Financial assets at fair value through other comprehensive income | 43,814 | 45,908 | [1] |
Trading portfolio liabilities | (75,880) | (53,291) | [1] |
Financial liabilities designated at fair value | (255,787) | (251,131) | [1] |
Derivative financial instruments | (321,526) | (256,523) | [1] |
At fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 126,896 | 146,871 | |
Financial assets at fair value through the income statement | 210,430 | 188,226 | |
Derivative financial instruments | 344,396 | 262,291 | |
Financial assets at fair value through other comprehensive income | 43,814 | 45,908 | |
Investment property | 5 | 7 | |
Total assets | 725,541 | 643,303 | |
Trading portfolio liabilities | (75,880) | (53,291) | |
Financial liabilities designated at fair value | (255,787) | (251,131) | |
Derivative financial instruments | (321,526) | (256,523) | |
Total liabilities | (653,193) | (560,945) | |
Quoted market prices (Level 1) | At fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 58,340 | 80,836 | |
Financial assets at fair value through the income statement | 1,037 | 4,953 | |
Derivative financial instruments | 11,653 | 6,150 | |
Financial assets at fair value through other comprehensive income | 15,993 | 16,070 | |
Investment property | 0 | 0 | |
Total assets | 87,023 | 108,009 | |
Trading portfolio liabilities | (47,118) | (26,701) | |
Financial liabilities designated at fair value | (193) | (174) | |
Derivative financial instruments | (12,674) | (6,571) | |
Total liabilities | (59,985) | (33,446) | |
Observable inputs (Level 2) | At fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 64,300 | 63,754 | |
Financial assets at fair value through the income statement | 203,230 | 177,194 | |
Derivative financial instruments | 328,870 | 252,131 | |
Financial assets at fair value through other comprehensive income | 27,785 | 29,800 | |
Investment property | 0 | 0 | |
Total assets | 624,185 | 522,879 | |
Trading portfolio liabilities | (28,680) | (26,563) | |
Financial liabilities designated at fair value | (255,155) | (250,553) | |
Derivative financial instruments | (304,473) | (243,893) | |
Total liabilities | (588,308) | (521,009) | |
Significant unobservable inputs (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Total assets | 14,333 | 12,415 | |
Total liabilities | (4,900) | (6,490) | |
Significant unobservable inputs (Level 3) | At fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 4,256 | 2,281 | |
Financial assets at fair value through the income statement | 6,163 | 6,079 | |
Derivative financial instruments | 3,873 | 4,010 | |
Financial assets at fair value through other comprehensive income | 36 | 38 | |
Investment property | 5 | 7 | |
Total assets | 14,333 | 12,415 | |
Trading portfolio liabilities | (82) | (27) | |
Financial liabilities designated at fair value | (439) | (404) | |
Derivative financial instruments | (4,379) | (6,059) | |
Total liabilities | £ (4,900) | £ (6,490) | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Fair value of financial instr_4
Fair value of financial instruments - Level 3 assets and liabilities held at fair value disaggregated by product type (Details) - Significant unobservable inputs (Level 3) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Disclosure of detailed information about financial instruments [line items] | ||
Assets | £ 14,333 | £ 12,415 |
Liabilities | (4,900) | (6,490) |
Asset backed securities | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 291 | 558 |
Liabilities | 0 | 0 |
Corporate debt | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,171 | 1,205 |
Liabilities | (13) | (21) |
Reverse repurchase and repurchase agreements | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 178 | 13 |
Liabilities | (188) | (172) |
Non-asset backed loans | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 6,435 | 3,743 |
Liabilities | 0 | 0 |
Equity cash products | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 422 | 393 |
Liabilities | (3) | 0 |
Private equity investments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 123 | 148 |
Liabilities | 0 | 0 |
Other | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,840 | 2,345 |
Liabilities | (317) | (238) |
Interest rate derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,573 | 1,091 |
Liabilities | (1,849) | (1,351) |
Foreign exchange derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 786 | 376 |
Liabilities | (560) | (374) |
Credit derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 234 | 323 |
Liabilities | (615) | (709) |
Equity derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,280 | 2,220 |
Liabilities | £ (1,355) | £ (3,625) |
Fair value of financial instr_5
Fair value of financial instruments - Analysis of movements in Level 3 assets and liabilities (Details) - GBP (£) £ in Millions | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | [1] | |
Net assets (liabilities) [abstract] | ||||
Derivative financial assets | £ 344,396 | £ 262,291 | ||
Derivative financial instruments | 321,526 | £ 256,523 | ||
Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 12,415 | |||
Ending balance, financial assets | 14,333 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | (6,490) | |||
Ending balance, financial liabilities | (4,900) | |||
Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, Assets (liabilities) net | 5,925 | £ 4,278 | ||
Purchases, fair value measurement, assets (liabilities) net | 9,507 | 3,824 | ||
Sales, fair value measurement, assets (liabilities) net | (7,170) | (3,405) | ||
Issues, fair value measurement, assets (liabilities) net | (13) | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | (525) | (543) | ||
Total gains or losses recognised in OCI, assets (liabilities) | (2) | 1 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 574 | 458 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 87 | 174 | ||
Ending balance, Assets (liabilities) net | 9,433 | 4,354 | ||
Derivative financial assets | 3,873 | 3,656 | ||
Derivative financial instruments | 4,379 | 5,599 | ||
Recurring fair value measurement | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 866 | (458) | ||
Recurring fair value measurement | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 184 | 25 | ||
Recurring fair value measurement | Investment property | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 7 | 10 | ||
Purchases, fair value measurement, assets | 0 | 0 | ||
Sales, fair value measurement, assets | (1) | (2) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Ending balance, financial assets | 5 | 8 | ||
Recurring fair value measurement | Investment property | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Recurring fair value measurement | Investment property | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | (1) | 0 | ||
Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, Assets (liabilities) net | (2,049) | (1,771) | ||
Purchases, fair value measurement, assets (liabilities) net | (94) | (424) | ||
Sales, fair value measurement, assets (liabilities) net | 5 | 1 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | 217 | 54 | ||
Total gains or losses recognised in OCI, assets (liabilities) | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 217 | 53 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 358 | 477 | ||
Ending balance, Assets (liabilities) net | (506) | (1,943) | ||
Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 849 | (336) | ||
Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (9) | 3 | ||
Trading portfolio liabilities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial liabilities | ||||
Beginning balance, financial liabilities | (27) | (28) | ||
Purchases, fair value measurement, liabilities | (35) | (3) | ||
Sales, fair value measurement, liabilities | 3 | 14 | ||
Issues, fair value measurement, liabilities | 0 | 0 | ||
Settlements, fair value measurement, liabilities | 0 | 0 | ||
Total gains or losses recognised in OCI, liabilities | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, liabilities | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, liabilities | 6 | 7 | ||
Ending balance, financial liabilities | (82) | (17) | ||
Trading portfolio liabilities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category trading | ||||
Financial liabilities | ||||
Total gains and losses in the period recognised in the income statement, liabilities | (29) | (7) | ||
Trading portfolio liabilities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category other income | ||||
Financial liabilities | ||||
Total gains and losses in the period recognised in the income statement, liabilities | 0 | 0 | ||
Financial liabilities designated at fair value | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial liabilities | ||||
Beginning balance, financial liabilities | (404) | (341) | ||
Purchases, fair value measurement, liabilities | (5) | 0 | ||
Sales, fair value measurement, liabilities | 0 | 0 | ||
Issues, fair value measurement, liabilities | (13) | 0 | ||
Settlements, fair value measurement, liabilities | 47 | 98 | ||
Total gains or losses recognised in OCI, liabilities | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, liabilities | 81 | 78 | ||
Transfers out of Level 3 of fair value hierarchy, liabilities | 37 | 18 | ||
Ending balance, financial liabilities | (439) | (296) | ||
Financial liabilities designated at fair value | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category trading | ||||
Financial liabilities | ||||
Total gains and losses in the period recognised in the income statement, liabilities | (22) | 7 | ||
Financial liabilities designated at fair value | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category other income | ||||
Financial liabilities | ||||
Total gains and losses in the period recognised in the income statement, liabilities | 2 | 0 | ||
Asset backed securities | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 558 | |||
Ending balance, financial assets | 291 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | 0 | |||
Ending balance, financial liabilities | 0 | |||
Interest rate derivatives | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 1,091 | |||
Ending balance, financial assets | 1,573 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | (1,351) | |||
Ending balance, financial liabilities | (1,849) | |||
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, Assets (liabilities) net | (260) | (2) | ||
Purchases, fair value measurement, assets (liabilities) net | 25 | 9 | ||
Sales, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | (4) | 33 | ||
Total gains or losses recognised in OCI, assets (liabilities) | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 271 | 21 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 6 | (296) | ||
Ending balance, Assets (liabilities) net | (276) | (352) | ||
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (305) | (121) | ||
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (9) | 4 | ||
Foreign exchange derivatives | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 376 | |||
Ending balance, financial assets | 786 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | (374) | |||
Ending balance, financial liabilities | (560) | |||
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, Assets (liabilities) net | 2 | 1 | ||
Purchases, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Sales, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | (9) | 58 | ||
Total gains or losses recognised in OCI, assets (liabilities) | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (65) | 3 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 25 | (34) | ||
Ending balance, Assets (liabilities) net | 226 | 22 | ||
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 273 | (6) | ||
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Credit derivatives | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 323 | |||
Ending balance, financial assets | 234 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | (709) | |||
Ending balance, financial liabilities | (615) | |||
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, Assets (liabilities) net | (386) | (155) | ||
Purchases, fair value measurement, assets (liabilities) net | (36) | (118) | ||
Sales, fair value measurement, assets (liabilities) net | 5 | 2 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | 60 | (5) | ||
Total gains or losses recognised in OCI, assets (liabilities) | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 20 | 1 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 55 | (1) | ||
Ending balance, Assets (liabilities) net | (381) | (265) | ||
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (99) | 12 | ||
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | (1) | ||
Equity derivatives | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 2,220 | |||
Ending balance, financial assets | 1,280 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | (3,625) | |||
Ending balance, financial liabilities | (1,355) | |||
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, Assets (liabilities) net | (1,405) | (1,615) | ||
Purchases, fair value measurement, assets (liabilities) net | (83) | (315) | ||
Sales, fair value measurement, assets (liabilities) net | 0 | (1) | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | 170 | (32) | ||
Total gains or losses recognised in OCI, assets (liabilities) | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (9) | 28 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 272 | 808 | ||
Ending balance, Assets (liabilities) net | (75) | (1,348) | ||
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 980 | (221) | ||
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Corporate debt | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 1,205 | |||
Ending balance, financial assets | 1,171 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | (21) | |||
Ending balance, financial liabilities | (13) | |||
Non-asset backed loans | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 3,743 | |||
Ending balance, financial assets | 6,435 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | 0 | |||
Ending balance, financial liabilities | 0 | |||
Equity cash products | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 393 | |||
Ending balance, financial assets | 422 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | 0 | |||
Ending balance, financial liabilities | (3) | |||
Private equity investments | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 148 | |||
Ending balance, financial assets | 123 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | 0 | |||
Ending balance, financial liabilities | 0 | |||
Other | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 2,345 | |||
Ending balance, financial assets | 1,840 | |||
Financial liabilities | ||||
Beginning balance, financial liabilities | (238) | |||
Ending balance, financial liabilities | (317) | |||
Trading portfolio assets | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 2,281 | 1,863 | ||
Purchases, fair value measurement, assets | 2,957 | 1,071 | ||
Sales, fair value measurement, assets | (781) | (529) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (319) | (135) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 284 | 398 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (291) | (175) | ||
Ending balance, financial assets | 4,256 | 2,552 | ||
Trading portfolio assets | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 125 | 59 | ||
Trading portfolio assets | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 454 | 686 | ||
Purchases, fair value measurement, assets | 72 | 112 | ||
Sales, fair value measurement, assets | (80) | (294) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (297) | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 100 | 43 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (66) | (48) | ||
Ending balance, financial assets | 163 | 489 | ||
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | (20) | (10) | ||
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 389 | 151 | ||
Purchases, fair value measurement, assets | 90 | 305 | ||
Sales, fair value measurement, assets | (144) | (87) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (17) | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 43 | 40 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (11) | (11) | ||
Ending balance, financial assets | 404 | 423 | ||
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 54 | 25 | ||
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 758 | 709 | ||
Purchases, fair value measurement, assets | 2,448 | 620 | ||
Sales, fair value measurement, assets | (459) | (131) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | (84) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 50 | 124 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (113) | (106) | ||
Ending balance, financial assets | 2,695 | 1,145 | ||
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 11 | 13 | ||
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 303 | 214 | ||
Purchases, fair value measurement, assets | 21 | 13 | ||
Sales, fair value measurement, assets | (56) | (17) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 52 | 29 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (17) | (9) | ||
Ending balance, financial assets | 327 | 262 | ||
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 24 | 32 | ||
Trading portfolio assets | Equity cash products | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 377 | 103 | ||
Purchases, fair value measurement, assets | 326 | 21 | ||
Sales, fair value measurement, assets | (42) | 0 | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (5) | (51) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 39 | 162 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (84) | (1) | ||
Ending balance, financial assets | 667 | 233 | ||
Trading portfolio assets | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 56 | (1) | ||
Trading portfolio assets | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Financial assets at fair value through the income statement | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 6,079 | 4,392 | ||
Purchases, fair value measurement, assets | 6,684 | 3,180 | ||
Sales, fair value measurement, assets | (6,396) | (2,889) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (470) | (555) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 154 | 85 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (23) | (47) | ||
Ending balance, financial assets | 6,163 | 4,007 | ||
Financial assets at fair value through the income statement | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | (57) | (181) | ||
Financial assets at fair value through the income statement | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 192 | 22 | ||
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 2,985 | 2,280 | ||
Purchases, fair value measurement, assets | 1,848 | 696 | ||
Sales, fair value measurement, assets | (757) | (299) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (315) | (388) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 52 | 69 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | (47) | ||
Ending balance, financial assets | 3,737 | 2,321 | ||
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | (76) | 10 | ||
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 84 | 320 | ||
Purchases, fair value measurement, assets | 0 | 166 | ||
Sales, fair value measurement, assets | 0 | (194) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Ending balance, financial assets | 89 | 139 | ||
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 3 | (171) | ||
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 2 | 18 | ||
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 148 | 88 | ||
Purchases, fair value measurement, assets | 19 | 22 | ||
Sales, fair value measurement, assets | (60) | (7) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | (7) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 3 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (4) | 0 | ||
Ending balance, financial assets | 124 | 98 | ||
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 7 | (1) | ||
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 11 | 3 | ||
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 2,862 | 1,704 | ||
Purchases, fair value measurement, assets | 4,817 | 2,296 | ||
Sales, fair value measurement, assets | (5,579) | (2,389) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (155) | (160) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 99 | 16 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (19) | 0 | ||
Ending balance, financial assets | 2,213 | 1,449 | ||
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 9 | (19) | ||
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 179 | 1 | ||
Financial assets at fair value through other comprehensive income | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 38 | 153 | ||
Purchases, fair value measurement, assets | 0 | 0 | ||
Sales, fair value measurement, assets | 0 | 0 | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | (5) | ||
Total gains or losses recognised in OCI, assets | (2) | 1 | ||
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | (106) | ||
Ending balance, financial assets | 36 | 43 | ||
Financial assets at fair value through other comprehensive income | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 38 | 47 | ||
Purchases, fair value measurement, assets | 0 | 0 | ||
Sales, fair value measurement, assets | 0 | 0 | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | (5) | ||
Total gains or losses recognised in OCI, assets | (2) | 1 | ||
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Ending balance, financial assets | 36 | 43 | ||
Financial assets at fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Financial assets at fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | £ 0 | 0 | ||
Financial assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | ||||
Financial assets | ||||
Beginning balance, financial assets | 106 | |||
Purchases, fair value measurement, assets | 0 | |||
Sales, fair value measurement, assets | 0 | |||
Issues, fair value measurement, assets | 0 | |||
Settlements, fair value measurement, assets | 0 | |||
Total gains or losses recognised in OCI, assets | 0 | |||
Transfers into Level 3 of fair value hierarchy, assets | 0 | |||
Transfers out of Level 3 of fair value hierarchy, assets | (106) | |||
Ending balance, financial assets | 0 | |||
Financial assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | |||
Financial assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Financial assets | ||||
Total gains and losses in the period recognised in the income statement, assets | £ 0 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Fair value of financial instr_6
Fair value of financial instruments - Unrealised gains and losses recognised in the period on Level 3 assets and liabilities held at period end (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | £ 5,026 | £ 3,467 | [1] |
Other income | 31 | 35 | [1] |
Other compre-hensive income | 280 | (1,631) | [2] |
Significant unobservable inputs (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | 950 | (398) | |
Other income | 7 | 35 | |
Other compre-hensive income | (2) | 0 | |
Total | 955 | (363) | |
Significant unobservable inputs (Level 3) | Investment properties | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | 0 | 0 | |
Other income | (1) | 0 | |
Other compre-hensive income | 0 | 0 | |
Total | (1) | 0 | |
Significant unobservable inputs (Level 3) | Net derivative financial instruments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | 862 | (367) | |
Other income | (1) | 0 | |
Other compre-hensive income | 0 | 0 | |
Total | 861 | (367) | |
Trading portfolio liabilities | Significant unobservable inputs (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | (35) | (6) | |
Other income | 0 | 0 | |
Other compre-hensive income | 0 | 0 | |
Total | (35) | (6) | |
Financial liabilities designated at fair value | Significant unobservable inputs (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | (14) | 7 | |
Other income | 0 | 0 | |
Other compre-hensive income | 0 | 0 | |
Total | (14) | 7 | |
Trading portfolio assets | Significant unobservable inputs (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | 121 | 35 | |
Other income | 0 | 0 | |
Other compre-hensive income | 0 | 0 | |
Total | 121 | 35 | |
Financial assets at fair value through the income statement | Significant unobservable inputs (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | 16 | (67) | |
Other income | 9 | 35 | |
Other compre-hensive income | 0 | 0 | |
Total | 25 | (32) | |
Financial assets at fair value through other comprehensive income | Significant unobservable inputs (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Net trading income | 0 | 0 | |
Other income | 0 | 0 | |
Other compre-hensive income | (2) | 0 | |
Total | £ (2) | £ 0 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Fair value of financial instr_7
Fair value of financial instruments - Sensitivity analysis of valuations using unobservable inputs (Details) - Recurring fair value measurement - Significant unobservable inputs (Level 3) - GBP (£) | Jun. 30, 2022 | Dec. 31, 2021 |
Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | £ 669,000,000 | £ 555,000,000 |
Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (809,000,000) | (651,000,000) |
Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Corporate debt | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 36,000,000 | 38,000,000 |
Corporate debt | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Corporate debt | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (35,000,000) | (28,000,000) |
Corporate debt | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Non-asset backed loans | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 233,000,000 | 99,000,000 |
Non-asset backed loans | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Non-asset backed loans | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (260,000,000) | (150,000,000) |
Non-asset backed loans | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity cash products | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 56,000,000 | 25,000,000 |
Equity cash products | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity cash products | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (112,000,000) | (42,000,000) |
Equity cash products | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Private equity investments | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 9,000,000 | 10,000,000 |
Private equity investments | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Private equity investments | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (9,000,000) | (11,000,000) |
Private equity investments | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Other | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 27,000,000 | 19,000,000 |
Other | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Other | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (36,000,000) | (20,000,000) |
Other | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Interest rate derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 75,000,000 | 51,000,000 |
Interest rate derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Interest rate derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (108,000,000) | (79,000,000) |
Interest rate derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Foreign exchange derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 15,000,000 | 20,000,000 |
Foreign exchange derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Foreign exchange derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (22,000,000) | (28,000,000) |
Foreign exchange derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Credit derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 111,000,000 | 112,000,000 |
Credit derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Credit derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (115,000,000) | (103,000,000) |
Credit derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 107,000,000 | 181,000,000 |
Equity derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (112,000,000) | (190,000,000) |
Equity derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | £ 0 | £ 0 |
Fair value of financial instr_8
Fair value of financial instrument - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2021 | ||
Disclosure of detailed information about financial instruments [line items] | |||
Deposits at amortised cost | £ 311,465 | £ 262,828 | [1] |
Brokered certificates of deposit | |||
Disclosure of detailed information about financial instruments [line items] | |||
Deposits at amortised cost | 3,065 | 790 | |
Significant unobservable inputs (Level 3) | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase in fair value measurement due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions, assets (liabilities) | 669 | 555 | |
Decrease in fair value measurement due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions, assets (liabilities) | 809 | 651 | |
Exit price adjustments derived from market bid-offer spreads | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase Decrease In Derivative Fair Value Adjustments | 33 | ||
Fair value adjustments | 531 | 498 | |
Uncollateralised derivative funding | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase Decrease In Derivative Fair Value Adjustments | (45) | ||
Fair value adjustments | 82 | 127 | |
Derivative credit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase Decrease In Derivative Fair Value Adjustments | (176) | ||
Fair value adjustments | 388 | 212 | |
Derivative debit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase Decrease In Derivative Fair Value Adjustments | (117) | ||
Fair value adjustments | (208) | (91) | |
Financial instruments at fair value, category | Significant unobservable inputs (Level 3) | Recurring fair value measurement | |||
Disclosure of detailed information about financial instruments [line items] | |||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 106 | 122 | |
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 19 | 59 | |
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 35 | 40 | |
Financial instruments at amortised cost, category | Significant unobservable inputs (Level 3) | Recurring fair value measurement | |||
Disclosure of detailed information about financial instruments [line items] | |||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 27 | 28 | |
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 0 | 0 | |
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | £ 1 | £ 2 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Fair value of financial instr_9
Fair value of financial instruments - Fair value adjustments (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Exit price adjustments derived from market bid-offer spreads | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ (531) | £ (498) |
Uncollateralised derivative funding | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (82) | (127) |
Derivative credit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (388) | (212) |
Derivative debit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ 208 | £ 91 |
Fair value of financial inst_10
Fair value of financial instruments - Comparison of carrying amounts and fair values for assets and liabilities not held at fair value (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Financial assets | ||||
Loans and advances at amortised cost | £ 180,098 | £ 145,259 | [1] | |
Reverse repurchase agreements and other similar secured lending | 1,060 | 3,177 | [1] | |
Financial liabilities | ||||
Deposits at amortised cost | (311,465) | (262,828) | [1] | |
Repurchase agreements and other similar secured borrowing | (12,805) | (12,769) | [1] | |
Debt securities in issue | (68,656) | (48,388) | [1] | |
Subordinated liabilities | (32,241) | (32,185) | [1] | £ (32,005) |
Fair value | ||||
Financial assets | ||||
Loans and advances at amortised cost | 180,103 | 145,665 | ||
Reverse repurchase agreements and other similar secured lending | 1,060 | 3,177 | ||
Financial liabilities | ||||
Deposits at amortised cost | (311,455) | (262,843) | ||
Repurchase agreements and other similar secured borrowing | (12,807) | (12,776) | ||
Debt securities in issue | (68,504) | (48,350) | ||
Subordinated liabilities | (32,230) | (33,598) | ||
Gross exposure | ||||
Financial assets | ||||
Loans and advances at amortised cost | 180,098 | 145,259 | ||
Reverse repurchase agreements and other similar secured lending | 1,060 | 3,177 | ||
Financial liabilities | ||||
Deposits at amortised cost | (311,465) | (262,828) | ||
Repurchase agreements and other similar secured borrowing | (12,805) | (12,769) | ||
Debt securities in issue | (68,656) | (48,388) | ||
Subordinated liabilities | £ (32,241) | £ (32,185) | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Subordinated liabilities (Detai
Subordinated liabilities (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Dec. 31, 2021 | |||
Disclosure of detailed information about borrowings [line items] | ||||
Opening balance | £ 32,185 | [1] | £ 32,005 | |
Issuances | 4,803 | 9,099 | ||
Redemptions | (4,221) | (7,241) | ||
Other | (526) | (1,678) | ||
Closing balance | 32,241 | 32,185 | [1] | |
Subordinated liabilities, including those designated at fair value | 32,821 | 32,668 | ||
At fair value | ||||
Disclosure of detailed information about borrowings [line items] | ||||
Opening balance | 483 | |||
Closing balance | £ 580 | £ 483 | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Subordinated liabilities - Narr
Subordinated liabilities - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about borrowings [line items] | ||
Issuances | £ 4,803 | £ 9,099 |
Redemption of subordinated debt | 4,221 | 7,241 |
Barclays Bank PLC loans issued intra-group Barclays PLC | Barclays PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 4,544 | |
Redemption of subordinated debt | 3,087 | |
Barclays Bank PLC externally issued | Barclays PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | 1,060 | |
USD Notes | Floating interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 128 | |
USD Notes | Floating interest rate | Other subsidiaries | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | £ 74 | |
ZAR Notes | Floating interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 89 | |
EUR Notes | Floating interest rate | Other subsidiaries | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 42 | |
EUR 6.625% fixed rate notes | Fixed interest rate | Barclays PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | £ 838 | |
Interest rate | 6.625% | |
6.86% euro notes | Fixed interest rate | Barclays PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | £ 147 | |
Interest rate | 6.86% | |
EUR floating rate notes | Floating interest rate | Barclays PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | £ 42 | |
GBP floating rate notes | Floating interest rate | Barclays PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | 21 | |
GBP 6% callable perpetual core tier one notes | Fixed interest rate | Barclays PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | £ 12 | |
Interest rate | 6% |
Provisions - Total provisions (
Provisions - Total provisions (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of other provisions [line items] | |||
Provisions | £ 2,645 | £ 1,110 | [1] |
Customer redress | |||
Disclosure of other provisions [line items] | |||
Provisions | 1,629 | 266 | |
Legal, competition and regulatory matters | |||
Disclosure of other provisions [line items] | |||
Provisions | 406 | 211 | |
Redundancy and restructuring | |||
Disclosure of other provisions [line items] | |||
Provisions | 23 | 46 | |
Undrawn contractually committed facilities and guarantees | |||
Disclosure of other provisions [line items] | |||
Provisions | 487 | 499 | |
Onerous contracts | |||
Disclosure of other provisions [line items] | |||
Provisions | 0 | 2 | |
Sundry provisions | |||
Disclosure of other provisions [line items] | |||
Provisions | £ 100 | £ 86 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Provisions - Narrative (Details
Provisions - Narrative (Details) £ in Millions, $ in Millions | 6 Months Ended | 12 Months Ended | 13 Months Ended | ||
Jun. 30, 2022 GBP (£) | Jun. 30, 2022 GBP (£) | Dec. 31, 2021 GBP (£) | Mar. 10, 2022 USD ($) | ||
Disclosure of other provisions [line items] | |||||
Provisions | £ 2,645 | £ 2,645 | £ 1,110 | [1] | |
Over-issuance of securities | |||||
Disclosure of other provisions [line items] | |||||
Increase (decrease) in other provisions | 1,757 | 220 | |||
Over-issuance of structured notes | |||||
Disclosure of other provisions [line items] | |||||
Increase (decrease) in other provisions | 1,592 | 220 | |||
Accrued income including contract assets | 34 | 34 | |||
Securities issued in excess of limit | $ | $ 60 | ||||
Reduction in the market value of the structured notes and additional accrued penalty interest | |||||
Disclosure of other provisions [line items] | |||||
Increase in existing provisions, other provisions | £ 1,372 | ||||
Recission right | |||||
Disclosure of other provisions [line items] | |||||
Increase (decrease) in other provisions | £ 165 | £ 0 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Retirement benefits - Narrative
Retirement benefits - Narrative (Details) - GBP (£) £ in Billions | Jun. 30, 2022 | Dec. 31, 2021 |
Disclosure of fair value of plan assets [line items] | ||
Surplus in plan | £ 5 | £ 3.6 |
Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | Pension defined benefit plans | United Kingdom | ||
Disclosure of fair value of plan assets [line items] | ||
Surplus in plan | £ 5.2 | £ 3.8 |
Retirement benefits - UKRF fund
Retirement benefits - UKRF funding valuations (Narrative) (Details) - GBP (£) £ in Millions | 1 Months Ended | 6 Months Ended | ||||
Sep. 30, 2022 | Apr. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Disclosure of fair value of plan assets [line items] | ||||||
Deficit in plan | £ (5,000) | £ (3,600) | ||||
Forecast | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Reasonably possible decrease in capital ratio | 0.30% | |||||
United Kingdom | Total loans and advances at amortised cost | The senior notes | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Notional contract amount | 1,250 | |||||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Deficit in plan | (5,200) | £ (3,800) | ||||
Employer contributions | £ 147 | 700 | ||||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | Deficit contributions valuation recovery plan 2019 | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Deficit in plan | £ 900 | |||||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | Deficit contributions valuation recovery plan 2020 | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Deficit in plan | £ (600) | |||||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | 2022 | Barclays Bank PLC | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Employer contributions | 294 | |||||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | 2023 | Barclays Bank PLC | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Employer contributions | 286 | |||||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | Later than one month and not later than three months | ||||||
Disclosure of fair value of plan assets [line items] | ||||||
Estimate of contributions expected to be paid to plan for next annual reporting period | £ 147 |
Called up share capital - Narra
Called up share capital - Narrative (Details) £ / shares in Units, £ in Millions | Jun. 30, 2022 GBP (£) £ / shares shares | Jun. 30, 2022 € / shares | Jun. 30, 2022 $ / shares | Dec. 31, 2021 GBP (£) £ / shares shares |
Ordinary shares | ||||
Number of shares issued (in shares) | 2,342,000,000 | 2,342,000,000 | ||
Par value per share | £ / shares | £ 1 | £ 1 | ||
Preference share capital | ||||
Called up share capital | £ | £ 6 | £ 6 | ||
Sterling 1 Preference Shares | ||||
Number of shares issued (in shares) | 1,000 | 1,000 | ||
Par value per share | £ / shares | £ 1 | |||
Euro Preference Shares | ||||
Number of shares issued (in shares) | 31,856 | 31,856 | ||
Par value per share | € / shares | € 100 | |||
US Dollar Preference Shares $100 | ||||
Number of shares issued (in shares) | 58,133 | 58,133 | ||
Par value per share | $ / shares | $ 100 |
Other equity instruments (Detai
Other equity instruments (Details) £ in Millions | 6 Months Ended | |||||||
Jun. 30, 2022 GBP (£) Redemptions issuance | Dec. 31, 2021 GBP (£) | Jun. 30, 2021 GBP (£) | Dec. 31, 2020 GBP (£) | |||||
Total equity | £ 58,916 | [1] | £ 56,317 | [1] | £ 53,636 | [2] | £ 53,710 | [2] |
Other equity instruments | ||||||||
Total equity | £ 9,794 | [3] | £ 9,693 | [3] | £ 8,621 | [3],[4] | £ 8,621 | [4] |
Number of share issuances | issuance | 1 | |||||||
Number of share redemptions | Redemptions | 1 | |||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[3]Details of share capital, other equity instruments and other reserves are shown on pages 29 to 51.[4]Details of share capital, other equity instruments and other reserves are shown on pages 42 to 43. |
Other reserves (Details)
Other reserves (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of reserves within equity [line items] | |||
Other reserves | £ 53 | £ 861 | [1] |
Currency translation reserve | |||
Disclosure of reserves within equity [line items] | |||
Other reserves | 4,589 | 2,581 | |
Fair value through other comprehensive income reserve | |||
Disclosure of reserves within equity [line items] | |||
Other reserves | (917) | (118) | |
Cash flow hedging reserve | |||
Disclosure of reserves within equity [line items] | |||
Other reserves | (3,492) | (618) | |
Own credit reserve | |||
Disclosure of reserves within equity [line items] | |||
Other reserves | (103) | (960) | |
Other reserves | |||
Disclosure of reserves within equity [line items] | |||
Other reserves | £ (24) | £ (24) | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Other reserves - Narrative (Det
Other reserves - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | |||||||
Jun. 30, 2022 | Dec. 30, 2021 | [2] | Jun. 30, 2021 | [3] | Dec. 31, 2021 | |||
Disclosure of reserves within equity [line items] | ||||||||
Other reserves | £ 53 | £ 861 | [1] | |||||
Other | 12 | [2] | £ 3 | £ (2) | ||||
Currency translation reserve | ||||||||
Disclosure of reserves within equity [line items] | ||||||||
Other reserves | 4,589 | 2,581 | ||||||
Movements | (2,008) | |||||||
Fair value through other comprehensive income reserve | ||||||||
Disclosure of reserves within equity [line items] | ||||||||
Other reserves | (917) | (118) | ||||||
Movements | 799 | |||||||
Changes in fair value | 1,083 | |||||||
Tax | (284) | |||||||
Cash flow hedging reserve | ||||||||
Disclosure of reserves within equity [line items] | ||||||||
Other reserves | (3,492) | (618) | ||||||
Movements | 2,874 | |||||||
Changes in fair value | 3,908 | |||||||
Tax | 1,032 | |||||||
Own credit reserve | ||||||||
Disclosure of reserves within equity [line items] | ||||||||
Other reserves | (103) | (960) | ||||||
Movements | (857) | |||||||
Tax | 403 | |||||||
Loss on change in value of foreign currency basis spreads, before tax | 1,258 | |||||||
Other reserves | ||||||||
Disclosure of reserves within equity [line items] | ||||||||
Other reserves | £ (24) | £ (24) | ||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[3]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Contingent liabilities and co_3
Contingent liabilities and commitments (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | £ 24,275 | £ 23,746 |
Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 336,371 | 284,451 |
Guarantees and letters of credit pledged as collateral security | Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 16,743 | 15,759 |
Performance guarantees, acceptances and endorsements | Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 7,532 | 7,987 |
Documentary credits and other short-term trade related transactions | Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 1,888 | 1,584 |
Standby facilities, credit lines and other commitments | Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | £ 334,483 | £ 282,867 |
Legal, competition and regula_2
Legal, competition and regulatory matters (Details) £ in Thousands, $ in Thousands, € in Millions, SFr in Millions | 1 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||
Jun. 30, 2022 GBP (£) | Apr. 30, 2021 USD ($) | Dec. 31, 2020 GBP (£) | Jun. 30, 2019 settlement | May 31, 2019 EUR (€) settlement | Jan. 31, 2017 CHF (SFr) | Jun. 30, 2022 GBP (£) settlement lawsuits plaintiff | Jun. 30, 2022 USD ($) settlement lawsuits plaintiff | Jun. 30, 2021 GBP (£) | [1] | Jul. 01, 2007 lawsuits | Dec. 31, 2021 GBP (£) settlement | Dec. 31, 2021 USD ($) settlement | Dec. 31, 2020 USD ($) defendant pensionFund | Dec. 31, 2018 GBP (£) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 lawsuits | Dec. 31, 2016 USD ($) lawsuits | Dec. 31, 2015 USD ($) | Dec. 31, 2013 GBP (£) | Dec. 31, 2012 USD ($) lawsuits | Dec. 31, 2008 USD ($) agreement | Mar. 31, 2022 GBP (£) | ||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | £ 1,833,000 | £ 164,000 | £ 374,000 | |||||||||||||||||||||
Provisions | £ 2,645,000 | £ 2,645,000 | 1,110,000 | [2] | ||||||||||||||||||||
Over-issuance of structured notes | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Increase (decrease) in other provisions | 1,592,000 | 220,000 | ||||||||||||||||||||||
Over-issuance of securities | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Increase (decrease) in other provisions | 1,757,000 | £ 220,000 | ||||||||||||||||||||||
USD LIBOR cases in MDL court | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of settlements | settlement | 2 | 2 | 2 | 2 | ||||||||||||||||||||
Sterling LIBOR case in SDNY | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | |||||||||||||||||||||||
Japanese Yen LIBOR civil actions | Exchange-based class claims | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | £ 17,750 | |||||||||||||||||||||||
Non-US forex civil actions | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | 2 | ||||||||||||||||||||||
Foreign exchange investigations | Fines settlement | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of settlements | settlement | 2 | 2 | ||||||||||||||||||||||
Losses on litigation settlements | € 210 | £ 54,000 | ||||||||||||||||||||||
Foreign exchange investigations | Violation of NPA | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | SFr | SFr 27 | |||||||||||||||||||||||
Metals related civil actions | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | £ 50,000 | |||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | RMBS repurchase requests | Originated and sold to third parties by Acquired Subsidiary | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | |||||||||||||||||||||||
Number of settlements | settlement | 2 | 2 | ||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | £ 32,500 | |||||||||||||||||||||||
Asset-backed debt instruments held | $ | $ 22,000 | |||||||||||||||||||||||
Number of defendants | defendant | 6 | |||||||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | NEW MEXICO | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of retirement benefit funds | pensionFund | 2 | |||||||||||||||||||||||
Supranational, sovereign and agency bonds civil actions | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits dismissed | lawsuits | 1 | 1 | ||||||||||||||||||||||
Civil actions in respect of VRDO | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | 2 | ||||||||||||||||||||||
Civil actions in respect of the US anti-terrorism act | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 6 | 6 | ||||||||||||||||||||||
Number of plaintiffs | plaintiff | 4,000 | 4,000 | ||||||||||||||||||||||
Number of lawsuits dismissed | lawsuits | 3 | 3 | ||||||||||||||||||||||
Number of lawsuits subject to appeal | lawsuits | 1 | 1 | ||||||||||||||||||||||
Civil actions in respect of the US anti-terrorism act - SDNY | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 2 | 2 | ||||||||||||||||||||||
Derivative transactions civil action | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Loss Contingency, damages sought, claimed amounts, value | 329,000 | |||||||||||||||||||||||
CFS remediation of ASL loans | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Expected reimbursement, other provisions | £ 181,000 | |||||||||||||||||||||||
HMRC assessments concerning UK VAT | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Loss Contingency, damages sought, claimed amounts, value | £ 181,000 | |||||||||||||||||||||||
HMRC assessments concerning UK VAT | Barclays UK PLC | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Loss Contingency, damages sought, claimed amounts, value | 128,000 | |||||||||||||||||||||||
Civil actions in respect of VRDO - SNDY | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 3 | 3 | ||||||||||||||||||||||
Investigation into the use of unapproved communications platforms | Securities and Exchange Commission | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Loss Contingency, damages sought, claimed amounts, value | £ 125,000 | |||||||||||||||||||||||
Investigation into the use of unapproved communications platforms | CFTC | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Loss Contingency, damages sought, claimed amounts, value | 75,000 | |||||||||||||||||||||||
Barclays Bank PLC | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Provisions | £ 2,334,000 | £ 2,334,000 | £ 919,000 | |||||||||||||||||||||
Barclays Bank PLC | FCA proceedings and other investigations | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of advisory service agreements | agreement | 2 | |||||||||||||||||||||||
Loss contingency, financial penalty warning | £ 50,000 | |||||||||||||||||||||||
Barclays Bank PLC | USD LIBOR cases in MDL court | Lawsuits with damages sought | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits with damages sought | lawsuits | 1 | |||||||||||||||||||||||
Loss Contingency, damages sought, claimed amounts, value | $ | $ 100,000 | |||||||||||||||||||||||
Barclays Bank PLC | USD LIBOR cases in MDL court | Exchange-based class claims | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | $ | $ 7,500 | $ 7,100 | ||||||||||||||||||||||
Barclays Bank PLC | USD LIBOR cases in MDL court | Debt securities class claims | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | $ | $ 1,950 | $ 20,000 | ||||||||||||||||||||||
Barclays Bank PLC | SIBOR/SOR case In SDNY | Exchange-based class claims | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | $ | $ 91,000 | |||||||||||||||||||||||
Barclays Bank PLC | Non-US forex civil actions | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Number of lawsuits pending | lawsuits | 1 | |||||||||||||||||||||||
Barclays Bank PLC | Foreign exchange investigations | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | $ | $ 2,380,000 | |||||||||||||||||||||||
Barclays Bank PLC | Consolidated FX action | Barclays Capital Inc | Securities and Exchange Commission | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Losses on litigation settlements | $ | $ 384,000 | |||||||||||||||||||||||
Barclays Bank PLC | BDC Finance LLC | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Litigation settlements approved, value | $ | $ 3,300 | $ 298,000 | ||||||||||||||||||||||
Barclays Bank PLC | HMRC assessments concerning UK VAT | ||||||||||||||||||||||||
Disclosure of contingent liabilities [line items] | ||||||||||||||||||||||||
Loss Contingency, damages sought, claimed amounts, value | £ 53,000 | |||||||||||||||||||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Related party transactions - Am
Related party transactions - Amounts included in the barclays bank group's financial statements with other barclays group companies (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |||
Disclosure of transactions between related parties [line items] | |||||
Total income | £ 9,990 | £ 8,189 | [1] | ||
Operating expenses | (7,092) | (5,223) | [1] | £ (10,259) | |
Total assets | 1,272,745 | 1,061,778 | [2] | ||
Total liabilities | 1,213,829 | 1,005,461 | [2] | ||
Parent | |||||
Disclosure of transactions between related parties [line items] | |||||
Total income | (342) | (304) | |||
Operating expenses | (34) | (31) | |||
Total assets | 6,768 | 6,491 | |||
Total liabilities | 35,140 | 32,141 | |||
Fellow subsidiaries | |||||
Disclosure of transactions between related parties [line items] | |||||
Total income | 12 | 10 | |||
Operating expenses | (1,647) | £ (1,560) | |||
Total assets | 3,395 | 909 | |||
Total liabilities | £ 4,626 | £ 3,962 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Barclays Bank PLC parent cond_3
Barclays Bank PLC parent condensed balance sheet (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | [3] | Dec. 31, 2020 | |||
Assets | ||||||||
Cash and balances at central banks | £ 221,698 | £ 169,085 | [1] | |||||
Cash collateral and settlement balances | 128,501 | 88,085 | [1] | |||||
Loans and advances at amortised cost | 180,098 | 145,259 | [1] | |||||
Reverse repurchase agreements and other similar secured lending | 1,060 | 3,177 | [1] | |||||
Trading portfolio assets | 126,896 | 146,871 | [1] | |||||
Financial assets at fair value through the income statement | 210,430 | 188,226 | [1] | |||||
Derivative financial instruments | 344,396 | 262,291 | [1] | |||||
Financial assets at fair value through other comprehensive income | 43,814 | 45,908 | [1] | |||||
Investments in associates and joint ventures | 24 | 24 | [1] | |||||
Goodwill and intangible assets | 1,656 | 1,449 | [1] | |||||
Property, plant and equipment | 1,330 | 1,248 | [1] | |||||
Current tax assets | 1,116 | 589 | [1] | |||||
Deferred tax assets | 3,052 | 2,981 | [1] | |||||
Retirement benefit assets | 5,234 | 3,879 | [1] | |||||
Other assets | 3,440 | 2,706 | [1] | |||||
Total assets | 1,272,745 | 1,061,778 | [1] | |||||
Liabilities | ||||||||
Deposits at amortised cost | 311,465 | 262,828 | [1] | |||||
Cash collateral and settlement balances | 123,387 | 79,047 | [1] | |||||
Repurchase agreements and other similar secured borrowing | 12,805 | 12,769 | [1] | |||||
Debt securities in issue | 68,656 | 48,388 | [1] | |||||
Subordinated liabilities | 32,241 | 32,185 | [1] | £ 32,005 | ||||
Trading portfolio liabilities | 75,880 | 53,291 | [1] | |||||
Financial liabilities designated at fair value | 255,787 | 251,131 | [1] | |||||
Derivative financial instruments | 321,526 | 256,523 | [1] | |||||
Current tax liabilities | 449 | 688 | [1] | |||||
Deferred tax liabilities | 0 | 6 | [1] | |||||
Retirement benefit liabilities | 236 | 246 | [1] | |||||
Other liabilities | 8,752 | 7,249 | [1] | |||||
Provisions | 2,645 | 1,110 | [1] | |||||
Total liabilities | 1,213,829 | 1,005,461 | [1] | |||||
Equity | ||||||||
Called up share capital and share premium | 2,348 | 2,348 | [1] | |||||
Other equity instruments | 9,794 | 9,693 | [1] | |||||
Other reserves | 53 | 861 | [1] | |||||
Retained earnings | 46,721 | 43,415 | [1] | |||||
Total equity | 58,916 | [2] | 56,317 | [2] | £ 53,636 | £ 53,710 | [3] | |
Total liabilities and equity | 1,272,745 | 1,061,778 | [1] | |||||
Barclays Bank PLC | ||||||||
Assets | ||||||||
Cash and balances at central banks | 195,796 | 144,964 | ||||||
Cash collateral and settlement balances | 89,878 | 75,571 | ||||||
Loans and advances at amortised cost | 247,192 | 199,782 | ||||||
Reverse repurchase agreements and other similar secured lending | 3,873 | 4,982 | ||||||
Trading portfolio assets | 84,976 | 96,724 | ||||||
Financial assets at fair value through the income statement | 240,618 | 236,577 | ||||||
Derivative financial instruments | 295,680 | 234,409 | ||||||
Financial assets at fair value through other comprehensive income | 41,479 | 44,163 | ||||||
Investments in associates and joint ventures | 12 | 12 | ||||||
Investment in subsidiaries | 19,338 | 19,134 | ||||||
Goodwill and intangible assets | 108 | 109 | ||||||
Property, plant and equipment | 121 | 128 | ||||||
Current tax assets | 1,286 | 671 | ||||||
Deferred tax assets | 1,763 | 1,679 | ||||||
Retirement benefit assets | 5,179 | 3,825 | ||||||
Other assets | 2,495 | 1,941 | ||||||
Total assets | 1,229,794 | 1,064,671 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 345,322 | 286,761 | ||||||
Cash collateral and settlement balances | 83,284 | 56,419 | ||||||
Repurchase agreements and other similar secured borrowing | 26,893 | 29,202 | ||||||
Debt securities in issue | 50,638 | 32,585 | ||||||
Subordinated liabilities | 31,694 | 31,875 | ||||||
Trading portfolio liabilities | 55,518 | 50,116 | ||||||
Financial liabilities designated at fair value | 284,345 | 291,062 | ||||||
Derivative financial instruments | 288,032 | 227,991 | ||||||
Current tax liabilities | 249 | 342 | ||||||
Deferred tax liabilities | 0 | 6 | ||||||
Retirement benefit liabilities | 105 | 104 | ||||||
Other liabilities | 6,147 | 4,597 | ||||||
Provisions | 2,334 | 919 | ||||||
Total liabilities | 1,174,561 | 1,011,979 | ||||||
Equity | ||||||||
Called up share capital and share premium | 2,348 | 2,348 | ||||||
Other equity instruments | 14,500 | 14,400 | ||||||
Other reserves | (2,877) | (1,236) | ||||||
Retained earnings | 41,262 | 37,180 | ||||||
Total equity | 55,233 | 52,692 | ||||||
Total liabilities and equity | £ 1,229,794 | £ 1,064,671 | ||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[3]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details. |
Uncategorized Items - _IXDS
Label | Element | Value | |
Issue and/or exchange of other equity instruments | c070_IssueAndExchangeOfOtherEquityInstruments | £ 1,378,000,000 | [1] |
Expense from equity-settled share-based payment transactions | ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets | (785,000,000) | [1] |
Other comprehensive income, net of tax, financial assets measured at fair value through other comprehensive income | ifrs-full_OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | (50,000,000) | [1] |
Increase (decrease) other equity instruments coupons paid | c070_IncreaseDecreaseOtherEquityInstrumentsCouponsPaid | (886,000,000) | [1] |
Increase (decrease) through exercise of options, equity | ifrs-full_IncreaseDecreaseThroughExerciseOfOptions | 338,000,000 | [1] |
Other reserves [member] | |||
Comprehensive income | ifrs-full_ComprehensiveIncome | (595,000,000) | [2] |
Other comprehensive income, net of tax, change in fair value of financial liability attributable to change in credit risk of liability | ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability | 34,000,000 | [2] |
Increase (decrease) through other changes, equity | ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity | 7,000,000 | [2] |
Other comprehensive income, net of tax, financial assets measured at fair value through other comprehensive income | ifrs-full_OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | (50,000,000) | [2] |
Other comprehensive income, net of tax, exchange differences on translation of foreign operations | ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation | 397,000,000 | [2] |
Other comprehensive income, net of tax, cash flow hedges | ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges | (976,000,000) | [2] |
Retained earnings [member] | |||
Issue and/or exchange of other equity instruments | c070_IssueAndExchangeOfOtherEquityInstruments | 3,000,000 | [1] |
Comprehensive income | ifrs-full_ComprehensiveIncome | 2,138,000,000 | [1] |
Expense from equity-settled share-based payment transactions | ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets | (785,000,000) | [1] |
Increase (decrease) through other changes, equity | ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity | (4,000,000) | [1] |
Dividends paid, ordinary shares | ifrs-full_DividendsPaidOrdinaryShares | 781,000,000 | [1] |
Profit (loss) | ifrs-full_ProfitLoss | 1,597,000,000 | [1] |
Increase (decrease) other equity instruments coupons paid | c070_IncreaseDecreaseOtherEquityInstrumentsCouponsPaid | (255,000,000) | [1] |
Dividends paid, other shares | ifrs-full_DividendsPaidOtherShares | 27,000,000 | [1] |
Increase (decrease) through exercise of options, equity | ifrs-full_IncreaseDecreaseThroughExerciseOfOptions | 338,000,000 | [1] |
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans | ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans | 541,000,000 | [1] |
Other equity interest [member] | |||
Issue and/or exchange of other equity instruments | c070_IssueAndExchangeOfOtherEquityInstruments | 1,375,000,000 | [2] |
Comprehensive income | ifrs-full_ComprehensiveIncome | 328,000,000 | [2] |
Profit (loss) | ifrs-full_ProfitLoss | 328,000,000 | [2] |
Increase (decrease) other equity instruments coupons paid | c070_IncreaseDecreaseOtherEquityInstrumentsCouponsPaid | £ (631,000,000) | [2] |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 29 for further details.[2]Details of share capital, other equity instruments and other reserves are shown on pages 29 to 51. |